A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in Combination With Brivanib Alaninate (ZL-2301) in Patients With Advanced Liver Cancer
Phase: PHASE1
Conditions: Advanced Hepatocellular Carcinoma (HCC)
Sponsor: Zai Lab (Shanghai) Co., Ltd.

ZL-MGD013-202
NCT04212221 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 1 of 106 
Clinical Study Protocol 
(Amendment 1) 
Study Title 
A Multicenter, Open-label, Phase I/II Dose Escalation and 
Expansion Clinical Study to Assess the Safety and Efficacy of 
MGD013 Monotherapy and in Combination with Brivanib 
Alaninate (ZL-2301) in Patients with Advanced Liver Cancer 
Project No. 
ZL-MGD013-202 
Version No. and Version 
Date 
Amendment 1/Jun30, 2020 
Investigational Drug 
Brivanib Alaninate (ZL-2301), MGD-013 
Study Phase 
Phase I/II 
Sponsor 
Zai Lab (Shanghai) Co., Ltd. 
Principal Investigator 
Confidentiality Statement 
Confidential information of the investigational drugs involved in this protocol belongs to Zai 
Lab. The document is accessible to investigators, research consultants or relevant personnel, 
Institutional Review Board/Independent Ethics Committee only. The contents inside the 
document may not be disclosed to any third party without the written approval of the sponsor. 
Revision History 
Status 
Date 
Original Protocol: Version 1.1 
July 24, 2019 
Protocol Amendment 1 
June 30, 2020 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 2 of 106 
Summary of Changes in Protocol Amendment 1 
ZL-MGD013-202  
Synopsis, Section 
3.1, Section 3.2.1  
The starting dose of brivanib in combination therapy is revised to 400mg 
QD; 
If the dose of 400mg q2w as MGD 013 monotherapy is clear, the 
combination therapy will be opened from MGD013 400mg q2w+brivanib 
400mg qd. 
Synopsis, Section 
3.1.4  
Clarify the population of phase 2 is “≥2 line HCC with or without immune 
checkpoint inhibitor treatment” 
Synopsis, section 
4.1 
Clarify the antiviral therapy is not required for patients with HCV infection. 
Section 3.1.3  
Update the DLT criteria to keep consistence with global MGD-013. 
Add 3 new criteria in Other ≥ Grade 3 non-hematological toxicity to 
exclude DLT: 
● 
Grade 3 fever that lasts < 72 hours and is not associated with 
hemodynamic compromise 
● 
Grade 3 fatigue that lasts < 72 hours 
● 
Grade 3 skin toxicity that resolves to ≤ Grade 2 within 14 
days of initiation of oral corticosteroids 
Section 4.3.1  
 
Clarify the criteria of end of treatment, including 2 additional of “death and 
Completion of protocol-defined therapy (MGD013 mono)”  
Section 4.3.2  
 
Clarify the criteria of End of Study 
● 
Death 
● 
Lost to follow up 
● 
Withdrawn of consent 
● 
The study is terminated 
Section 5.2  
 
Add the section of infusion preparation based on the global practice of 
MGD013. 
5.2.1 General Guidelines and Precautions  
5.2.2 Study Drug Preparation and Administration 
Section 8.3.8  
 
Update the SAE reporting process  
Section 8.4.1.1 
 
Update the Management of Observed Infusion Reactions (G1 and G2) 
Grade 1: Note: Per Section 8.4.1, the following prophylactic pre-infusion 
medications are required prior to all infusions of MGD013, including future 
infusions for patients who experience Grade 1 infusion reactions: 
Grade 2: For patients with Grade 2 infusion reactions, despite 
premedication with diphenhydramine, ranitidine or equivalent, and 
acetaminophen (or equivalent) and/or ibuprofen, corticosteroids (10-20 mg 
dexamethasone IV, or equivalent IV steroid) may be added to the 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 3 of 106 
premedication regimen for the next dosing of MGD013. Reduce 
corticosteroid dosing by 50% for the subsequent dose and hold thereafter, if 
there are no reactions 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 4 of 106 
Protocol synopsis 
Name of 
Sponsor/Company Zai Lab (Shanghai) Co., Ltd. 
Investigational 
Drug 
MGD013 (anti-LAG-3 and PD-L1 bispecific antibody), 
Brivanib Alaninate (ZL-2301) 
Study Title 
A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical 
Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in 
Combination with Brivanib Alaninate (ZL-2301) in Patients with Advanced Liver 
Cancer 
Protocol No. 
ZL-MGD013-202 
Investigator 
 
Study Site 
Approx. 25 sites 
Study Duration  
Approx. 3 years 
Study Phase 
Phase I/II 
Study Objectives 
 
This study consists of two parts: Phase I is a dose escalation study to determine 
the Recommended Phase II Dose (RP2D) of MGD013 monotherapy and that of 
MGD013 when in combination with Brivanib Alaninate (ZL-2301) in subjects 
with advanced liver cancer (including hepatocellular carcinoma and intrahepatic 
cholangiocarcinoma). Phase II is a dose expansion study and consists of two 
parts: Part 1 is to assess the safety and efficacy of MGD013 monotherapy and 
MGD013 in combination with ZL-2301 in subjects with advanced 
hepatocellular carcinoma (HCC); in Part 2, a therapeutic method (MGD013 
monotherapy or MGD013 in combination with ZL-2301, determined by the 
sponsor according to the obtained data) will be selected for dose expansion 
study in HCC subjects who have previously failed immune checkpoint inhibitor 
treatment, to further evaluate the safety and efficacy of the study treatments in 
the specific group of subjects. 
Objectives of Phase I study 
Primary Objectives 
- 
To assess the safety of MGD013 in subjects with advanced liver cancer; 
- 
To determine the recommended phase II dose (RP2D) of MGD013 
monotherapy in subjects with advanced liver cancer; 
- 
To assess the safety of MGD013 in combination with Brivanib Alaninate 
(ZL-2301) in subjects with advanced liver cancer; 
- 
To determine the recommended phase II dose (RP2D) of MGD013 when 
co-administered with Brivanib Alaninate (ZL-2301). 
Secondary Objectives 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 5 of 106 
- 
To assess the preliminary efficacy of MGD013 monotherapy and MGD013 
in combination with Brivanib Alaninate in subjects with advanced liver 
cancer by investigator-assessed objective response rate (ORR) according to 
RECIST1.1 and irRECIST criteria respectively. 
Exploratory objective 
- 
To explore the correlation between MGD013/Brivanib Alaninate-related 
biomarkers and subject safety, antitumor activity. 
Objectives of Phase II study (Part 1) 
Primary Objectives: 
- 
To assess the safety of MGD013 monotherapy at RP2D in subjects with 
advanced HCC; 
- 
To assess the safety of MGD013 at RP2D in combination with Brivanib 
Alaninate in subjects with advanced HCC; 
- 
To assess the efficacy of MGD013 monotherapy and in combination with 
Brivanib Alaninate in subjects with advanced HCC, with blinded 
independent central review (BICR)-assessed ORR according to RECIST 
1.1 as the primary efficacy endpoint. 
Secondary Objectives: 
- 
To assess the secondary efficacy endpoints of MGD013 monotherapy and 
in combination with Brivanib Alaninate: BICR-assessed ORR according to 
irRECIST, investigator-assessed ORRs (inv-ORRs) according to RECIST 
1.1 and irRECIST respectively, disease control rate (DCR), time to tumor 
progression (TTP), duration of response (DoR), progression-free survival 
(PFS), survival rate at 6, 9 and 12 months, overall survival (OS). 
Exploratory objective 
- 
To explore the potential biomarker for MGD013/Brivanib Alaninate and its 
correlation with subject safety and antitumor activity. 
Objectives of Phase II study (Part two) 
Primary Objectives: 
- 
To assess the safety of the investigational drugs in subjects with advanced 
HCC who have previously failed immune checkpoint inhibitor treatment; 
- 
To assess the efficacy of the investigational drugs in subjects with 
advanced HCC who have previously failed immune checkpoint inhibitor 
treatment, with BICR-assessed ORR according to RECIST1.1 as the 
primary efficacy endpoint. 
Secondary Objectives: 
- 
To assess the secondary efficacy endpoints of the investigational drugs in 
subjects with advanced HCC: BICR-assessed ORR according to irRECIST, 
investigator-assessed ORRs (inv-ORRs) according to RECIST 1.1 and 
irRECIST respectively, disease control rate (DCR), time to tumor 
progression (TTP), duration of response (DoR), progression-free survival 
(PFS), survival rate at 6, 9 and 12 months, overall survival (OS). 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 6 of 106 
Study Design 
 
This is a multicenter, open-label, phase I/II clinical study. This study consists of 
two phases: the dose escalation study (Phase I) and the dose expansion study 
(Phase II). Phase II study will consist of two parts: Part 1 and Part 2. 
Study Design of Phase I Study 
Phase I study will enroll subjects with unresectable advanced HCC, intrahepatic 
cholangiocarcinoma and/or mixed hepatocellular-cholangiocarcinoma who have 
previously received at least first-line systematic treatment and recurred/not 
toraltable to the treatment. The dose escalation study of MGD013 monotherapy 
will be first conducted. After 400mg Q2w of MGD013 monotherapy is clear, the 
dose escalation study of the combination therapy will be conducted. The 
schematic diagram of the study is shown as below: 
 
 
During dose escalation study of monotherapy, the starting dose escalation of 
MGD013 will be 120 mg Q2W with one subject. If the first dose level (120 mg 
Q2W) is well tolerated (without CTCAE Grade 2 or above AE within 28 days 
after first study drug treatment; see Section 3.1.2 for details), the dose level may 
escalate sequentially following traditional 3+3 dose escalation scheme. If study 
drug-related adverse events with CTCAE Grade 2 or above severity are 
observed in the subject of the initial dose group, the study will adopt traditional 
3+3 dose escalation scheme from the initial dose level (120 mg Q2W), and an 
additional of 2 subjects will be enrolled in the initial dose group (see Section 
3.1.2 for details). The highest dose level of MGD013 monotherapy will be 600 
mg Q2W. Monotherapy RP2D group should enroll at least 6 evaluable subjects. 
The combination therapy will be initiated after the MGD013 400mg Q2w is 
clear. The combination dose of MGD013 could be escalated to RP2D of 
MGD013 after determining. Dose escalation study of the combination therapy 
will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will 
start from 400 mg once daily (QD), and may escalate to 600 mg QD and a 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 7 of 106 
maximum of 800 mg QD (if possible). Two points should be noted: one is the 
combination dose of MGD 013 600mg Q2w +brivanib 400mg qd can be opened 
after both monotherapy RP2D of 600mg Q2w is determined and the starting 
dose of combination therapy is tolerant; the other is combination dose of 
MGD013 400mg Q2w + brivanib 600mg qd could be further explored once the 
starting dose of combination therapy is tolerant and the dose of MGD013 
600mg Q2w+brivanib 400mg qd is not tolerant. 
While two or more 2 subjects experience DLT in the start dose group of the 
combination therapy, the combination dose level escalation will be terminated, 
and Phase II dose-extension study will be conducted with MGD013 alone. 
RP2D dose group of the combination therapy should at least enroll 6 evaluable 
subjects. 
The treatment cycle is two weeks and the observation cycle of DLT is 28 days 
(the first two cycles). Subjects will continue to receive study treatment until 
disease progression, death or the occurrence of intolerable toxicity, whichever 
comes first. MGD013 will be used for at most 48 cycles. If subjects do not have 
disease progression after 48 cycles, MGD013 will be discontinued. The 
treatment will be continued with Brivanib Alaninate alone. 
In Phase I dose escalation period, the Safety Review Committee (SRC) will 
decide whether to escalate to the next dose level or discontinue the escalation 
after reviewing the data from each dose group. 
 
Design of Phase II study 
Phase II, the dose expansion study, will only enroll subjects with HCC. There 
are two cohorts in Part 1, MGD013 monotherapy and MGD013 in combination 
with Brivanib Alaninate. After determining the RP2D of MGD013 
monotherapy, dose expansion study of monotherapy will be conducted. Subjects 
of the combination therapy cohort will be enrolled after determining the RP2D 
of combination therapy in Phase I study. The schematic diagram of the dose 
extension study is shown as below: 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 8 of 106 
 
Each cohort will enroll approximately 30 advanced HCC subjects who 
progressed after receiving immune checkpoint inhibitor treatment, and 
approximately 40 advanced HCC subjects who have not previously received 
immune checkpoint inhibitor treatment. The SWOG two-stage design will be 
employed. In the first stage, 20 advanced HCC subjects who have not 
previously received immune checkpoint inhibitor treatment will be enrolled. If 
response by image evaluation is observed in 3 or more subjects (according to 
RECIST 1.1), additional 20 evaluable subjects will be enrolled for the second 
stage. Similarly, for the cohort of advanced HCC subjects who have previously 
received immune checkpoint inhibitor treatment, enrollment of the second stage 
will initiate to have 30 evaluable subject in the cohort after 1 or more subjects in 
the first stage reaches response (according to RECIST 1.1) by image evaluation. 
Phase II Part 2 will expand the study cohort according to the safety and efficacy 
data obtained in Part 1. About 120 advanced HCC subjects who have progressed 
following immune checkpoint inhibitor treatment will be enrolled to further 
assess the safety and efficacy of the study treatment in the specific group of 
subjects. 
Subjects will continue to receive study treatments (MGD013 monotherapy or 
combination therapy) until disease progression, death or the occurrence of 
intolerable toxicity (whichever comes first). MGD013 will be used for at most 
48 cycles. If subjects do not have disease progression after 48 cycles, MGD013 
will be discontinued. Subjects of the combination therapy group may continue 
to take Brivanib Alaninate. 
Phase II study will assess the safety and efficacy of the study treatments, with 
BICR-assessed ORR according to RECIST 1.1 as the primary efficacy endpoint. 
Secondary efficacy endpoints will provide supporting data. 
Number of 
Subjects Planning 
to be Enrolled 
A total of 30 to 43 evaluable subjects, 158 subjects, and 120 subjects will be 
enrolled in Phase I, Phase II Part 1, and Phase II Part 2 respectively.  
Main Inclusion 
Criteria: 
1. 
Subjects who voluntarily sign the informed consent form (ICF); 
2. 
Male or female subjects who are aged 18-75 years old; 
3. 
Subjects with histologic, cytologic or clinical confirmed diagnosis of 
advanced HCC (Phase I could include intrahepatic cholangiocarcinoma or 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 9 of 106 
mixed hepatocellular-cholangiocarcinoma), and are not suitable for surgery 
or loco-regional therapy or have progressed following surgery and/or loco-
regional therapy; 
4. 
Subject who has at least one measurable lesion according to RECIST v1.1 
criteria. 
5. 
Phase I study: subjects who have previously received at least one line of 
systemic therapy, including immune checkpoint inhibitors, molecular 
targeted drugs or systematic chemotherapy, alone or in combination, and 
failed (progression confirmed by imaging) or were intolerant at the 
discretion of investigator; 
PhaseII：Advanced HCC cohort with subjects who have previously 
received immune checkpoint inhibitor treatment: subjects who have failed 
(progression confirmed by imaging) prior one line immune checkpoint 
inhibitor treatment, including anti-PD-1 antibody/anti-PD-L1 antibody and 
/ or anti-CTLA-4 antibody, and/or molecular targeted therapy or systematic 
chemotherapy (monotherapy or in combination); 
Phase II: Advanced HCC cohort with subjects who have not previously 
received immune checkpoint inhibitor treatment: subjects who have failed 
(progression confirmed by imaging) or were intolerant to (at the discretion 
of investigator) previous molecular targeted therapy or systematic 
chemotherapy, without receiving immune checkpoint inhibitor treatment 
(including anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 
antibody, and bispecific antibodies including the above targets). 
6. 
Previous anti-tumor therapy must be completed no less than 2 weeks prior 
to the study treatment and all adverse events related to previous treatment 
must have recovered to CTCAE Grade ≤1; if subjects who have received 
prior immune checkpoint inhibitors have immune-related endocrinopathy, 
it should be controlled with hormone replacement therapy. 
7. 
Phase I: Child-Pugh Class A; Phase II: Child-Pugh Class A or B with a 
score of ≤ 7; 
8. 
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; 
9. 
Subjects with life expectancy ≥12 weeks; 
10. Subjects with chronic HBV infection must have HBV-DNA <500 IU/ml, 
and have received at least 14 days of anti-HBV treatment (e.g. entecavir, 
tenofovir) prior to the initiation of study treatment and are willing to 
receive antiviral treatment throughout the study; Antiviral therapy is not 
required for patients with HCV infection and the elevation of their liver 
enzymes must not exceed the level of CTCAE Grade 1; 
11. Adequate vital organ function as shown below: 
(1) Blood system function (subjects must have not received blood 
transfusion or stimulating growth factors within 14 days prior to 
screening test): neutrophil count ≥1.5×109/L, platelet count ≥ 
75×109/L, hemoglobin ≥ 90 g/L; 
(2) Liver and kidney function (no albumin transfusion within 14 days 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 10 of 106 
prior to screening test): serum total bilirubin ≤ 2.5×ULN, serum 
albumin ≥ 29 g/L, ALT and AST ≤ 5×ULN; serum creatinine ≤
1.5×ULN or eGFR (Cockcroft-Gault formula) ≥ 60 ml/min; 
(3) Coagulation function: international normalized ratio (INR)≤2.3 or 
prothrombin time (PT) of ≤ 6 seconds above control; 
(4) Left ventricular ejection fraction (LVEF) ≥50% by two-dimensional 
echocardiography. 
12. Female subjects (except for females who have underwent surgical 
sterilization and those have been menopausal for more than one year) who 
are of childbearing potential are required to adopt a medically proven 
method for contraception (e.g. intrauterine contraception device, 
contraceptive pill or condom) throughout the study and up to 120 days 
after the last dose of investigational products; females who are of 
childbearing age and who do not underwent surgical sterilization must 
have negative serum or urine HCG tests within 7 days prior to enrollment; 
female subjects must not be breastfeeding; male subjects whose partners 
are of childbearing potential should use effective contraceptive methods 
throughout the study and up to 120 days after the last dose of 
investigational product. 
13. Subjects who are willing to provide oncological tissues (if applicable) for 
biomarker test. 
Exclusion criteria: 1. 
Subjects who have known fibrolamellar carcinoma of liver for phase I and 
subjects who have fibrolamellar carcinoma, mixed HCC- 
cholangiocarcinoma or cholangiocarcinoma for phase II; 
2. 
Subjects with brain metastasis or leptomeningeal metastasis confirmed by 
brain MRI during screening period; 
3. 
Subjects with a diagnosis of other malignant tumors within 5 years prior to 
first administration, except for skin basal cell carcinoma, skin squamous 
cell carcinoma and/or in situ cancer following radical resection; 
4. 
Subjects who had liver or other sites loco-regional treatment (including 
transcatheter arterial chemoembolization (TACE), transcatheter arterial 
embolization (TAE), hepatic artery infusion (HAI), local radiotherapy, 
radioembolization, radiofrequency ablation, cryoablation or percutaneous 
ethanol injection) , or who had major surgery of liver or other sites within 4 
weeks prior to first administration, or had minor surgical procedures (e.g. 
simple excision, tooth extraction) within one week prior to first 
administration, or had received palliative radiotherapy for bone metastasis 
within 2 weeks and radiotherapy-related toxicity ≥ CTCAE Grade 2. 
5. 
Subjects who have moderate or severe ascites (detected by B-ultrasound or 
CT), or require therapeutic abdominal paracentesis or drainage;  
6. 
Subjects with a history of hepatic encephalopathy; 
7. 
Subjects with a history of unhealed wounds or ulcers or bone fractures 
within 3 months prior to study enrollment; 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 11 of 106 
8. 
Subjects who plan to have or had allogenic organ or bone marrow 
transplantation; 
9. 
Subjects who are at increased risk of bleeding or have history of 
thrombosis: 
(1) Clinically significant bleeding within 3 months prior to screening or 
clear bleeding tendency; 
(2) Gastrointestinal hemorrhage within 6 months prior to screening or 
clear tendency of gastrointestinal hemorrhage; 
(3) Arterial/venous thromboembolic events within 6 months prior to 
screening, such as cerebrovascular accident (including transient 
ischemic attack), pulmonary embolism, etc.; 
(4) Require anticoagulation therapy with an agent such as warfarin or 
heparin; 
(5) Require chronic anti-platelet therapy (such as aspirin≥100 mg/day, 
clopidogrel, etc.); 
10. Subjects who have clinically significant cardiovascular diseases: 
(1) NYHA (New York Heart Association) stage 3 and 4 congestive heart 
failure; 
(2) Unstable angina pectoris or newly diagnosed angina pectoris or 
myocardial infarction within 12 months prior to screening; 
(3) Arrhythmias requiring medications other than β-blockers; 
(4) Valvular heart disease of ≥ CTCAE grade 2; 
(5) Hypertension inadequately controlled by drugs (systolic 
pressure >150 mmHg or diastolic pressure >90 mmHg); 
11. Subjects who have history of symptomatic pulmonary fibrosis, or have 
interstitial pneumonitis, pneumoconiosis, radiation pneumonitis, drug-
related pneumonitis, severe impairment of pulmonary function, or other 
suspicious pulmonary diseases that may interfere with drug-related 
pulmonary toxicity detection and treatment; 
12. Subjects who have suffered active bacterial or fungal infections requiring 
systemic treatment within 7 days prior to screening; or active tuberculosis; 
13. Subjects with active co-infection of Hepatitis B and C, confirmed by 
positive HBV surface antigen or HBV DNA and HCV RNA 
14. Subjects who have any active, known or suspected autoimmune disease; 
15. Subjects with a condition requiring systematic treatment with 
corticosteroids (>10 mg/day prednisone or equivalent) or other 
immunosuppressive drugs within 14 days before administration of the 
investigational drug. In the absence of active autoimmune diseases, 
inhalation or topical use of steroids (>10 mg/day prednisone or equivalent) 
is allowed; 
16. Other laboratory abnormalities: 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 12 of 106 
(1) Hyponatremia, hypokalemia or hypophosphatemia that have occurred 
before the first administration, and failed to restore to normal level 
after electrolyte supplementation therapy; 
(2) Confirmed diagnosis of thyroid dysfunction, which cannot be 
maintained within normal range following thyroid hormone 
replacement therapy; 
(3) Positive Human immunodeficiency virus (HIV) test; 
17. QTc interval >480 ms on two consecutive ECGs; 
18. Female subjects during pregnancy or lactation; female subjects of 
childbearing potential or male subjects who are not willing to use 
contraception or contraceptive measures during the study; 
19. Subjects who have previously received two lines and above tumor immune 
checkpiont inhibitor treatment, mainly including anti-PD-1, anti-PD-L1 
and anti-CTLA-4 antibodies, etc, or bispecific antibodies including the 
above targets, or received anti-LAG-3 antibody; whether subjects who 
have previously received other tumor immunotherapy can be enrolled 
should be determined by the sponsor; 
20. Known or suspected history of severe allergy to investigational drugs; 
21. Subjects who have received live attenuated vaccines or any investigational 
drugs that have not been marketed in China within 4 weeks prior to first 
administration; 
22. If subjects who have previously used immune checkpoint inhibitors (such 
as anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies) have the following 
drug-related adverse events, they will be not suitable for inclusion 
regardless of recovered or not: 
a) 
≥ Grade 3 eye-related adverse events 
b) 
Grade 4 abnormal liver function 
c) 
≥ Grade 3 neurotoxicity 
d) 
≥ Grade 3 colitis 
e) 
≥ Grade 3 renal toxicity 
f) 
≥ Grade 3 pneumonitis 
23. Subjects who are not suitable for inclusion as judged by the investigators. 
Investigational 
Drugs and Dosing 
Regimen 
Investigational Drugs: 
● 
Brivanib Alaninate: 200 mg, tablets, oral administration; 
● 
MGD013 injection, active ingredients: PD-1x LAG-3 bispecific, 
tetravalent diabody DART®, 300 mg/15 mL. 
Dosing Regimen: 
● 
MGD-013 is administered intravenously at a fixed dose according to 
subject’s dose group, regardless of body weight or body surface area, 
for 60 - 75 minutes once every other week; 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 13 of 106 
● 
In the combination therapy cohort, brivanib alaninate is given orally 
at a fixed dose according to subject’s dose group once daily at a fixed 
time, and can be taken with or without meals; 
● 
Both drugs are consecutively administered until disease progression, 
death or the occurrence of intolerable toxicity (whichever occurs 
first). However, MGD013 will be administered for at most 48 cycles. 
If subjects do not have disease progression after 48 cycles, MGD013 
will be discontinued. Subjects of the combination therapy group may 
continue with brivanib alaninate. 
Evaluation 
criteria 
Safety Assessment 
- 
Vital signs, physical examination, ECOG score; 
- 
The type, occurrence time and severity of adverse events (AEs) (CTCAE 5.0 
classification); 
- 
12-lead ECG, and echocardiography (as clinically indicated); 
- 
Laboratory tests 
● 
Hematology (complete blood count [CBC]) 
● 
Urinalysis 
● 
Blood biochemistry (liver and kidney function, blood glucose, 
electrolytes, amylase, lipase, etc.) 
● 
Coagulation 
● 
Thyroid function 
Efficacy Assessment 
Primary Efficacy Endpoint: 
Objective response rate (ORR) is the primary efficacy endpoint for both phase I 
and II, as assessed by investigator (Phase I) and Blinded Independent Central 
Review (BICR) (Phase II) according to RECIST 1.1 respectively. 
ORR is defined as the proportion of enrolled subjects whose best response is CR 
or PR. Subjects assessed as CR or PR initially are required to be confirmed at 
the interval of at least 4 weeks. 
Secondary Efficacy Endpoints: 
Phase I: irRECIST-based ORR. 
Phase II: secondary efficacy endpoints of phase II study include: 
BICR-assessed ORR according to irRECIST; Investigator-assessed ORRs 
according to RECIST 1.1 and irRECIST respectively; 
Disease control rate (DCR): defined as the proportion of enrolled subjects 
with best response of CR, PR or SD assessed using RECIST 1.1 and 
irRECIST criteria respectively. 
Time to tumor progression (TTP): defined as the time from the first 
administration to the time of radiographic disease progression under 
RECIST 1.1 and irRECIST criteria. Subjects without documented 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 14 of 106 
radiographic progression due to loss to follow-up or changing treatment 
regimen during follow-up will be censored on the last radiographic follow-
up date on which no disease progression is confirmed. 
Duration of response (DoR): defined as the time from radiographic response 
to disease progression or death in subjects whose best response is CR or PR. 
DoR is assessed with RECIST 1.1 and irRECIST criteria respectively 
Progression-free survival (PFS): defined as the time from the first dose to 
the date of tumor progression or death due to any cause. Disease progression 
is assessed using RECIST 1.1 and irRECIST criteria respectively. Subjects 
without documented radiographic progression or death during follow-up will 
be censored on the last follow-up date on which no disease progression is 
confirmed. For subjects without progression till the date of analysis, they 
will be censored on the last tumor assessment date. 
Overall survival (OS): defined as the time from first administration to death 
caused by any reason. Subjects who are alive during the follow-up or are lost 
to follow-up without documented death will be censored on their last known 
alive date. For subjects alive till the date of analysis, they will be censored 
on their last known alive date. 
Statistical Method Analysis Set 
Statistical analysis is performed using full analysis set (FAS), per-protocol set 
(PPS) and safety set (SS). 
FAS: it includes all subjects who have received at least one dose of the 
investigational drug and have measurable tumors at baseline. 
PPS: it includes subjects with at least one post-treatment imaging assessment of 
tumors, good compliance, and no serious violation or deviation against the study 
protocol in FAS population. 
SS: it includes subjects who have received at least one dose of the 
investigational drug and undergone safety assessment. 
Sample Size Determination 
During phase I dose escalation study of MGD013 monotherapy, the starting 
dose of MGD013 will be 120 mg Q2W in one subject which has been enrolled 
in the group. The subsequent dose groups will adopt traditional 3+3 dose 
escalation scheme , with 3 - 6 evaluable subjects in each group; during dose 
escalation study of combination therapy, the traditional 3+3 dose escalation 
scheme will be used, and it is expected to have 30 - 43 subjects in total in Phase 
I. 
There will be two cohorts in Phase II Part 1. Subjects who have previously 
received and not received immune checkpoint inhibitor treatment will be 
administered with MGD013 monotherapy or MGD013 in combination with 
brivanib alaninate. The SWOG two-stage design will be employed. 
 
 
 30 subjects are needed 
 There are two 
stages in this part. In the first stage, if response (according to RECIST 1.1 
criteria) is observed radiologically in 1 or more out of 15 evaluable subjects, the 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 15 of 106 
enrollment of second stage will be open and an additional of 15 evaluable 
subjects will be enrolled.
 
 
40 subjects are needed 
 
Similarly, there are 2 stages for the cohort. At least 
response of 3 out of 20 evaluable subjects at the first stage will support the 
decision to proceed to the second stage of subject accrual till there are 40 
evaluable subjects in this cohort. Each cohort will have 70 evaluable subjects. 
Considering 10% dropout rate, up to 158 subjects will be enrolled. 
According to safety and efficacy data of Phase II Part 1, a study treatment 
(MGD013 monotherapy or MGD013 in combination with brivanib alaninate) 
will be selected for Part 2 dose expansion in subjects who have previously 
received immune checkpoints inhibitor treatment. It is estimated to enroll 120 
subjects for further assessment of its efficacy and safety. 
Statistical Analysis Method 
Safety Analysis 
Safety analysis is performed in the SS population. Safety parameters include 
physical examination, vital signs, AEs and laboratory tests, ECG, etc. AEs will 
be coded using the most updated MedDRA System Organ Class and Preferred 
Term. 
The incidence and severity of AEs, dose-limiting toxicity (DLT, phase I study), 
AEs leading to withdrawal from study, AEs leading to drug discontinuation, 
AEs leading to death, and serious adverse events (SAEs)will be summarized. 
For laboratory parameters and ECG, the change during the study will be 
summarized by descriptive analysis. The normal and abnormal laboratory values 
before and after treatment will be summarized using a shift table based on the 
lab normal range. Listing of data will be also provided. Some specified 
parameters will be summarized descriptively per protocol. 
Efficacy Analysis 
FAS and PPS are both used for efficacy analysis, and of which, PPS is the main 
analysis set and FAS analysis can provide supporting evidence. 
Primary efficacy endpoints: ORR. Secondary endpoints are PFS, TTP, DCR, 
DoR and OS. 
For ORR, its point estimation and the p-value (1-sided) and corresponding 95% 
confidence interval (95% CI) of the single-arm test will be provided. For TTP, 
PFS and OS, Kaplan-Meier method is adopted to estimate survival function and 
draw survival curve. The median TTP, median PFS, total survival rate at 
specific time points (at 6, 9 and 12 months) and their corresponding 95% CIs 
will be provided. 
Study Visit Schedule and Assessments: See Table 1 
 

ZL-2301/MGD013 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 16 of 106 
Table 1 Clinical Study Flow Chart (Each cycle = 2 weeks) 
 
Screening Period 
Cycle 1 
Day 1 
Cycle 1 
Day 8 
Cycle 2 
Day 1 
Cycle 2 
Day 8 
Cycle 3 
Day 1 
Cycle 4 
Day 1 
Day 1 
of each 
cycle 
Day 1 of 
every two 
cycles 
Ever
y 8 
week
s 
End of 
Treatm
ent1 
(EOT) 
Safety 
Follo
w-up 
Follow-up 
after 
treatment 
Day 
D-28~0 
D-7~0 
D1 
D8 
D15 
D22 
D29±2d 
D43±2d 
±3d 
±3d 
±7d 
+7d 
30±7d 
Every 
60±7d 
weeks 
 
 
Week 1 
Day 1 
Week 2 
Day 1 
Week 3 
Day 1 
Week 4 
Day 1 
Week 5 
Day 1 
Week 7 
Day 1 
 
 
 
 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion 
Criteria 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
History of tumor 
treatment and other 
diseases 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Archival tumor 
tissue sample 
collection 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECOG performance 
status 
X 
 
X 
 
X 
 
X 
X 
X 
 
 
X 
 
 
Physical 
examination and 
body weight 
X 
 
X 
 
X 
 
X 
X 
X 
 
 
X 
X 
 
Vital signs 2 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
Two-dimensional 
echocardiography 
X 
 
 
Perform as clinically indicated 
 
 
12-Lead ECG 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
Adverse event 
evaluation3 
 
------------------------------------------------------------------------------ X ----------------------------------------------------------------------------- 
 
Evaluation of 
concomitant 
treatments 
 
----------------------------------------------------------------------------- X ------------------------------------------------------------------------------ 
 
HBV, HCV 
virological test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 

ZL-2301/MGD013 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 17 of 106 
 
Screening Period 
Cycle 1 
Day 1 
Cycle 1 
Day 8 
Cycle 2 
Day 1 
Cycle 2 
Day 8 
Cycle 3 
Day 1 
Cycle 4 
Day 1 
Day 1 
of each 
cycle 
Day 1 of 
every two 
cycles 
Ever
y 8 
week
s 
End of 
Treatm
ent1 
(EOT) 
Safety 
Follo
w-up 
Follow-up 
after 
treatment 
Day 
D-28~0 
D-7~0 
D1 
D8 
D15 
D22 
D29±2d 
D43±2d 
±3d 
±3d 
±7d 
+7d 
30±7d 
Every 
60±7d 
weeks 
 
 
Week 1 
Day 1 
Week 2 
Day 1 
Week 3 
Day 1 
Week 4 
Day 1 
Week 5 
Day 1 
Week 7 
Day 1 
 
 
 
 
 
 
HBV-DNA (when 
HBsAg is positive) 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
 
HCV-RNA (when 
HCV antibody is 
positive) 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Serology HIV 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematology 
 
X 
 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
 
Blood chemistry 
(liver and kidney 
function, fasting 
blood glucose, 
electrolytes, 
amylase, lipase) 
 
X 
 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
 
AFP test 
 
X 
 
 
 
 
 
 
 
 
X 
X 
 
 
Urinalysis 
 
X 
 
 
X 
 
X 
X 
X 
 
 
X 
 
 
Thyroid function 
 
X 
 
 
 
 
X 
 
 
X 
 
X 
 
 
Pregnancy test (if 
required) 
 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
Coagulation 
 
X 
 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
Biomarkers (Phase I 
and part 1 of Phase 
II)4 
 
 
Xa 
Xb 
Xc 
 
Xd 
 
 
 
 
 
 
 
Brain MRI scan5 
X 
 
 
Perform as clinically indicated 
 
 
Radiographic tumor 
assessment6 
X 
 
 
Every 8 weeks until disease progression 
 
 
Brivanib alaninate 
(combination 
treatment group) 
 
 
----------------------------------------------QD------------------------------------------------ 
 
 
 

ZL-2301/MGD013 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 18 of 106 
 
Screening Period 
Cycle 1 
Day 1 
Cycle 1 
Day 8 
Cycle 2 
Day 1 
Cycle 2 
Day 8 
Cycle 3 
Day 1 
Cycle 4 
Day 1 
Day 1 
of each 
cycle 
Day 1 of 
every two 
cycles 
Ever
y 8 
week
s 
End of 
Treatm
ent1 
(EOT) 
Safety 
Follo
w-up 
Follow-up 
after 
treatment 
Day 
D-28~0 
D-7~0 
D1 
D8 
D15 
D22 
D29±2d 
D43±2d 
±3d 
±3d 
±7d 
+7d 
30±7d 
Every 
60±7d 
weeks 
 
 
Week 1 
Day 1 
Week 2 
Day 1 
Week 3 
Day 1 
Week 4 
Day 1 
Week 5 
Day 1 
Week 7 
Day 1 
 
 
 
 
 
 
MGD013 
 
 
X 
 
X 
 
X 
X 
X 
 
 
 
 
 
Survival and 
subsequent 
antineoplastic 
therapy (Phase II 
study) 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
1. 
The end of treatment (EOT) visit is within 7 days after the last dose (or early withdrawal); if the corresponding examination was done within 7 days, it was not necessary to repeat the 
examination. 
2. 
Vital signs are only examined once at the visit in the screening period and that at EOT visit; on Cycle 1 Day 1, vital signs are examined at the following time points: prior to infusion of 
MGD013 (within 30 minutes prior to infusion), at 15 minutes (± 5 minutes), 30 minutes (± 5 minutes) after infusion, at the end of infusion (± 10 minutes), at 1 hour (± 10 minutes), 3 hours 
(± 10 minutes) after the completion of infusion. For subsequent visits vital signs are examined at the following time points: prior to infusion of MGD013 (within 30 minutes prior to infusion), 
at the end of infusion (± 10 minutes), at 1 hour (± 10 minutes) after the completion of infusion. Additional vital signs examination may be performed at other time points as clinically indicated. 
3. 
Adverse events will be recorded up to 30 days after the subject's treatment ends. 
4. 
Analysis and sampling of biomarkers: a. Serum cytokines, receptor occupancy [only in dose escalation study], cell subset and markers prior to administration of MGD013; b. serum cytokines, 
receptor occupancy [only in dose escalation study], cell subset and markers prior to administration; c. for analysis of serum cytokinesand receptor occupancy [only in dose escalation study], 
samples will be collected prior to administration of MGD013 and after the completion of infusion respectively; for analysis of cell subset and markers, samples will be collected prior to 
administration of MGD013; d. for analysis of serum cytokinesand receptor occupancy [only in dose escalation study], samples will be collected prior to administration of MGD013 and after 
the completion of infusion; for analysis of cell subset and markers, samples will be collected prior to administration of MGD013. In addition, for subjects with immune- and infusion-related 
reactions or cytokine release syndrome, additional sampling for analysis of serum cytokinesmay be performed. 
5. 
MRI can only be performed in subjects who are clinically suspected of central nervous system metastasis in the screening and subsequent periods. If the subject is contradicted to MRI, cranial 
CT can be performed. 
6. 
Radiographic tumor assessments (contrast-enhanced CT of the chest, enhanced CT/MRI of the abdomen and pelvis at baseline, and subsequent contrast-enhanced CT/MRI of the abdomen 
and pelvis and clinically indicated sites) will be performed prior to treatment (baseline) using the same radiologic imaging modalities and will be repeated every 8 weeks throughout the study, 
with contrast enhancement required if not medically contraindicated. Subjects who discontinued from the study due to study drug toxicity or for any reason other than unequivocal tumor 
progression continued to undergo tumor assessment every 8 weeks during survival follow-up until disease progression confirmed or death. Subjects radiologically assessed as CR or PR for 
the first time should undergo confirmation of efficacy at the interval of at least 4 weeks. 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 19 of 106 
Table of Abbreviations and Definitions of Terms 
Abbreviations and Special 
Terminology  
Interpretation 
AE 
Adverse Event 
AESI 
Adverse Events of Special Interest 
AFP 
α-fetoprotein 
ALT 
Alanine aminotransferase 
APTT 
Active partial thromboplastin time 
AST 
Aspartate aminotransferase 
BCLC 
Barcelona liver cancer staging 
BSC 
Best supportive treatment 
NMPA 
National Medical Products Administration 
Child-Pugh 
Liver function grading standard 
CR 
Completely released 
CRF 
Case Report Form 
CTCAE 
Common Terminology Criteria for Adverse 
Events 
DCR 
Disease control rate 
DDI 
Drug-Drug Interactions 
DLT 
Dose-limiting toxicity 
DoR 
Duration of tumor response 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
EMA 
European Medicines Agency 
FAS 
Full Analysis Set 
FDA 
Food and Drug Administration 
FGFR 
Fibroblast growth factor receptor 
GCP 
Good Clinical Practice 
GMP 
Good Manufacturing Practice 
HCC 
Primary Hepatocellular Carcinoma 
HBV 
Hepatitis B virus 
HCV 
Hepatitis C virus 
HIV 
Human Immunodeficiency Virus (HIV) 
HR 
Hazard ratio 
ICH 
International Conference on Harmonization of 
Technical Requirements for Registration of 
Pharmaceuticals for Human Use 
ICF 
Informed consent form 
IEC 
Independent ethics committee 
ICR 
Independent imaging center review 
irAEI 
Immune-related Adverse Events of Interest 
INR 
International Normalized Ratio 
LVEF 
Left ventricular ejection fraction 
mOS 
Median overall survival 
mPFS 
Median progression-free survival 
MedDRA 
Medical Dictionary for Regulatory Activities 
MRI 
Magnetic Resonance Imaging 
MTD 
Maximum Tolerated Dose 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 20 of 106 
ORR 
Objective Response Rate 
OS 
Total Survival 
PD 
Progressive Disease 
PPS 
Per Protocol Set 
PFS 
Progression-free survival 
PR 
Partial Response 
PDGFR 
Platelet-derived growth factor receptor 
RECIST 
Response evaluation criteria in solid tumors 
RP2D 
Recommended Phase II Dose 
Q2W 
Once every 2 weeks 
QD (qd) 
Once a day 
RPLS 
Reversible posterior leukoencephalopathy 
syndrome 
SAE 
Severe adverse event 
SD 
Stable disease 
TTP 
Time to tumor progression  
ULN 
Upper Limit of Normal 
Vss 
Apparent volume of distribution at steady state 
 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 21 of 106 
Table of Contents 
Summary of Changes in Protocol Amendment 1 ....................................................................... 2 
Protocol synopsis ....................................................................................................................... 4 
Table of Abbreviations and Definitions of Terms .................................................................... 19 
1. Introduction .......................................................................................................................... 25 
1.1 Study Background .............................................................................................................. 25 
1.1.1 Primary liver cancer ........................................................................................................ 25 
1.1.2 Treatment of Advanced Hepatocellular Carcinoma ........................................................ 25 
1.1.3 MGD013 ......................................................................................................................... 27 
1.1.4 Brivanib Alaninate .......................................................................................................... 29 
1.2 Study Rationale and Risk/Benefit Assessment .................................................................. 33 
1.2.1 Study Rationale ............................................................................................................... 33 
1.2.2 Dose Selection and Safety .............................................................................................. 34 
2. Study Objectives .................................................................................................................. 36 
2.1 Objectives of Phase I study ................................................................................................ 36 
2.1.1 Primary Objectives.......................................................................................................... 36 
2.1.2 Secondary Objectives...................................................................................................... 36 
2.1.3 Exploratory objective ...................................................................................................... 36 
2.2 Objectives of Phase II study (Part 1) ................................................................................. 36 
2.2.1 Primary Objectives.......................................................................................................... 36 
2.2.2 Secondary Objectives...................................................................................................... 36 
2.2.3 Exploratory objective ...................................................................................................... 36 
2.3 Objectives of Phase II study (Part two) ............................................................................. 37 
2.3.1 Primary Objectives.......................................................................................................... 37 
2.3.2 Secondary Objectives...................................................................................................... 37 
3. Study Design ........................................................................................................................ 38 
3.1 Overall Design ................................................................................................................... 38 
3.1.1 Study Design of Phase I Study........................................................................................ 38 
3.1.2 Dose Escalation Rules..................................................................................................... 39 
3.1.3 Dose-Limiting Toxicity (DLT) ........................................................................................ 41 
3.1.4 Design of Phase II study ................................................................................................. 43 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 22 of 106 
3.2 Discussion of Study Design ............................................................................................... 44 
3.2.1 Dose Selection for Phase I Study .................................................................................... 44 
3.2.2 Study Patient Population ................................................................................................. 45 
3.2.3 Selection of Efficacy Endpoints ...................................................................................... 46 
4. Study Population .................................................................................................................. 47 
4.1 Inclusion criteria ................................................................................................................ 47 
4.2 Exclusion criteria ............................................................................................................... 48 
4.3 Discontinuation of Subjects from Treatment ..................................................................... 50 
4.3.1 End of Treatment............................................................................................................. 50 
4.3.2 End of Study  ................................................................................................................. 51 
5. Study Treatment ................................................................................................................... 52 
5.1 Investigational Products ..................................................................................................... 52 
5.2 Infusion preparation ........................................................................................................... 52 
5.2.1 General Guidelines and Precautions ............................................................................... 52 
5.2.2 Study Drug Preparation and Administration ................................................................... 52 
5.3 Concomitant medication .................................................................................................... 53 
5.3.1 Prohibited Medications ................................................................................................... 53 
5.3.2 Drug-drug Interactions .................................................................................................... 53 
5.3.3 Best supportive care ........................................................................................................ 54 
5.4 Treatment Compliance ....................................................................................................... 54 
5.5 Investigational Drug Management ..................................................................................... 54 
5.5.1 Packaging and Storage .................................................................................................... 54 
5.5.2 Responsibilities for Reception, Storage, and Management of Investigational Drugs .... 55 
6. Visit Schedule and Assessments .......................................................................................... 56 
6.1 Study visits and assessments .............................................................................................. 56 
6.1.1 Screening Period (Day-28 to Day0) ................................................................................ 56 
6.1.2 Cycle 1 ............................................................................................................................ 57 
6.1.3 Cycle 2 ............................................................................................................................ 57 
6.1.4 Day 1 of subsequent cycles ............................................................................................. 58 
6.2 End of Study Treatment (completion of visits within 7 days after last dose of 
investigational drugs/withdrawal) .................................................................................... 59 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 23 of 106 
6.3 Safety Follow-up (30 days ± 7 days after end of study treatment) .................................... 59 
6.4 Post-Treatment Assessments (Subjects in phase II are not required to have visits in the 
study site) ......................................................................................................................... 60 
7. Study Endpoints ................................................................................................................... 61 
7.1 Safety Assessments ............................................................................................................ 61 
7.1.1 Laboratory Tests .............................................................................................................. 61 
7.1.2 Electrocardiogram Assessment ....................................................................................... 61 
7.1.3 Physical examination ...................................................................................................... 62 
7.1.4 Vital signs ........................................................................................................................ 62 
7.1.5 Eastern Cooperative Oncology Group (ECOG) Performance Status Score ................... 62 
7.1.6 Echocardiography ........................................................................................................... 62 
7.2 Efficacy assessments .......................................................................................................... 62 
7.2.1 Blinded independent central review (BICR) procedures ................................................ 63 
7.3 Exploratory study ............................................................................................................... 63 
8. Safety Monitoring, Reporting and Management ................................................................. 65 
8.1 Definition of adverse event (AE) ....................................................................................... 65 
8.2 Definition of Serious Adverse Event (SAE) ...................................................................... 65 
8.3 Collection, Record, Follow-up and Report of Adverse Events .......................................... 65 
8.3.1 Time Limit for Collection of Adverse Events ................................................................. 65 
8.3.2 Follow-up of Adverse Events.......................................................................................... 66 
8.3.3 Elements of Adverse Event Collection ........................................................................... 66 
8.3.4 Causality Assessment ...................................................................................................... 67 
8.3.5 Adverse Events based on Laboratory Examinations and Tests ....................................... 67 
8.3.6 Progressive Disease ........................................................................................................ 67 
8.3.7 Death ............................................................................................................................... 67 
8.3.8 SAE Reporting ................................................................................................................ 68 
8.3.9 Adverse Event of Special Interest (AESI) ...................................................................... 68 
8.3.10 Pregnancy ...................................................................................................................... 69 
8.3.11 Overdose ....................................................................................................................... 69 
8.4 Management of study drug-related adverse events ............................................................ 70 
8.4.1 Prevention and treatment of MGD013-related adverse events ....................................... 70 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 24 of 106 
8.4.2 Brivanib Alaninate-related Adverse Reactions ............................................................... 79 
8.4.3 Toxicity and Management of Combination Toxicity ...................................................... 80 
9. Statistical Analysis ............................................................................................................... 82 
9.1 Analysis Set ........................................................................................................................ 82 
9.2 Sample Size Determination................................................................................................ 82 
9.3 Statistical Analysis Method................................................................................................ 82 
9.3.1 Safety Analysis................................................................................................................ 82 
9.3.2 Efficacy Analysis ............................................................................................................ 83 
10. Clinical Trial Management ................................................................................................ 84 
10.1 Statement.......................................................................................................................... 84 
10.2 Ethical Considerations ..................................................................................................... 84 
10.3 Source Data Verification .................................................................................................. 84 
10.4 Quality Assurance and Auditing ...................................................................................... 84 
10.5 Informed consent form ..................................................................................................... 84 
10.6 Protocol Amendment ....................................................................................................... 85 
10.7 Case Report Form (CRF) ................................................................................................. 85 
10.8 Monitoring ....................................................................................................................... 85 
10.9 Confidentiality Agreement and Subject Privacy .............................................................. 85 
11. Publication of study protocol and results ........................................................................... 86 
12. Data Archival ..................................................................................................................... 87 
13. References .......................................................................................................................... 88 
14. Appendix ............................................................................................................................ 90 
Appendix A Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) 
Guideline .......................................................................................................................... 90 
Appendix B. Immune-Related RECIST Guidelines ................................................................ 98 
Appendix C. Barcelona Clinic Liver Cancer (BCLC) ........................................................... 105 
Appendix D. Child-Pugh Classification ................................................................................ 106 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 25 of 106 
1. Introduction 
1.1 Study Background 
1.1.1 Primary liver cancer 
Primary liver cancer (PLC) is the sixth most common cancer and the second leading cause of 
cancer-related death worldwide, mainly including hepatocellular carcinoma (HCC) arising 
from the cells of the liver and cholangicarcinoma from the cells of bile ducts. Other rare types 
include fibromellar carcinoma and angiosarcoma. Among them, hepatocellular carcinoma 
(HCC) is most commonly seen which accounts for 85-90% of primary liver cancers (PLCs). 
It is the fifth most common malignancy in men and the seventh in women worldwide. 
Primary hepatocellular carcinoma is the third leading cause of cancer-related death after lung 
and gastric cancer. Globally, it is estimated that there are 782,000 new cases of HCC and 
causing approximate 600,000 deaths each year. Important risk factors associated with HCC 
include: chronic viral hepatitis (hepatitis B and C, most commonly observed), aflatoxin 
intake, alcoholism, and nonalcoholic steatohepatitis (NASH)[1]. 
There is wide geographical variability in the incidence and etiology of primary hepatocellular 
carcinoma. Hepatocellular carcinoma is particularly prevalent in Asian countries as compared 
to Western countries. Of new HCC cases worldwide, 75% occurred in Asia with 50% in 
China each year. China had the highest number of new cases and deaths of liver cancer in the 
world, with about 394,000 new cases and 326,000 deaths annually. HCC is the second 
leading cause of cancer-related death following lung cancer in China. Hepatitis C, alcoholic 
liver disease, and nonalcoholic steatohepatitis are main causes of HCC in Western countries. 
In contrast, a majority of HCC cases in China are associated with chronic hepatitis B (more 
than 80%) [2]. 
Due to the insidious nature of the onset of liver cancer, more than 80% of HCC patients are 
diagnosed at advanced stage, thus precluding potentially curative treatment. Only 5 to 15% of 
patients with early stage HCC have the opportunity of surgical resection. But they still have a 
high recurrence rate (2-year recurrence rate of 62.4% to 77.8%). Therefore, the prognosis of 
advanced hepatocellular carcinoma is very poor globally, with a 5-year survival rate of only 
6.9% and a median overall survival of 11 months. The prognosis in Chinese patients is even 
worse [3]. 
Intrahepatic cholangiocarcinoma (ICC) is a rare malignant tumor which arises from the 
epithelial cells of intrahepatic bile ducts. The incidence of ICC is reported to be only about 
10% of primary liver cancers. Risk factors of ICC are similar to those of HCC. Besides, they 
also include primary sclerosing cholangitis and primary biliary cirrhosis. For non-resectable 
cases, the prognosis is very poor and overall mean duration of survival is 6-10 months[4]. 
1.1.2 Treatment of Advanced Hepatocellular Carcinoma 
For patients with unresectable or metastatic HCC, non-surgical systematic treatment is 
commonly used in clinical practice. Current systemic therapies for advanced hepatocellular 
carcinoma (HCC) in China mainly include anti-angiogenesis treatment targeting the vascular 
endothelial growth factor (VEGF) pathway, oxaliplatin-based systemic chemotherapy, and 
immunotherapy. 
Three VEGFR tyrosine kinase inhibitors (TKIs) are approved to treat HCC in China: 
sorafenib, lenvatinib, and regorafenib. Sorafenib and lenvatinib are approved as first-line 
treatment of advanced HCC. The global SHARP study[5] of sorafenib and the Asia-Pacific 
Oriental study[6] both showed that sorafenib prolonged overall survival as compared with 
placebo (median overall survival (mOS) 10.7 months vs. placebo 7.9 months, HR 0.69, P < 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 26 of 106 
0.001 in SHARP study; mOS 6.5 months vs.placebo 4.2 months, HR 0.68, P = 0.014 in 
Oriental study). However, the objective response rate (ORR) was relatively low, ranging from 
2% to 3%. A phase III clinical study of lenvatinib (REFLECT study)[7] enrolled 954 patients 
with unresectable HCC and demonstrated non-inferiority to sorafenib in the primary endpoint 
of OS (mOS 13.6 months vs. 12.3 months, HR 0.92, 95% CI 0.79-1.06) with an objective 
response rate (as assessed by RECIST 1.1) of 18.8% (6.5% for sorafenib). Regorafenib is 
approved as second-line treatment for HCC patients who have progressed after sorafenib. 
Results of a placebo-controlled, multinational phase III study (RESORCE study)[8] showed 
that treatment with regorafenib improved TTP (3.2 vs. 1.5 months, HR 0.44, P < 0.0001), 
ORR (mRECIST, 11% vs.4%, P = 0.0047) and DCR (65% vs. 36%, P < 0.0001), and 
prolonged survival (10.6 vs.7.8 months, HR 0.63, P < 0.0001) as compared with placebo in 
sorafenib-failed HCC patients. 
An open-label, randomized, controlled international multicenter phase III clinical study 
(EACH study) [9,10] included 371 patients with advanced HCC who were not suitable for 
surgery or local treatment, of which 75% were Chinese patients. The results showed that, 
comparing with Adriamycin alone, chemotherapy with FOLFOX4 regimen significantly 
prolonged mPFS (1.77 vs. 2.93 months, P < 0.001), improved ORR (2.67% vs.8.15%, P = 
0.02) and DCR (31.55% vs. 52.17%, P < 0.0001) ; analysis after further follow-up for 7 
months showed that OS continued to benefit in the FOLFOX4 group (6.47 vs.4.90 months, P 
= 0.04). In the sub-cohort of Chinese patients, mOS was significantly longer in the 
FOLFOX4 group (5.9 vs. 4.3 months, P = 0.0281), and mPFS, ORR, and DCR also showed a 
significant benefit. 
Recently, the introduction of immune checkpoint inhibitors, such as PD-1 or PD-L1 antibody, 
into the treatment of HCC has shown promising efficacy. Nivolumab was conditionally 
approved by the FDA as the second line treatment of HCC. The CheckMate-040 study, which 
is a phase I/II open-label, multicenter, single-arm clinical study[11], indicated that the ORR 
(according to RECIST 1.1) of nivolumab in second-line HCC cohort (N = 145) was 14%, the 
12-month overall survival rate was 60%, and the 18-month overall survival rate was 44%; the 
ORR in first-line cohort (N = 80) was 20%, and the 12-month and 18-month overall survival 
rate was 73% and 57% respectively. Pembrolizumab was also conditionally approved by the 
US FDA as the second-line treatment of HCC based on data from Keynote-224[12], a phase II 
nonrandomized, international multicenter, open-label clinical study. The ORR (as assessed by 
RECIST1.1) of Pembrolizumab in second-line HCC cohort (N = 104) was 17% and the 12-
month overall survival rate was 54%. Currently these two drugs have not been approved for 
the treatment of HCC in China. 
Patients with advanced ICCs who are unresectable or have progressed following loco-
regional therapy are usually treated by chemotherapy agents, such as 5-fluorouracil with 
leucovorin, gemcitabine as a single agent, or gemcitabine plus cisplatin, irinotecan, or 
capecitabine. The preliminary efficacy has been demonstrated by clinical studies of immune 
checkpoint inhibitors in ICC patients which are ongoing. Of 24 biliary tract neoplasms with 
PD-L1 expression ≥ 1% in the basket study KEYNOTE-028 of pembrolizumab[13], 4 
patients (17%, including 3 patients with bile duct carcinoma and 1 patient with carcinoma of 
gallbladder) reached partial response (PR) and 4 patients (17%) reached stable disease. It has 
been reported that 5 - 10% of patients with bile duct carcinoma have DNA mismatch-repair 
(MMR) deficiency. A study of pembrolizumab in tumor patients with MMR deficiency 
indicated[14] that 25% patients (1/4) with bile duct carcinoma reached partial response (PR) 
and the remaining 3 patients reached stable disease (SD), with a disease control rate (DCR) of 
100%. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 27 of 106 
Although systemic treatments with VEGFR TKIs or oxaliplatin-based chemotherapy can 
prolong the overall survival of patients with advanced HCC, the objective response rate to 
these therapies is relatively low, and the survival benefit is also limited. The available options 
for advanced ICCs are limited and the prognosis is very poor. Therefore, there is still great 
unsatisfied medical need in patients with these two types of advanced liver cancer. The 
immune checkpoint inhibitors (anti PD-1/PD-L1 antibody) are expected to have better 
efficacy in both advanced HCCs and ICCs, but current data are limited given relevant studies 
are still ongoing. There is still no effective treatment or relevant study in patients who have 
progressed following immune checkpoint inhibitor treatment. 
1.1.3 MGD013 
MGD013, developed by MacroGenics (US), is a humanized PD-1 + LAG-3 bispecific, 
tetravalent diabody DART® molecule consisting of Fc domains, engineered as a hinge-
stabilized IgG4 molecule and is designed to concomitantly bind PD-1 and LAG-3. Zai Lab 
obtained the exclusive right of research & development, production and sales of MGD013 in 
Greater China in December 2018. 
1.1.3.1 Preclinical Studies 
1.1.3.1.1 Pharmacology 
In vitro, MGD013 bound with high affinity to human and cynomolgus monkey PD-1- and 
LAG-3-expressing cells. For human PD-1-expressing cells, equilibrium dissociation constant 
(KD) was 0.9 nM; for cynomolgus monkey PD-1-expressing cells, KD was 7.5 nM. In 
addition, KD was 0.022 nM for human LAG-3-expressing cells and 0.190 nM for cynomolgus 
monkey LAG-3-expressing cells. FACS analysis showed a dose-dependent binding of 
MGD013 to human peripheral blood mononuclear cells (PBMCs), human T cells (and other 
immune cell populations), human PD-1+ NS0 Cells and human LAG-3+ NS0 Cells on 
modified cells and PBMCs of cynomolgus monkeys. When stimulating PBMCs with 
staphylococcal enterotoxin B (SEB) to induce PD-1 and LAG-3 genes expression, binding of 
MGD013 to human and non-human primate PBMCs was enhanced. As its specific binding 
characteristics, MGD013 can block PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) 
interactions. Co-culture reporter gene assay system indicated that MGD013 also directly 
blocked the PD-1/PD-L1 axis between cell lines, which was measured by enhanced T cell 
receptor (TCR) -mediated NFAT-driven luciferase signaling by the PD-1 expressing cell line. 
In addition, MGD013 can enhance human PBMC stimulated by SEB or memory T cells 
stimulated by tetanus toxoid (TTd) to secret interferon-γ (IFN-γ), which is beyond that 
observed with the combination of nivolumab and relatlimab (anti-LAG-3 monoclonal 
antibody [mAb]) replicas. These studies showed that MGD013 has the functional activity of 
intervening with PD-1/PD-L1/L2 and LAG-3/MHC-II inhibitory signal transduction pathway. 
Besides, binding characteristics of MGD013 are equal to nivolumab and relatlimab replicas. 
The functional characteristics of MGD013 are beyond those of the combination of nivolumab 
and relatlimab replicas, indicating that MGD013 can provide an additional effect over the 
antibody combination. Nivolumab and relatlimab replicas are IgG4κ molecules constructed 
based on public sequence by MacroGenics (MG). 
1.1.3.1.2 Toxicology 
The cynomolgus monkey was selected as the most appropriate animal model for nonclinical 
safety evaluation of MGD013 given the sequency homology of extracellular domains of 
cynomolgus monkey and human PD-1 and LAG-3 (96% and 92% respectively) and the 
ability of MGD013 to bind to both PD-1 and LAG-3 in humans and monkeys with similar 
affinity, and bind to PBMC in humans and monkeys following SEB stimulation to PD-1. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 28 of 106 
MacroGenics (MG) conducted single-dose and repeat-dose toxicology studies in cynomolgus 
monkey. MGD013 was administered at a dose range of 0 - 150 mg/kg by 1-hour intravenous 
infusion. They were well tolerated and there were no premature deaths. MGD013 did not 
induce the increase of IFN γ, IL 2, IL 4, IL 5 or TNF α levels in serum. Only transient 
increase in IL6 was observed. Occupancy of MGD013 receptor on PD-1+ circulating T cells 
occurred. MGD013-related changes were only observed at the dose level of 150 mg/kg within 
23 - 71 hours after infusion, that is, a transient decrease in circulating immune cells followed 
by increasing. Sporadic vomiting, and watery and/or green feces were observed clinically in 
some males at ≥ 40 mg/kg/dose and in some females at ≥ 100 mg/kg/dose; mild 
mononuclear cell infiltrates were microscopically observed in several organs of males at ≥ 
10 mg/kg/dose and females at ≥ 40 mg/kg/dose at the end of the dosing phase, and showed 
a trend towards reversibility at the end of a 10-week recovery. 
Please refer to the latest MGD013 Investigator’s Brochure for more details. 
1.1.3.2 Clinical Studies 
At present, the phase I, first-in-human study of CP MGD013-01 is ongoing in patients with 
unresectable or metastatic neoplasms. This trial will characterize safety, tolerability, PK, 
pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of MGD013 
administered intravenously. 
As of November 11, 2018, the data cut-off date, a total of 36 patients with different types of 
solid tumors received MGD013 treatment ranging from 1 mg - 1200 mg Q2W in the dose 
escalation period. Subjects at each dose level are as follows: 1 patient at 1 mg, 1 patient at 3 
mg, 4 patients at 10 mg, 5 patients at 30 mg, 4 patients at 120 mg, 9 patients at 400 mg, 8 
patients at 800 mg and 4 patients at 1,200 mg. More patients were enrolled in the dose 
cohorts of 400 mg and 800 mg to obtain more data. 
Of 36 patients treated with MGD013 in the dose escalation period, 33 patients (91.7%) 
experienced at least one adverse event (AE), irrespective of the causality. The most 
commonly reported AEs in ≥ 10% patients included diarrhea (n = 8 [22.2%]), lassitude and 
nausea (n = 7 [19.4%] each), infusion-related reaction and fever (n = 6 [16.7%] each); 
abdominal pain, diarrhea, vomiting, coldness, dyspnea, joint pain and back pain (n = 5 
[13.9%] each); blood creatinine increased, hyponatremia, headache, cough, rash and itching 
(n = 4 [11.1%] each). 
Most treatment-related AEs were mild to moderate (that is, grade 1 or 2). However, of 36 
patients (19.4%) treated with MGD013 in the dose escalation period, 7 experienced at least 
one grade 3 treatment-related AE. These events included infusion-related reaction (n = 2 
[5.6%]), diarrhea, vomiting, lassitude, immune-mediated hepatitis, blood bilirubin increased, 
transaminases increased, hypoadrenalism, hypotension, colitis, hypophosphatemia, arthritis 
and myalgia (n = 1 [2.8%] each). No grade 4 or 5 treatment-related AEs occurred. 
Of 36 patients treated with MGD013 in the dose escalation period, only 8 (22.2%) 
experienced serious adverse events (SAEs). Four (11.1%) experienced treatment-related 
SAEs, including: immune-mediated hepatitis (n = 1, 1,200 mg); colitis (n = 1,800 mg); 
hypoadrenalism with hypotension (n = 1,400 mg) and ALT increased, blood bilirubin 
increased and hypophosphatemia (n = 1,400 mg). The SAEs which were considered unrelated 
to MGD013 included urinary tract infection, dyspnea, small intestine obstruction and lung 
hemorrhage. They were considered to be related to patients’ underlying malignant tumor or 
concomitant disease. 
Please refer to the latest MGD013 Investigator’s Brochure for more details. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 29 of 106 
MGD013 showed anti‑tumor effects and was generally well tolerated in the dose escalation 
period. Of the first 3 patients in the 1,200 mg dose cohort, 1 had an SAE and immune-
mediated hepatitis meeting DLT criteria; according to 3+3 principle, 3 more patients were 
enrolled at the dose level and completed DLT evaluation period, without new DLTs. It did not 
reach the MTD (1,600 mg specified in the protocol), which would not be adopted by 
MacroGenics. Therefore, the cohort of 1,200 mg became the maximum dose level in the 
study CP-MGD013-01. While evaluating the dose level of 1,200 mg in the dose escalation 
period, MacroGenics will further evaluate 600 mg Q2W in the dose expansion period. The 
decision was made on the basis of clinical, PK data and receptor occupancy. 
1.1.4 Brivanib Alaninate 
Brivanib is a novel small molecule tyrosine kinase inhibitor (TKI) of the vascular endothelial 
growth factor (VEGF) and fibroblast growth factor (FGF) receptor families. Brivanib 
alaninate (also known as ZL-2301) is the L-alanine ester prodrug of brivanib. This product is 
licensed by Zai Lab (Shanghai) Co., Ltd. (abbreviation: Zai Lab) from Bristol-Myers Squibb 
Company (BMS). Zai Lab has the exclusive right to develop, manufacture and market the 
product in China. At present, this product is proposed to be an oral small-molecule targeted 
drug which is being developed alone or in combination with other agents for the treatment of 
malignant tumours (including HCC). 
1.1.4.1 Summary of Preclinical Studies 
1.1.4.1.1 Pharmacology 
In vitro, brivanib alaninate inhibited the proliferation of human umbilical vein endothelial 
cells (HUVECs) when stimulated with VEGF and basic FGF (bFGF), respectively. 
In vivo, both brivanib alaninate and the active metabolite BMS540215 exhibited a broad 
spectrum of antitumor activity, with cytostatic effects observed in all human tumor models 
tested. In addition, complete tumor suppression was seen in advanced tumor xenograft 
models in HCC subjects. 
1.1.4.1.2 Pharmacokinetics 
Nonclinical pharmacokinetic (PK) and metabolic studies in mice, rats, dogs, and monkeys 
have shown that brivanib alaninate is rapidly converted to Brivanib (BMS-540215) by 
hydrolysis. Bioavailability of BMS-540215 following oral administration of brivanib 
alaninate ranged from 52% to 97% in mice, rats, dogs, and monkeys. BMS-540215 has the 
following nonclinical PK properties: 
● 
High serum protein-binding rate 
● 
Moderate extravascular distribution 
● 
Low to moderate systemic clearance in each animal species studied 
● 
Metabolized by oxidation (mainly by CYP3A4) and conjugation pathways 
● 
Moderate inhibition of CYP3A4, CYP2C8, CYP2C9 and P-glycoprotein 
● 
Very little potential to induce CYP3A4, CYP1A2 and CYP2B6 
1.1.4.1.3 Toxicology 
Single- and multiple-dose toxicity studies have been conducted in multiple animal species to 
evaluate the nonclinical toxicity of brivanib alaninate. Dose increase toxicity studies with 
brivanib alaninate in rodents (rats and mice) showed that 400 mg/kg was the highest dose at 
which a single oral dose was non-lethal, while single doses ≥ 800 mg/kg were lethal. 
In the 30-day toxicology study, the no-observed-adverse-effect level (NOAEL) was 60 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 30 of 106 
mg/kg/day in rats (mean AUC 13 to 21 μg/h/mL) and 9 mg/kg/day in monkeys (mean AUC 7 
to 12 μg/h/mL). In monkeys, fatal gastrointestinal toxicity and irreversible vascular and 
skeletal toxicity were observed at a dose of 45 mg/kg/day (mean AUC ≥ 70 μg/h/mL). 
In a 6-month oral toxicity study in rats, brivanib alaninate (mean AUC ≥ 3.63 μg/h/mL) 
caused dose-related, partially reversible cardiac valve changes. Other reversible (e.g., after a 
30-day recovery period) toxicological findings were related to bone and teeth, hematopoietic 
system, blood vessels, coagulation system, and gastrointestinal tract. 
In a 12-month oral toxicity study in monkeys, slight to mild increases in ALT levels and 
microscopic changes in the ovaries were observed at all dose levels of brivanib alaninate. At 
doses ≥ 20 mg/kg/day (mean AUC ≥ 45 μg/h/mL), changes in the femur and teeth, and 
reversible decreases in heart rate in male animals were observed, and no effect of the drug on 
cardiac repolarization was found on the electrocardiogram. In addition, no changes in cardiac 
biomarkers or histopathological changes in the heart valves were observed. 
Direct genotoxicity was not observed with brivanib alaninate. 
1.1.4.2 Summary of Clinical Studies 
1.1.4.2.1 Clinical Pharmacokinetics 
After oral administration of brivanib alaninate, at least 86% was absorbed and rapidly 
converted to brivanib (BMS-540215, the main active circulating moiety found in human 
plasma). 
Two phase 1 studies (Study CA182001, CA182002) investigated PK profile of brivanib 
alaninate and BMS-540215 following single dose (dose ranging from 15 to 1200 mg) in 
healthy subjects and following both single and multiple dosing (dose ranging from 180 to 
1000 mg/day) in cancer subjects. Across the dose range, PK parameters were linear with 
AUC increased proportionally to dose. The mean terminal half-life of BMS-540215 was 12 to 
16 hours. The overall 24-hour steady-state drug exposure at 400 mg BID was similar to that 
at 800 mg QD, but Cmax was lower as expected. 
The extent of absorption, metabolism, and clearance of [14C] -labeled brivanib alaninate after 
a single oral dose was evaluated in subjects with cancer. Absorption, metabolism and 
clearance degree of brivanib alaninate after single-dose oral administration in 4 patients with 
advanced cancer Most radioactivity (82%) was recovered in feces, while 12% was recovered 
in urine as metabolites. No pro-drug (brivanib alaninate) was detected in feces, plasma or 
urine. 
Brivanib is primarily metabolized in the liver into several inactive metabolites through 
several metabolic pathways with minimal renal excretion. Population PK analyses indicated 
that there was no effect of race, age and gender on brivanib PK. Five drug-drug interactions 
studies performed in humans demonstrated that brivanib can be safely co-administered 
without dose adjustments with CYP3A4 substrates, with CYP2C8 substrates, with CYP3A4 
inhibitors, and with P-gp substrates. There was no effect of a high-fat meal on PK parameters 
of brivanib alaninate. 
A phase II study comparing PK, pharmacodynamic and safety profiles between two dosing 
regimens: 800 mg once daily and 400 mg twice daily in Chinese HCC patients is ongoing. 
The preliminary results showed no significant difference in the exposure between the two 
dosing regimens. 
Sixty-eight cancer patients in a Phase I dose escalation study (CA182002) were treated with 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 31 of 106 
brivanib alaninate. In the first part of the study, 18 patients received brivanib alaninate at 
doses of 180, 320, 600, 800, or 1,000 mg once daily. Two DLTs (mental disorder and grade 3 
fatigue) occurred in the 1,000 mg group. The DLT in the 800 mg group was mild. Therefore, 
800 mg daily was established as the maximum tolerated dose (MTD) of brivanib alaninate. In 
the second part (pharmacodynamic study), dynamic contrast-enhanced magnetic resonance 
imaging (MRI) revealed a significant reduction in the permeability and vascularity of the 
tumor in the continuous 800 mg, once daily, or 400 mg, twice daily groups. Therefore, 800 
mg daily was considered as the recommended dose for further clinical trials. 
1.1.4.2.2 Efficacy 
Two phase II studies and four phase III clinical studies of brivanib alaninate have been 
conducted in patients with advanced HCC globally. Of these, BRISK-PS and BRISK-FL are 
main completed Phase III studies. 
BRISK-FL was a multicenter, randomized, double-blind controlled study designed to 
compare the efficacy of brivanib alaninate and sorafenib as first-line treatment in patients 
with unresectable HCC. A total of 1,155 patients were recruited and randomized 1:1 to 
brivanib- or sorafenib-group. The study did not meet its primary objective of demonstrating 
non-inferiority in OS for brivanib alaninate compared to sorafenib (median overall survival 
was 9.5 months for brivanib alaninate and 9.9 months for sorafenib). The upper limit of 95% 
confidence interval (CI) around the hazard ratio (HR) didn't reached the preset non-inferiority 
boundary of 1.08 (HR: 1.06, 95% CI: 0.93 - 1.22, P=0.3730). In addition, there was no 
statistically significant difference in the median time to progression (TTP, 4.2 month vs 4.1 
months, P = 0.85), objective response rate (ORR, 12% vs 9%, P = 0.057) and disease control 
rate (DCR, 66% vs 65%, P= 0.87) between the two groups. Data of TTP, ORR and DCR 
showed that the antitumor activity of brivanib alaninate was similar to that of sorafenib. 
BRISK-PS is a multicenter, randomized, double-blind, placebo-controlled study comparing 
the efficacy of brivanib alaninate and placebo as second-line treatment of unresectable HCC. 
A total of 395 patients were randomized in a 2:1 ratio to the brivanib alaninate group (n = 
263) and the placebo group (n = 132). Compared with the placebo group, brivanib alaninate 
subjects showed improvement in the following response-related secondary endpoints: disease 
control rate (DCR) (71.2% vs 9.1%, P < 0.0001), ORR: 11.5% vs 1.9%, P = 0.0032, median 
time to progression (TTP): 4.2 months vs 2.7 months, P = 0.0001. However, it had no 
statistically significant difference in median OS between the two groups (9.4 months vs 8.2 
months, P =0.3307). Although statistical analysis indicated that there was significant 
improvement in secondary endpoints, there was no statistically significant difference in the 
primary endpoint between the two groups. It is noteworthy that the proportion of patients 
with vascular invasion was higher in the brivanib alaninate-group (31%) vs 18% in placebo 
group. This imbalance in baseline disease characteristics may have confounded the results. 
A total of 90 second-line HCC patients are enrolled in the ongoing phase II clinical study in 
China. As of June 2018, the interim analysis showed similar antitumor activity of brivanib 
alaninate among Chinese patients as compared with western patients, with the ORR of 8.3% 
and the median time to tumor progression (TTP) of 4.2 months in the 800 mg QD dose group 
(N = 36). 
1.1.4.2.3 Safety 
As of February 2019, a total of 2741 subjects (including 185 healthy subjects) have been 
treated with brivanib alaninate. A total of 14 Phase I studies, 2 Phase II studies, and 4 Phase 
III HCC studies have been completed, and 1 Phase II study is ongoing in China. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 32 of 106 
As a potent VEGFR inhibitor, the safety profile of brivanib alaninate reflects both class 
effects associated with VEGF pathway inhibition as well as AEs that are more specific to 
brivanib alaninate. Cumulatively calculated across all studies, the most frequently reported 
adverse events (> 25%) of any grade were: fatigue (54%), diarrhea (44%), anorexia (39%), 
nausea (35%), and vomiting (32%). The most commonly reported grade 3/4 adverse events 
(≥ 5%) across all studies were: fatigue (16%), ALT increased (9%), AST increased (7%), 
hypertension (5%), abdominal pain (5%), and diarrhea (5%). 
Important identified risks (known class effect of compounds targeting the VEGF signaling 
pathway or identified risk in clinical studies) for Brivanib Alaninate include hypertension, 
reversible posterior leukoencephalopathy syndrome (RPLS), hepatic events, hyponatremia, 
hypothyroidism, proteinuria, and arterial thrombotic events. Potential risks based on the 
mechanism of action of compounds targeting the VEGF signaling pathway or the safety 
profile of other VEGF inhibitors include: bleeding, venous thrombotic events, left ventricular 
dysfunction, gastrointestinal perforation, and impaired wound healing. (See Investigator's 
Brochure for a detailed list of clinical safety information.) 
The important identified risks in clinical studies with brivanib alaninate are as follows: 
Hepatic Events 
The most common hepatic events were laboratory test abnormalities in liver enzymes (e.g. 
AST, ALT) and bilirubin. Since a majority of subjects treated with brivanib alaninate were 
reported with elevated liver enzymes or bilirubin (≥ CTCAE Grade 1), liver function should 
be monitored regularly throughout the study and dose interruption or reduction should be 
considered if abnormalities ≥ CTCAE Grade 3 occur. 
As indicated by phase III studies in HCC patients, clinically important events of hepatic 
encephalopathy (4.6% vs.1.5%), hepatic failure (3.1% vs.1.5%), and acute hepatic failure 
(0.4% vs.1.5%), though slightly more common for brivanib alaninate than placebo, occurred 
infrequently. 
Hypothyroidism 
Hypothyroidism is a known event and risk in drugs with an anti-VEGFR inhibitory 
mechanism of action. In phase III studies of brivanib alaninate, hypothyroidism (all grades) 
was more commonly observed in the brivanib alaninate group than control group as indicated 
by reported AEs and TSH measurements > upper limit of the normal range; Grade 3/4 
hypothyroidism events were infrequent (≤1%), and were rarely serious (< 1%), or required 
investigational drug discontinuation (< 1%). 
Hyponatremia 
Approximately one third of subjects treated with brivanib alaninate were reported with 
hyponatremia ≥ CTCAE Grade 1. CTCAE Grade 4 hyponatremia (Na < 120 mEq/L) 
occurred in 4% of subjects. The severity of hyponatremia is related to the degree of hepatic 
impairment in patients with cirrhosis. 
Proteinuria 
Proteinuria is a known class-effect of compounds targeting the VEGF signaling pathway. In 
phase III studies, the incidence of proteinuria was around 10% to 31% in the brivanib 
alaninate group, but few events (< 1%) were serious or led to investigational drug 
discontinuation. 
Hypertension 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 33 of 106 
Hypertension is a relatively common adverse event and was observed in 24% of subjects 
treated with brivanib alaninate. In addition, there is evidence of dose-effect, with 
hypertension reported in 21% of subjects taking 320 mg QD, 32% of subjects taking 800 mg 
QD, and 75% of subjects taking 1000 mg QD in clinical studies. Hypertension can be 
managed and treated by concomitant administration of antihypertensive drugs, dose 
interruption, and/or dose reduction. Through the management of hypertension, serious events 
of hypertension or discontinued cases from studies due to this AE were infrequently reported. 
Reversible posterior leukoencephalopathy syndrome (RPLS) 
Reversible Posterior Leukoencephalopathy Syndrome (RPLS) is a syndrome characterized by 
headache, confusion, seizures and visual loss. It manifests as patchy brain tissue edema on 
brain MRI, and the symptoms tend to be self-limiting. Two SAEs of Grade 3 RPLS were 
reported during studies of brivanib alaninate, both of which were considered to be related to 
investigational drug, and 1 subject discontinued due to the event. 
Arterial thrombotic events (ATEs) 
Thromboembolic events are a known risk for drugs with anti-VEGFR mechanisms of action. 
Most ATEs in the HCC studies were reported as SAEs, most were considered related to study 
drug, and most subjects discontinued due to these events. The incidence of ATE was 
numerically higher in the brivanib alaninate group than the placebo group (5 subjects, 1.9%; 
compared to 1 subject in the placebo group, 0.8%). 
1.2 Study Rationale and Risk/Benefit Assessment 
1.2.1 Study Rationale 
Although a variety of targeted anti-angiogenic drugs have been currently approved for the 
treatment of advanced HCC in China, the response rate of these drugs is relatively low and 
the prolongation of survival is limited. The available options for advanced ICCs are limited 
and the prognosis is very poor. The immune checkpoint inhibitors (anti PD-1/PD-L1 
antibody) are expected to have better efficacy, but current data are limited given relevant 
studies are still ongoing. There is still no effective treatment or relevant study in patients who 
have progressed following immune checkpoint inhibitor treatment. Therefore, huge unmet 
medical demand for treatment of advanced liver cancer exists, and it is urgent to develop new 
treatments to effectively prolong patients’ survival. 
As an immune checkpoint molecule different from PD-1, LAG-3 also has 
immunosuppressive action[15]. Blockade of PD-1 and LAG-3 in animal tumor models 
enhanced antitumor immunity[16,17] via distinct, nonredundant signaling pathways that 
fostered the accumulation of functionally competent CD8+ T cells in mice. Specifically, dual 
targeting of PD-1 and LAG-3 may help reverse effector cell exhaustion, and increase the 
effectiveness of immunotherapy compared with that with single agents alone. LAG-3 positive 
tumor-infiltrating lymphocytes (TILs) were detected in different types of cancers in 
preclinical studies[18]. Internal data of Macrogenics indicated that LAG-3 was expressed in 
100% (18/18) HCC samples detected through IHC, where 83.3% (15/18) were intermediate 
or high expression (intermediate expression is defined as 5 - 15 LAG-3 positive lymphocytes 
under 40X field of a microscope; high expression is defined over 15 LAG-3 positive 
lymphocytes), indicating LAG-3 immune inhibitory pathways may play an important role in 
hepatocellular carcinoma. 
In the dose escalation period of the ongoing phase I, first-in-human study (CP MGD013-01) 
of MGD013 in patients with advanced neoplasms by Macrogenics, anti-tumor activity was 
observed in patients with triple negative breast cancer, pleural mesothelioma and gastric 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 34 of 106 
cancer. One gastric cancer patient has progressed after receiving multiple lines of antitumor 
treatment including standard chemotherapy and nivolumab. Target lesions of the patient 
shrank by 24% at the end of the first cycle of treatment, by 76% at the end of the second 
cycle of treatment. The patient reached confirmed partial response, and continued the 
treatment. This preliminary revealed that MGD013 had antitumor effect and may be effective 
in cancer patients who failed prior immune checkpoint inhibitor treatment. 
In recent years, except anti PD-1/PD-L1 antibody monotherapy, the combination of immune 
checkpoint inhibitors and anti‑angiogenic agents has shown synergy in anti-tumor effect in a 
growing number of preclinical and clinical studies. In the tumor microenvironment (TME), 
elevated VEGF levels induce tumor-associated immunosuppression through the following 
mechanisms: 1) increased level of VEGF directly inhibits the migration, proliferation, and 
effector function of cytotoxic T lymphocytes (CTL); 2) VEGF inhibits the maturation and 
antigen presentation of dendritic cells, thus hindering the activation of T cells and T-cell-
mediated anti-tumor immunity; and 3) high levels of VEGF promote the recruitment and 
proliferation of immunosuppressive cells, including Treg cells, myeloid-derived suppressor 
cells (MDSCs), and M2-type tumor-associated macrophages (M2-like TAMs). 4) VEGF 
facilitates abnormal angiogenesis in tumors, leading to hypoxia and low pH in the tumor 
microenvironment, which further promotes local and systemic immunosuppression. 
Therefore, VEGF inhibitors can improve the immune microenvironment in tumors by 
inhibiting the above effects, being indicated by the normalization of tumor blood vessels, 
decreased number of abnormal blood vessels, and increased tumor-infiltrating lymphocytes 
(TIL), which in turn enhance the antitumor effect of immune checkpoint inhibitors[19]. 
This theory has been preliminarily verified in a number of clinical studies. The combination 
of VEGFR TKI and immune checkpoint inhibitor PD-1/PD-L1 antibody in clinical trials of 
advanced HCC has shown better efficacy than monotherapy. A phase Ib clinical study 
presented at the ESMO meeting in 2018 (NCT02715531) showed that the ORR (according to 
RECIST 1.1) of PD-L1 antibody atezolizumab in combination with a VEGF antibody 
bevacizumab as first-line HCC treatment (N = 68) was 34%, and the 6-month progression-
free survival (PFS) rate was 71%. Other similar studies are being conducted both globally 
and in China, such as the study of SHR-1210 in combination with apatinib (RESCUE) and 
the study of pembrolizumab in combination with lenvatinib. Preliminarily data of these 
studies have verified the promising efficacy and acceptable safety of the combination of anti-
angiogenic therapy and PD-1/PD-L1 antibody in HCC. 
MGD013 is a LAG-3/PD-1 bispecific antibody and may have stronger antitumor effect than 
PD-1 monoclonal antibody. Brivanib alaninate is a dual tyrosine kinase inhibitor (TKI) of 
VEGFR and FGFR. A number of clinical trials in HCC have demonstrated similar anti-tumor 
activity of Brivanib to other medications with the same mechanism of action and an 
acceptable safety profile. On the basis of the above study data, it is expected that MGD013 
monotherapy or co-administered with brivanib alaninate may have a better efficacy than PD-
1 antibodies and, in particular, may be effective in patients who failed prior immune 
checkpoint inhibitor treatment. Therefore, the study will explore the safety and efficacy of 
MGD013 monotherapy or in combination with brivanib alaninate in HCC patients who failed 
prior immune checkpoint inhibitor treatment and those who did not receive prior immune 
checkpoint inhibitor treatment. 
1.2.2 Dose Selection and Safety 
In Phase I of the study, MGD013 monotherapy dose escalation will be conducted first in 
patients with advanced solid tumors at the following dose levels: 1 patient at 1 mg, 1 patient 
at 3 mg, 4 patients at 10 mg, 5 patients at 30 mg, 4 patients at 120 mg, 9 patients at 400 mg, 8 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 35 of 106 
patients at 800 mg and 4 patients at 1,200 mg. In the dose escalation study of HCC cohort, 
the starting dose is 120 mg and has been escalated to 400 mg. The study is ongoing. In 
current study, 120 mg Q2W is the starting dose. Since 120mg Q2W has been tested and no 
obvious toxicity was observed in western patients with HCC, and a intermediate dose level of 
240 mg is added between 120 mg and 400 mg, only single patient will be enrolled in the 
starting dose cohort. 
Dose selection of antiangiogenic agents is an important consideration in combination therapy 
regarding to both safety and efficacy. Preclinical studies have suggested that[20], high dose of 
antiangiogenic drugs cause a reduction of blood vessels in tumors within a short period of 
time, resulting in further hypoxia and acidosis in the tumor microenvironment, and causing 
extracellular matrix deposition, which in turn promotes the infiltration of immunosuppressive 
cells. So high doses of antiangiogenic drugs may limit the effect of immunotherapy. By 
contrast, lower doses of anti-angiogenic drugs, such as one-fourth of the effective anti-
angiogenic dose in animal studies, can improve the tumor immune microenvironment by 
inducing the normalization of tumor blood vessels and increasing tumor-infiltrating 
lymphocytes (TILs)[20,21]. 
Therefore, after 400mg q2w of MGD013 is clear, combination therapy cohort will be open 
and the dose of MGD 013 could be escalated to RP2D after the RP2D is determined Brivanib 
alaninate starts at a low dose and may escalate to higher doses. This design allows finding the 
optimal dose for combination treatment and reduces the safety risk posed by brivanib as well. 
Due to the different mechanisms of action and different safety profiles of the two drugs, no 
major overlapping toxicities are expected when they are used in combination. This has been 
preliminarily verified in the clinical studies with other combination of drugs in the same 
class. For example, in the phase Ib study of PD-L1 atezolizumab in combination with 
bevacizumab (NCT02715531), no novel emerging adverse reactions or additive toxicities 
beyond the toxicity of each single agent were observed. In the study of PD-1 monoclonal 
antibody SHR-1210 combined with apatinib (NCT02942329), the dose of SHR-1210 was 
fixed and the dose of apatinib escalated to its RP2D. Preliminary results of this study also 
suggested acceptable safety and tolerability profile of the combination, which further 
supports the toxicity of the combination is manageable.  
In conclusion, the combination of brivanib alanine and MGD013 is expected to have 
synergistic activity and manageable toxicity in patients with HCC, indicationg by studies of 
check point inhibitor and anti-angiogenetic agent combinations, hence the risk-benefit ratio is 
likely to be favorable. Therefore, Zailab plans to conduct this phase I/II clinical study in 
Chinese patients with HCC. 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 36 of 106 
2. Study Objectives 
This study consists of two parts: Phase I is a dose escalation study to determine the 
recommended phase II dose (RP2D) of MGD013 monotherapy and that of MGD013 when in 
combination with ZL-2301 in subjects with advanced liver cancer (including hepatocellular 
carcinoma and intrahepatic cholangiocarcinoma); Phase II is a dose expansion study to assess 
the safety and efficacy of MGD013 monotherapy and MGD013 in combination with ZL-2301 
in subjects with advanced hepatocellular carcinoma (HCC). 
2.1 Objectives of Phase I study 
2.1.1 Primary Objectives 
- 
To assess the safety of MGD013 in subjects with advanced liver cancer (including 
hepatocellular carcinoma and intrahepatic cholangiocarcinoma); 
- 
To determine the recommended phase II dose (RP2D) of MGD013 monotherapy in 
subjects with advanced liver cancer; 
- 
To assess the safety of MGD013 in combination with brivanib alaninate (ZL-2301) in 
subjects with advanced liver cancer; 
- 
To determine the recommended phase II dose (RP2D) of MGD013 when co-
administered with brivanib alaninate (ZL-2301). 
2.1.2 Secondary Objectives 
- 
To assess the preliminary efficacy of MGD013 monotherapy and MGD013 in 
combination with brivanib alaninate in subjects with advanced liver cancer by 
investigator-assessed objective response rate (ORR) according to RECIST1.1 and 
irRECIST criteria respectively. 
2.1.3 Exploratory objective 
- 
To explore the correlation between MGD013/brivanib alaninate-related biomarkers and 
subject safety, antitumor activity. 
2.2 Objectives of Phase II study (Part 1) 
2.2.1 Primary Objectives 
- 
To assess the safety of MGD013 monotherapy at RP2D in subjects with advanced HCC; 
- 
To assess the safety of MGD013 at RP2D in combination with brivanib alaninate in 
subjects with advanced HCC; 
- 
To assess the efficacy of MGD013 monotherapy and in combination with brivanib 
alaninate in subjects with advanced HCC, with blinded independent central review 
(BICR)-assessed ORR according to RECIST 1.1 as the primary efficacy endpoint. 
2.2.2 Secondary Objectives 
- 
To assess the secondary efficacy endpoints of MGD013 monotherapy and in 
combination with brivanib alaninate: investigator-assessed ORRs (inv-ORRs) according 
to RECIST 1.1 and irRECIST respectively, BICR-assessed ORR according to 
irRECIST, disease control rate (DCR), time to tumor progression (TTP), duration of 
response (DoR), progression-free survival (PFS), survival rate at 6, 9 and 12 months, 
overall survival (OS), etc. 
2.2.3 Exploratory objective 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 37 of 106 
- 
To explore the potential biomarker for MGD013/brivanib alaninate and its correlation 
with subject safety and antitumor activity. 
2.3 Objectives of Phase II study (Part two) 
2.3.1 Primary Objectives 
- 
To assess the safety of the investigational drugs in subjects with advanced HCC who 
have previously failed immune checkpoint inhibitor treatment; 
- 
To assess the efficacy of the investigational drugs in subjects with advanced HCC who 
have previously failed immune checkpoint inhibitor treatment, with BICR-assessed 
ORR according to RECIST1.1 as the primary efficacy endpoint. 
2.3.2 Secondary Objectives 
- 
To assess the secondary efficacy endpoints of the investigational drugs in subjects with 
advanced HCC: BICR-assessed ORR according to irRECIST, investigator-assessed 
ORRs (inv-ORRs) according to RECIST 1.1 and irRECIST respectively, disease control 
rate (DCR), time to tumor progression (TTP), duration of response (DoR), progression-
free survival (PFS), survival rate at 6, 9 and 12 months, overall survival (OS). 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 38 of 106 
3. Study Design 
3.1 Overall Design 
This is a multicenter, open-label, Phase I/II clinical study, which will consist of two phases: 
the dose escalation study (Phase I) and the dose expansion study (Phase II). Phase II study 
will consist of two parts: Part 1 and Part 2.  
3.1.1 Study Design of Phase I Study 
Phase I study will enroll subjects with unresectable advanced HCC, intrahepatic 
cholangiocarcinoma and/or mixed hepatocellular-cholangiocarcinoma who have previously 
received at least first-line systematic treatment and recurred/not toraltable to the treatment. 
The dose escalation study of MGD013 monotherapy will be first conducted. After MGD013 
400mg Q2w as monotherapy is clear, the dose escalation study of the combination therapy 
will be conducted. The schematic diagram of the study is shown as below: 
 
MGD013 monotherapy 
In Phase I study, the dose escalation study of MGD013 monotherapy will be first conducted. 
After determining RP2D of MGD013 monotherapy, the dose escalation study of the 
combination therapy will be conducted. During dose escalation study of monotherapy, the 
starting dose of MGD013 will be 120 mg Q2W in single subject. If no ≥ Grade 2 drug-
related adverse event occurs in the DLT observation period within 28 days after the first dose, 
the dose may escalate sequentially. The subsequent dose groups will adopt traditional 3+3 
design. If adverse events of CTCAE Grade 2 or above related to the drug are observed in the 
subject of the starting dose group, the study will convert to traditional 3+3 escalation scheme, 
and at least another 2 evaluable subjects will be enrolled in the dose group. The dose of 
MGD013 monotherapy will be escalated to 240 mg Q2W, 400 mg Q2W and until 600 mg 
Q2W successively. 
MGD013 + Brivanib Alaninate (ZL-2301) 
The combination therapy will be initiated after the MGD013 400mg Q2w is clear. The 
combination dose of MGD013 could be escalated to RP2D of MGD013 after determining. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 39 of 106 
Dose escalation study of the combination therapy will adopt traditional 3+3 dose escalation 
scheme; the dosage of Brivanib will start from 400 mg once daily (QD), and may escalate to 
600 mg QD and a maximum of 800 mg QD (if possible). Two points should be noted: one is 
the combination dose of MGD 013 600mg Q2w +brivanib 400mg qd can be opened after 
both monotherapy RP2D of 600mg Q2w is determined and the starting dose of combination 
therapy is tolerant; the other is combination dose of MGD013 400mg Q2w + brivanib 600mg 
qd could be further explored once the starting dose of combination therapy is tolerant and the 
dose of MGD013 600mg Q2w+brivanib 400mg qd is not tolerant. 
While two or more subjects experience DLT in the starting dose group of the combination 
therapy, the combination dose level escalation will be terminated, and Phase II dose-
extension study will be conducted with MGD013 alone. Phase II dose-expansion study will 
be conducted with MGD013 alone.  
The group of combination RP2D should enroll at least 6 evaluable subjects. 
Definition of evaluable subject 
An evaluable subject is defined as a subject who received ≥ 75% of pre-specified total dose 
of MGD013 and brivanib alaninate (combination treatment cohort) within the first two cycles 
(28 days) and has completed primary safety evaluation, or experiences DLT at any time 
within 28 days. 
A cycle lasts for two weeks (14 days) in the study, and the first two cycles are the DLT 
evaluation period. Provided that 3 or 6 evaluable subjects in one dose group have completed 
the first two cycle evaluation and the dose escalation criteria is met, subsequent dose cohort is 
open to enroll. There will be no intra-subject dose escalations. Unevaluable subjects in Phase 
I will be replaced until at least 3 evaluable subjects are enrolled in each dose group. 
Approximately 30 ~ 43 evaluable subjects will be enrolled. The total number of subjects will 
depend upon the number of dose levels. 
Subjects will continue treatment until disease progression, death or the occurrence of 
intolerable toxicity, whichever comes first. MGD013 will be used for at most 48 cycles. 
Subjects receiving combination therapy can continue using brivanib alaninate if there is still 
no disease progression after discontinuing MGD013. 
3.1.2 Dose Escalation Rules 
During dose escalation study of monotherapy, the starting dose of MGD013 will be 120 mg 
Q2W with single subject in this dose cohort. If no ≥ Grade 2 drug-related adverse events 
occur during the DLT observation period within 28 days after the first administration, the 
dose may escalate sequentially. The subsequent dose groups will adopt traditional 3+3 dose 
escalation scheme. If adverse events of CTCAE Grade 2 or above related to the drug are 
observed in the subject of the starting dose group, the study will convert to traditional 3+3 
scheme for all dose groups, and at least another 2 evaluable subjects will be enrolled in 
starting dose group. 
The study will not proceed with the 3+3 design in case of the following drug-related adverse 
events, that is, only one subject enrolled in the starting dose group: 
● 
Grade 2 anemia 
● 
Grade 2 endocrinopathy that is well controlled with hormone replacement therapy 
● 
Grade 2 nausea, vomiting, dyspepsia, diarrhea or constipation that resolve to grade 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 40 of 106 
1 or baseline within 48 hours after medical intervention 
● 
Grade 2 fatigue that resolves to grade 1 within 4 days 
● 
Grade 2 fever or flu-like syndrome that resolves to grade 1 or baseline within 24 
hours after medical intervention 
● 
Grade 2 infection that resolves to grade 1 or baseline within 72 hours after medical 
intervention 
● 
Grade 2 lymphocytes or neutrophils decreased 
● 
Grade 2 amylase or lipase increased that resolves to Grade 1 or baseline within 72 
hours 
● 
Grade 2 electrolyte disturbance that resolves to Grade 1 or baseline within 72 hours 
after medical intervention 
● 
Grade 2 cancer pain 
● 
Grade 2 headache, cough and shortness of breath that resolve to grade 1 or baseline 
within 24 hours after medical intervention 
Except the starting dose group of monotherapy, other dose groups and combination therapy 
groups will adopt traditional 3+3 dose escalation scheme. Dose escalation follows the 
following principles: 
- 
If no dose-limiting toxicity (DLT) is observed in a cohort of at least 3 evaluable subjects 
then dose escalation may occur; 
- 
If one subject experiences a DLT in a group of 3 evaluable subjects, then the cohort will 
be expanded to include 3 evaluable subjects. If only one DLT is observed in the 
complete cohort of 6 evaluable subjects, then dose escalation may occur; 
- 
If 2 or more subjects experience a DLT in a group of up to 6 subjects, dose will be de-
escalated to prior dose level and more subjects may be enrolled until there are 6 
evaluable subjects in this dose group. 
- 
If 2 or more subjects in the lowest-dose group experience a DLT during MGD013 
monotherapy, the study will be terminated; 
- 
If 2 or more subjects experience DLT in the starting dose group of the combination 
therapy (MGD013 400mg q2w+brivanib 400mg qd), the combination dose level 
escalation will be terminated. 
- 
The dose of MGD013 and brivanib alaninate will not exceed 600mg Q2W and 800mg 
QD (monotherapy MTD). 
- 
RP2D dose groups of the monotherapy and combination therapy should at least enroll 6 
evaluable subjects. 
The 3+3 dose escalation scheme is shown below. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 41 of 106 
 
3.1.3 Dose-Limiting Toxicity (DLT) 
DLT was defined as the following adverse events (AEs) occurring within 4 weeks (the first 2 
cycles, 28 days) after the investigational drugs which is at least possibly related to the study 
drugs: 
➢ 
Hematologic Adverse Events: 
- 
Grade 4 neutropenia lasting ≥5 days; 
- 
Febrile neutropenia lasting > 48 hours or any febrile neutropenia with 
hemodynamic instability or an objective evidence of infection; 
- 
Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with obvious hemorrhage; 
- 
≥ Grade 3 haemolysis 
➢ 
Non-hematological adverse events: 
- 
≥ Grade 3 gastrointestinal reactions and electrolyte abnormal, e.g., nausea, 
vomiting, diarrhea constipation and abdominal pain that persist (more than 72 
hours) despite an adequate medical intervention; 
- 
Sustained /repeated ≥3 grade hypertension which recurred despite sufficient 
medical interventions (BP ≥ 150/100 mmHg means 2 measurements taken at 
least 24 hours (h) apart ≥ 150/100 mmHg, taken after the subject had been 
seated/lying quietly for 10 minutes. At least 1 week was taken to evaluate subject’s 
response to a change in antihypertensive medication (initiation or increase in anti-
hypertensive medication). Once stabilized on antihypertensives, for 1 week, a 
subsequent episode of ≥150/100 was to be considered the “second event”). 
- 
Other ≥ Grade 3 non-hematological toxicity, excluding: 
● 
Alopecia; 
● 
Grade 3 infusion-related reaction or cytokine release syndrome (CRS) that 
resolves after medical intervention within 12 hours 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 42 of 106 
● 
Grade 3 fever that lasts < 72 hours and is not associated with hemodynamic 
compromise 
● 
Grade 3 fatigue that lasts < 72 hours 
● 
Grade 3 skin toxicity that resolves to ≤ Grade 2 within 14 days of initiation 
of oral corticosteroids 
● 
Grade 3 endocrinopathy that is well controlled with hormone replacement 
therapy 
● 
Grade 3 amylase or lipase increased without clinical or radiographic evidence 
of pancreatitis 
● 
Grade 3 tumor inflammatory reaction (local inflammatory response at tumor or 
metastasis focuses attributed to an antitumor effect of drug, e.g., swelling, 
pain, fever) that resolves to ≤ Grade 2 within 7 days 
➢ 
≥ Grade 2 ocular pain or vision decreased that does not resolve to Grade 1 by topical 
therapy within 14 days, or that requires systemic treatment; 
➢ 
Hepatic dose-limiting toxicity: 
- 
For subjects with ≤ grade 2 baseline transaminases increased (≤ 3 × ULN): 
● 
Transaminases increased > 8 × the upper limit of normal (ULN); 
● 
Grade 3 elevated total bilirubin (> 5 × ULN); 
● 
Transaminases increased (5 × ULN to 8 × ULN) that does not resolve to Grade 
2 within 7 days and Grade 1 or baseline within 14 days. Oral steroids must be 
tapered to ≤ 10 mg of prednisone or equivalent dose within14 days. 
● 
Increased total bilirubin (3× ULN to 5× ULN) that does not resolve to Grade 2 
within 7 days and Grade 1 or baseline within 14 days. Oral steroids must be 
tapered to ≤ 10 mg of prednisone or equivalent dose within 14 days. 
- 
For subjects with Grade 2 baseline transaminases increased (3 × ULN to 5 × ULN), 
the DLT is defined as: 
● 
Elevation of one or more transaminases (> 10 × ULN) with increased total 
bilirubin (≥ 1 grade, for example: Grade 0 to 1, or Grade 1 to 2); 
● 
Elevation of one or more transaminases (> 10 × ULN) that does not recover to 
Grade 2 with steroids within 14 days or that requires another 
immunosuppressive agent. 
● 
Elevation of one or more transaminases (> 15 × ULN); 
● 
Grade 3 increased total bilirubin (> 5 × ULN). 
➢ 
Any other adverse events which in the judgment of the investigator required 
discontinuation from the study. 
Definition of maximum tolerated dose (MTD) 
It is defined as the maximum dose at which <33% subjects suffer from DLTs; if 2 or more 
DLTs occur in a certain dose group, this dose is considered as intolerable, its prior dose level 
is defined as the maximum tolerated dose (MTD). There must be at least 6 evaluable subjects 
in the MTD dose group. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 43 of 106 
In Phase I dose escalation period, the Safety Review Committee (SRC) will decide whether 
to escalate to the next dose level or discontinue the escalation after reviewing the data from 
each dose group. 
3.1.4 Design of Phase II study 
In the Phase II dose expansion study, Part 1 will enroll two cohorts, MGD013 monotherapy 
and MGD013 in combination with brivanib alaninate. After determining the RP2D of 
MGD013 monotherapy, dose expansion study of monotherapy will be conducted without 
waiting for the completion of the dose escalation study of the combination treatment. 
Subjects of the combination therapy cohort will be enrolled after determining the RP2D of 
combination therapy in Phase I study. 
Schematic diagram of the study: 
 
 
 
Each cohort will enroll approximately 30 evaluable advanced HCC subjects who progressed 
after immune checkpoint inhibitor treatment, and approximately 40 evaluable advanced HCC 
subjects who have not previously received immune checkpoint inhibitor treatment. The 
SWOG two-stage design will be employed. In the first stage, 20 advanced HCC subjects who 
have not previously received immune checkpoint inhibitor treatment will be enrolled. If 
response is observed in 3 or more subjects (according to RECIST 1.1), the enrollment of 
second stage will be open and an additional of 20 evaluable subjects will be enrolled. The 
enrollment of advanced HCC subjects who have previously received immune checkpoint 
inhibitor treatment will be similar, there are 2 stages for the group and the response 
(according to RECIST 1.1) of 1 and more out of 15 evaluable subjects at the first stage will 
support the decision to proceed to the second stage of subject accrual until there are 30 
evaluable subjects in this group. If the response in any treatment group is found less than the 
above standard in the first period, the enrollment of second stage will be terminated. 
In Phase II study, 2 weeks (14 days) will be defined as a cycle, and subjects will continue to 
receive study treatment until disease progression (according to irRECIST), death or the 
occurrence of intolerable toxicity (whichever comes first). MGD013 will be administered for 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 44 of 106 
at most 48 cycles. If subjects do not have disease progression after discontinuing MGD013, 
subjects of the combination therapy group may continue brivanib alaninate. 
Phase II Part 2 will expand the cohort study according to the safety and efficacy data obtained 
in Part 1. When at least 6 responders are observed among 30 evaluable patients (observed 
ORR=20%) in the post checkpoint inhibitor cohort in Part 1, the enrollment of Part 2 will be 
initiated. The treatment (MGD013 monotherapy or MGD013 in combination with Brivanib) 
that meets above criteria will proceed to Part 2. If both monotherapy and combination therapy 
achieve at least 6 responders in the post checkpoint inhibitor cohort, the decision of which 
treatment to proceed to Part 2 depends on the totality of safety and efficacy data from Part 1, 
and will be made by Safety Review Committee (SRC) after reviewing the data. About 120 
advanced HCC subjects who have progressed following immune checkpoint inhibitor 
treatment will be enrolled to further assess the safety and efficacy of the study treatment. 
Decision on the study treatment (MGD013 monotherapy or in combination with brivanib 
alaninate) in Part 2 will be made by the sponsor according to the obtained data from Part 1. 
The primary efficacy endpoint in Phase II study is BICR-assessed ORR according to 
RECIST1.1. Investigators will also evaluate objective anti-tumor efficacy and disease 
progression based on target lesions, non-target lesions and new lesions according to RECIST 
1.1 and irRECIST criteria. The radiological responses that determine whether treatment 
groups in Part 1 will enter the second period after the completion of the first period of the 
study will be evaluated by investigators according to RECIST1.1. The subjects will be 
managed and evaluated for a disease progression that requires the discontinuation of 
the investigational drug by the investigators preferably according to irRECIST. 
3.2 Discussion of Study Design 
3.2.1 Dose Selection for Phase I Study 
In Phase I of the study, MGD013 monotherapy dose escalation will be conducted first. 
MGD013 is a humanized PD-1 + LAG-3 bispecific, tetravalent diabody DART® molecule 
consisting of Fc domains, engineered as a hinge-stabilized IgG4 molecule and is designed to 
concomitantly bind PD-1 and LAG-3. As of November 2018, in the Phase I dose-escalation 
study (CP-MGD013-01), 36 patients with different types of solid tumors were administered 
MGD013 at a dose ranging from 1 mg to 1,200 mg Q2W, while single-patient dose escalation 
was adopted at dose levels of 1, 3 and 10 mg and 3+3 design was adopted at dose levels of 30 
mg, 120 mg, 400 mg, 800 mg and 1,200 mg. They are generally well tolerated by the 
patients. Preliminary data indicated that the safety profile of MGD013 was similar to that of 
known immune checkpoint inhibitors. The common AEs included constipation, fatigue, 
nausea, infusion-related reaction, fever, abdominal pain, diarrhea, vomiting, chills, dyspnea, 
joint pain, back pain, blood creatinine increased, hyponatremia, headache, cough, rash and 
itching. Most treatment-related AEs were mild to moderate (i.e. Grade 1 or 2). Seven (19.4%) 
experienced at least one grade 3 treatment-related AE. No grade 4 or 5 treatment-related AEs 
occurred. Of the first 3 treated patients in the 1,200 mg dose cohort, 1 experienced a SAE and 
immune-mediated hepatitis meeting DLT criteria; 3 more patients were enrolled at the dose 
level and completed DLT evaluation period, without new DLTs; It did not reach the MTD 
(1,600 mg specified in the protocol), which would not be adopted. Therefore, the cohort of 
1,200 mg became the maximum dose level in the study CP-MGD013-01. While evaluating 
the dose level of 1,200 mg in the dose escalation period, MacroGenics will further evaluate 
600 mg Q2W in the dose expansion period. 
MacroGenics chose 120 mg Q2W as the starting dose in HCCs for dose escalation. None of 
the 3 patients experienced DLT at the starting dose. As of April 1, 2019, enrollment of the 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 45 of 106 
dose group of 400 mg Q2W has been started. In this study, 120 mg Q2W was also used as the 
starting dose in one HCC patient since it has been validated safe in overseas studies, and a 
dose level of 240 mg was added between 120 mg and 400 mg. If no ≥ grade 2 drug-related 
adverse reactions occurred, it can be escalated to the next dose level. It will not be more than 
the RP2D (600 mg Q2W) that has been confirmed in other dose escalation studies of solid 
tumors for the monotherapy dose escalation. 
After determining the RP2D of MGD013 monotherapy, it will be co-administered with 
brivanib alaninate at that RP2D. A multicenter, phase I, open-label clinical trial of brivanib 
alaninate (CA182002) is a dose escalation study in patients with tumors. In Part 1 of the 
study, the starting dose of brivanib alaninate was 180 mg, and the dose sequentially escalated 
to 320, 600, 800, and 1,000 mg once daily. Two DLTs (Mental disorder and grade 3 fatigue) 
occurred in the 1,000 mg group. Therefore, 800 mg QD was established as the maximum 
tolerated dose (MTD) of brivanib alaninate. 800 mg QD will be used in subsequent studies. 
In combination therapy of the study, the starting dose of brivanib alaninate is as low as 400 
mg QD, to lower the risks of subjects. If the first dose is safe and well tolerated when in 
combination with MGD013, the dose may escalate sequentially to  600 mg, and 800 mg (if 
possible). If ≥2 patients experience a DLT in the first dose group of the combination 
therapy when MGD013 is administered at RP2D with brivanib alaninate (400mg QD), the 
dose of MGD013 will be de-escalated to the next level at which it will be combined with 
brivanib alaninate (400 mg QD). If there are still ≥ 2 DLTs, it indicates that there is a toxic 
multiply and the study will be terminated, and Phase II dose-extension study will be 
conducted with MGD013 alone. 
3.2.2 Study Patient Population 
In current clinical practice in China, the medications that are used as the first-line treatment 
of advanced HCC include: VEGFR TKIs, such as sorafenib, lenvatinib, or systemic 
chemotherapy with oxaliplatin-based single agent or in combination with other agents, such 
as the FOLFOX4 regimen. Other options include systemic oxaliplatin-based chemotherapy in 
combination with sorafenib, or arsenious acid chemotherapy, or traditional Chinese medicine. 
Immune checkpoint inhibitors (for example anti-PD-1 antibody nivolumab) were 
conditionally approved by the US FDA as the treatment of HCC patients who have 
progressed after sorafenib treatment. These drugs have not been approved in China for 
indications of HCC, but they have been widely used in clinical studies or off-label treatments. 
Intrahepatic cholangiocarcinoma (ICC) is a rare malignant tumor which arises from the 
epithelial cells of intrahepatic bile ducts. The incidence of ICC is reported to be only about 
10% of primary liver cancers. Unresectable advanced ICCs are usually treated by 
chemotherapy agents, such as 5-fluorouracil with leucovorin, gemcitabine as a single agent, 
or gemcitabine plus cisplatin, irinotecan, or capecitabine. For non-resectable cases, the 
prognosis is very poor and overall mean duration of survival is less than 6 months. 
Combining lenvatinib (Lenvima) with PD-1 inhibitors showed promising efficacy in patients 
with advanced intrahepatic cholangiocarcinoma (ICC) who have failed prior treatments with 
an ORR of 21.4% (3/14) and a median PFS of 5.0 months, according to preliminary data 
from a single-center study [22] reported at the 2018 Gastrointestinal Cancers Symposium. 
In Phase I of the study, besides HCC subjects who progressed after or were intolerant to 
toxicity of one or more systemic treatments, ICC or mixed HCC-ICC subjects will be also 
enrolled to explore the initial efficacy of monotherapy or combination therapy in these 
subjects. These subjects may receive prior first-line or above immune checkpoint inhibitor 
treatment, VEGFR inhibitors or systemic chemotherapy. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 46 of 106 
Phase II Part I will only enroll HCC subjects. Study population in the HCC cohort that has 
failed prior immune checkpoint inhibitors has radiologically confirmed disease progression 
following anti-PD-1 antibody, anti-PD-L1 antibody or CTLA-4 antibody that have been 
approved or are in the clinical research & development period. These subjects can only be 
previously treated with first-line immune checkpoint inhibitors, e.g., PD-1/PD-L1 antibody 
monotherapy, PD-1/PD-L1 antibody in combination with anti-CTLA-4 antibody or one 
targeted antiangiogenic drug, or systemic chemotherapy. The molecular targeted 
antiangiogenic drugs and chemotherapeutic drugs are only allowed to be co-administered. In 
the cohort that has not previously treated with immune checkpoint inhibitors, subjects have 
failed or are intolerant to toxicities of targeted antiangiogenic drug and/or systematic 
chemotherapy without receiving PD-1/PD-L1 antibody or CTLA-4 antibody and other 
immune checkpoint drugs. Phase II Part 2 will only enroll HCC subjects who have previously 
treated with immune checkpoint inhibitors to further evaluate the efficacy and safety of the 
investigational drugs in these subjects. 
3.2.3 Selection of Efficacy Endpoints 
The primary efficacy endpoint of the phase II study was objective response rate (ORR) 
according to RECIST 1.1. Secondary endpoints included ORR, TTP, PFS, OS, etc. according 
to irRECIST for immunotherapy, which could provide supportive evidence for clinical 
benefit.  
Current radiologic evaluation criteria that can be applied to HCC include RECIST 1.1 
criteria, mRECIST criteria, and irRECIST criteria for immunotherapy. Primary phase III 
clinical studies of immunotherapy in HCC adopted the RECIST 1.1 criteria (e.g., Checkmate-
040 study, study of Atezolizumab in combination with Bevacizumab). The mRECIST criteria 
have not been fully validated for immunotherapy. Therefore, the ORR assessed according to 
RECIST 1.1 criteria was used as the primary efficacy endpoint for comparing with other 
studies. Provided that the characteristics of immunotherapy have been fully considered and a 
better rationality than RECIST 1.1 in terms of subject management (e.g., discontinuation of 
investigational drugs after reaching PD), it should be subject to irRECIST in case of 
investigator-assessed progressive disease and discontinuation of the investigational drugs. 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 47 of 106 
4. Study Population 
4.1 Inclusion criteria 
1. 
Subjects who voluntarily sign the informed consent form (ICF); 
2. 
Male or female subjects who are aged 18-75 years old; 
3. 
Subjects with histologic, cytologic or clinical confirmed diagnosis of advanced HCC 
(phase I could include intrahepatic cholangiocarcinoma or mixed hepatocellular-
cholangiocarcinoma), and are not suitable for surgery or loco-regional therapy or have 
progressed following surgery and/or loco-regional therapy; 
4. 
Subject who has at least one measurable lesion according to RECIST v1.1 criteria. 
5. 
Phase I study: subjects who have previously received at least one line of systematic 
therapy, including immune checkpoint inhibitors, molecular targeted drugs or systematic 
chemotherapy, alone or in combination, and failed (progression confirmed by imaging) 
or were intolerant at the discretion of investigator; 
Phase II Advanced HCC cohort with subjects who have previously received immune 
checkpoint inhibitor treatment: subjects who have failed (progression confirmed by 
imaging) prior first-line immune checkpoint inhibitor treatment, including anti-PD-1 
antibody/anti-PD-L1 antibody and / or anti-CTLA-4 antibody, and/or molecular targeted 
therapy or systematic chemotherapy (monotherapy or in combination); 
Phase II Advanced HCC cohort with subjects who have not previously received immune 
checkpoint inhibitor treatment in Phase II study: subjects who have failed (progression 
confirmed by imaging) or were intolerant to (at the discretion of investigator) previous 
molecular targeted therapy or systematic chemotherapy, without receiving immune 
checkpoint inhibitor treatment (including anti-PD-1 antibody, anti-PD-L1 antibody, anti-
CTLA-4 antibody, and bispecific antibodies including the above targets).  
6. 
Previous anti-tumor therapy must be completed no less than 2 weeks prior to the study 
treatment and all adverse events related to previous treatment must have recovered to 
CTCAE Grade ≤1; if subjects who have received prior immune checkpoint inhibitors 
have immune-related endocrinopathy, it should be controlled with hormone replacement 
therapy. 
7. 
Phase I: cirrhotic status of Child-Pugh Class A; Phase II: cirrhotic status of Child-Pugh 
Class A or B with a score of 7; 
8. 
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. 
9. 
Subjects with life expectancy ≥12 weeks; 
10. Subjects with chronic HBV infection must have HBV-DNA <500 IU/ml, and have 
received at least 14 days of anti-HBV treatment (e.g. entecavir, tenofovir) prior to the 
initiation of study treatment and are willing to receive antiviral treatment throughout the 
study; Antiviral therapy is not required for patients with HCV infection and the 
elevation of their liver enzymes must not exceed the level of CTCAE Grade 1; 
11. Adequate organ function as outlined below: 
(1) Blood system function (subjects must have not received blood transfusion or 
stimulating growth factors within 14 days prior to screening test): neutrophil count 
≥1.5×109/L, platelet count ≥ 75×109/L, hemoglobin ≥ 90 g/L; 
(2) Liver and kidney function (no albumin transfusion within 14 days prior to 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 48 of 106 
screening test): serum total bilirubin ≤ 2.5×ULN, serum albumin ≥ 29 g/L, 
ALT and AST ≤ 5×ULN; serum creatinine ≤1.5×ULN or eGFR (Cockcroft-
Gault formula) ≥ 60 ml/min; 
(3) Coagulation function: international normalized ratio (INR)≤2.3 or prothrombin 
time (PT) of ≤ 6 seconds above control; 
(4) Left ventricular ejection fraction (LVEF) ≥50% by two-dimensional 
echocardiography. 
12. Female subjects (except for females who have underwent surgical sterilization and those 
have been menopausal for more than one year) who are of childbearing potential are 
required to adopt a medically acceptable contraceptive measure (such as intrauterine 
device, contraceptive pill or condom) throughout the study and up to 120 days after the 
last dose of investigational products; females must have negative serum or urine HCG 
tests within 7 days prior to enrollment; female subjects must not be breastfeeding; male 
subjects whose partners are of childbearing potential should use effective contraceptive 
methods throughout the study and up to 120 days after the last dose of investigational 
product. 
13. Subjects who are willing to provide oncological tissues (if applicable) for biomarker 
test. 
4.2 Exclusion criteria 
1. 
Subjects who have known fibrolamellar carcinoma of liver for phase I and subjects who 
have fibrolamellar carcinoma, mixed HCC- cholangiocarcinoma or cholangiocarcinoma 
for phase II; 
2. 
Subjects with brain metastasis or leptomeningeal metastasis confirmed by brain MRI 
during screening period; 
3. 
Subjects with a diagnosis of other malignant tumors within 5 years prior to first 
administration, except for skin basal cell carcinoma, skin squamous cell carcinoma 
and/or in situ cancer following radical resection; 
4. 
Subjects who had liver or other sites loco-regional treatment (including transcatheter 
arterial chemoembolization (TACE), transcatheter arterial embolization (TAE), hepatic 
artery infusion (HAI), local radiotherapy, radioembolization, radiofrequency ablation, 
cryoablation or percutaneous ethanol injection) , or who had major surgery of liver or 
other sites within 4 weeks prior to first administration, or had minor surgical procedures 
(such as simple excision, tooth extraction, etc.) within one week prior to first 
administration, or had received palliative radiotherapy for bone metastasis within 2 
weeks and radiotherapy-related toxicity ≥ CTCAE Grade 2. 
5. 
Subjects who have moderate or severe ascites (detected by B-ultrasound or CT), or 
require therapeutic abdominal paracentesis or drainage;  
6. 
Subjects with a history of hepatic encephalopathy; 
7. 
Subjects with a history of unhealed wounds or ulcers or bone fractures within 3 months 
prior to study treatment 
8. 
Subjects who plan to have or had allogenic organ or bone marrow transplantation 
9. 
Subjects who are at increased risk of bleeding or have history of thrombosis: 
(1) Clinically significant bleeding within 3 months prior to screening or clear bleeding 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 49 of 106 
tendency; 
(2) Gastrointestinal hemorrhage within 6 months prior to screening or clear tendency 
of gastrointestinal hemorrhage; 
(3) Arterial/venous thromboembolic events within 6 months prior to screening, such as 
cerebrovascular accident (including transient ischemic attack), pulmonary 
embolism, etc.; 
(4) Require anticoagulation therapy with an agent such as warfarin or heparin; 
(5) Require chronic anti-platelet therapy (such as aspirin≥100 mg/day, clopidogrel, 
etc.); 
10. Subjects who have clinically significant cardiovascular diseases: 
(1) NYHA (New York Heart Association) stage 3 and 4 congestive heart failure; 
(2) Unstable angina pectoris or newly diagnosed angina pectoris or myocardial 
infarction within 12 months prior to screening; 
(3) Arrhythmias requiring medications other than β-blockers; 
(4) Valvular heart disease of ≥ CTCAE Grade 2; 
(5) Hypertension inadequately controlled by drugs (systolic pressure >150 mmHg or 
diastolic pressure >90 mmHg); 
11. Subjects who have history of symptomatic pulmonary fibrosis, interstitial pneumonitis, 
pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severe impairment 
of pulmonary function, or other suspicious pulmonary diseases that may interfere with 
drug-related pulmonary toxicity detection and treatment 
12. Subjects who have suffered active bacterial or fungal infections requiring systematic 
treatment within 7 days prior to screening; or active tuberculosis;  
13. Subjects with active co-infection of Hepatitis B and C, confirmed by positive HBV 
surface antigen or HBV DNA and HCV RNA; 
14. Subjects who have any active, known or suspected autoimmune disease 
15. Subjects with a condition requiring systematic treatment with corticosteroids (>10 
mg/day prednisone or equivalent) or other immunosuppressive drugs within 14 days 
before administration of the investigational drug. In the absence of active autoimmune 
diseases, inhalation or topical use of steroids (>10 mg/day prednisone or equivalent) is 
allowed; 
16. Other laboratory abnormalities: 
(1) Hyponatremia, hypokalemia or hypophosphatemia that have occurred before the 
first administration, and failed to restore to normal level after electrolyte 
supplementation therapy; 
(2) Confirmed diagnosis of thyroid dysfunction, which cannot be maintained within 
normal range following thyroid hormone replacement therapy; 
(3) Positive Human immunodeficiency virus (HIV) test; 
17. QTc interval >480 ms on two consecutive ECGs; 
18. Female subjects during pregnancy or lactation; female subjects of childbearing potential 
or male subjects who are not willing to use contraception or contraceptive measures 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 50 of 106 
during the study; 
19. Subjects who have previously received two lines and above tumor immune checkpiont 
inhibitor treatment, mainly including anti-PD-1, anti-PD-L1 and anti-CTLA-4 
antibodies, etc, or bispecific antibodies including the above targets, or received anti-
LAG-3 antibody; whether subjects who have previously received other tumor 
immunotherapy can be enrolled should be determined by the sponsor; 
20. Known or suspected history of severe allergy to investigational drugs; 
21. Subjects who have received live attenuated vaccines or any investigational drugs that 
have not been marketed in China within 4 weeks prior to first administration; 
22. If subjects who have previously used immune checkpoint inhibitors (such as anti-PD-1, 
anti-PD-L1, anti-CTLA-4 antibodies) have the following adverse events related to 
immune checkpoints, they will be not suitable for inclusion regardless of recovered or 
not: 
a) 
≥ Grade 3 eye-related adverse events 
b) 
Grade 4 abnormal liver function 
c) 
≥ Grade 3 neurotoxicity 
d) 
≥ Grade 3 colitis 
e) 
≥ Grade 3 renal toxicity 
f) 
≥ Grade 3 pneumonitis 
23. Subjects who are not suitable for inclusion as judged by the investigators. 
4.3 Discontinuation of Subjects from Treatment 
4.3.1 End of Treatment 
Subjects may discontinue treatment at any time during the study. End of Treatment Visit 
(EOT) should be performed within 7 days of decision date to discontinue treatment. 
Study drug shall be permanently discontinued in any of the following cases: 
● 
Adverse Event 
- 
Occurrence of any CTCAE (V5.0) grade 3 or 4 treatment-related adverse 
event, which fails to recover to CTCAE Grade 1 or below within 4 weeks (28 
days) (unless the investigator believes that the subject may continue to benefit 
from treatment and the continuation requires the permission from sponsor's 
medical monitor); 
- 
CTCAE Grade 3 or 4 treatment-related adverse event recurs in combination 
treatment group despite dose reduction of brivanib alaninate;  
- 
Myocardial ischemia and/or infarction; 
- 
Evidence for abnormal cardiac valve function ≥ CTCAE Grade 2; 
- 
LVEF decrease by > 10% from baseline-ECHO and LVEF < 45%; 
- 
QTc > 500 milliseconds on 3 consecutive ECGs performed during the same 
visit and in the absence of possible causes other than study therapy; 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 51 of 106 
- 
Torsade de pointes or sustained ventricular tachycardia; 
- 
Hemorrhage ≥ CTCAE Grade 3; 
- 
Gastrointestinal perforation; 
- 
Arterial thromboembolic event; 
- 
Venous thromboembolic events of CTCAE Grade 3 or 4; 
- 
Hypertensive crisis; 
- 
Immune-related adverse events of grade 4. 
● Disease progression according to irRECIST criteria 
● Risk to the subject as judged by the investigator and/or sponsor 
● Critical violation to the protocol as judged by the investigator and/or sponsor 
● Subject’s decision 
● Pregnancy 
● Death 
● Completion of protocol-defined therapy (MGD013 monotherapy) 
If the reason for treatment discontinuation is not disease progression, death, withdrawal of 
informed consent or loss to follow-up, radiologic tumor assessments will still be performed at 
protocol-specified intervals until disease progression by irRECIST or the starting of 
subsequent antitumor therapy (Phase II). 
4.3.2 End of Study  
Patients who are no longer on treatment but are still followed on the study can be terminated 
from the study for the following reasons: 
• 
Death 
• 
Lost to follow up 
• 
Withdrawn of consent 
• 
The study is terminated  
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 52 of 106 
5. Study Treatment 
5.1 Investigational Products 
Investigational products of this study are shown in the table below: 
Table 2. Investigational Products for Clinical Study 
Name of 
investigational drug 
Brivanib alaninate Tablets 
MGD013 injection 
Appearance 
Light 
yellow 
to 
yellow 
biconvex oblong film-coated 
tablets 
Sterile injection 
Strength 
200mg 
300 mg/15 mL 
Administration 
route 
Oral administration 
Intravenous infusion 
Brivanib alaninate is given orally at the dose according to subject’s dose group once daily at a 
fixed time, and can be taken with or without meals; If subject vomits after a dose or misses a 
dose, additional dose should not be taken on the same day. 
In the dose escalation period, the starting dose of MGD013 was 120 mg IV on day 1 of each 
cycle, once every two weeks; the dose sequentially escalated to 240 mg, 400 mg and 600 mg 
IV, Q2W; MGD013 may be administered at a level or frequency beyond the above examples 
according to safety data obtained from the study and other studies. 
Before intravenous infusion, MGD013 at each dose level must be diluted with 0.9% sodium 
chloride injection, USP (normal saline) 100 mL or 250 mL of infusion bags. The final 
concentration of MGD013 for infusion after dilution with normal saline must be between 
0.12 mg/mL and 6.4 mg/mL. It is administered for 60 - 75 minutes. A 0.2 μm sterile and 
pyrogen-free inline filter made of polyether sulfone (PES) with a low protein-binding rate 
must be adopted for IV infusion since there may be visible semi-transparent protein particles 
in the solution. 
 
5.2 Infusion preparation 
5.2.1 General Guidelines and Precautions  
MGD013 should not be administered as an IV push or bolus. All doses of MGD013 will be 
diluted in normal saline and administered as an IV infusion with a commercially available 
infusion instructions, see Pharmacy Manual for details. The final concentration of MGD013 
for infusion after dilution with normal saline must be between 0.12 mg/mL and 6.4 mg/mL. It 
is administered for 60 - 75 minutes. All infusion instructions must be calibrated in accordance 
with the institutional standards, policies, and procedures to ensure consistent, accurate delivery 
of MGD013.  
Infusion or allergic reactions may occur with the infusion of mAbs and other protein-based 
therapeutics. Precautions for anaphylaxis should be observed during MGD013 administration. 
Supportive measures may include, but are not limited to, epinephrine, antihistamines, 
corticosteroids, IV fluids, vasopressors, oxygen, bronchodilators, diphenhydramine, and 
acetaminophen. Please refer to Section 8.4.1 for specific guidelines regarding the management 
of infusion reactions. Supportive care measures consistent with optimal patient care will be 
provided throughout the study according to institutional standards. 
5.2.2 Study Drug Preparation and Administration 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 53 of 106 
Visually inspect parenteral drug products for particulate matter and discoloration prior to 
administration. Return the vial if the solution is cloudy, there is pronounced discoloration 
(solution may have pale-yellow or pale brown color), or there is foreign particulate matter.  
Instructions on the preparation of the study drugs for IV infusion are detailed in the Pharmacy 
Manual.  
Do not mix the study drug with, or administer as an infusion with, other medicinal products.  
The study drugs do not contain preservatives. Once diluted in normal saline, the dose solution 
is stable up to 4 hours at room temperature or 24 hours stored refrigerated at 2° to 8°C with 
minimal exposure to light. If the dose solution is stored at 2° to 8°C, it should be removed from 
the refrigerator at least 30-60 minutes prior to administration to allow the dose solution to reach 
room temperature. Precautions should be taken to minimize the time between dose preparation 
and IV infusion.  
5.3 Concomitant medication 
Any medication the subject takes other than the study treatment, including prescribed, non-
prescribed, Chinese herbal medicine and dietary supplements, should be considered as 
concomitant medication. 
All previous and concomitant medications must be recorded in the eCRF. It must include: 
generic name, route of administration, start and completion time, dosage and indications 
related to each concomitant medication. Any changes to the product of concomitant 
medication should also be recorded in the eCRF. At Screening, subjects will be asked what 
medications they have taken during the last 30 days. At each subsequent study visit, subjects 
will be asked what concomitant medications they are currently taking. 
5.3.1 Prohibited Medications 
● 
Other anti-tumor therapies, such as chemotherapy, immunotherapy, therapeutic 
radiation, experimental anticancer drugs or loco-regional therapy, are not allowed while 
the subject is using the investigational drug; palliative radiotherapy is allowed for non-
target lesions that are present prior to enrollment with uncontrolled pain that cannot be 
relieved by local or systemic analgesics, provided that there is no disease progression. 
● 
Corticosteroids should be limited because MGD013 has a mechanism of action 
dependent upon the engagement of T lymphocytes. Chronic use of corticosteroids > 10 
mg/d of prednisone or equivalent are prohibited other than for the management of drug-
related adverse reactions. Corticosteroids for topical (e.g., ophthalmic, inhaled, or nasal) 
administration are allowed. 
● 
The concomitant use of rifampin (and its analogues); 
● 
Hypericum perforatum or traditional Chinese medicines with indications for the 
treatment of liver cancer (including but not limited to Xiaoaiping, Kanglaite, 
Cinobufotalin, Elemene and Delisheng Injection) is not allowed. 
● 
Vaccination with live vaccines is not allowed within 28 days prior to the first dose and 
during the study. 
● 
Prophylactic use of stimulating factors (eg, granulocyte colony-stimulating factor) is not 
allowed during the first cycle of therapy. 
● 
Anticoagulation therapy such as warfarin or heparin is not allowed when the subjects are 
administrated with the investigational products. 
5.3.2 Drug-drug Interactions 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 54 of 106 
Drug-drug interactions of MGD013 have not been evaluated in clinical studies. Bispecific 
antibodies to MGD013, for example, are not substrates for cytochrome P450s or drug 
transporters and are not likely to be cytokine modulators. No PK DDI is expected between 
MGD013 and small molecule drugs. 
In five drug-drug interaction (DDI) studies in human, no drug-drug interactions were detected 
in humans when brivanib alaninate was co-administered with CYP3A4 substrates, CYP2C8 
substrates, CYP3A4 inhibitors, and P-gp substrates without dose adjustment. Concomitant 
Rifampin should be avoided for it can significantly lower the exposure to Brivanib. 
5.3.3 Best supportive care 
All subjects participating in this clinical study are allowed to receive best supportive care 
(BSC). The BSC will be defined according to the institutional standards of the participating 
clinical centers. In general, BSC should be understood as a multi-professional focus on the 
overall physical, psychosocial, spiritual and cultural needs of the subjects at all stages of 
disease. This concept is applicable to the subjects of all ages and is independent of the intent 
of any anticancer therapy (EORTC Pain and Symptom Control Work Team). Based on the 
physical health status of HCC subjects participating in this study, BSC may include, but is not 
limited to: (1) analgesics, including non-steroidal anti-inflammatory drugs, opioids, etc.; (2) 
antiemetics; (3) vitamins and nutritional support; (4) hepatoprotective and choleretic therapy; 
(5) bisphosphonates for bone metastases, etc. Loco-regional radiation therapy is allowed to 
reduce symptoms, such as the pain caused by non-target lesions, as long as the total dose of 
treatment is within the palliative range specified by institutional standards. Palliative 
radiotherapy to the target lesion is not allowed if the subject is taking investigational drug. If 
jaundice is caused by obstruction of the biliary tree, percutaneous intrahepatic biliary 
drainage may be adopted. 
5.4 Treatment Compliance 
Brivanib alaninate is dispensed to subjects by trained medical personnel. It will be dispensed 
at the study center pharmacy and will be self-administered by subjects. Subjects must record 
the investigational drug administration information in the study diary provided by the 
Sponsor. At each visit, subjects must bring back the diary as well as all unused investigational 
drug and empty packing boxes or bottles. Compliance will be assessed by the investigator 
and/or study staff through the count of tablets and information provided by the subjects or 
caregivers. At each visit, the administration information of investigational drug (including 
planned administration dose, actual administration dose, dose change, administration 
interruption, etc.) must be recorded in the source documents and in the eCRF. 
Each dose of MGD013 will be administered at the study site and will be prepared and infused 
by trained medical staffs. The administration information of MGD013 (administration dose, 
infusion time, whether there is infusion reaction, etc.) should also be recorded in the source 
documents and in the eCRF. 
It is investigator’s and site staff's responsibility to evaluate and analyze potential 
noncompliance (such as AEs or missing dose) at the beginning and during the study with the 
sponsor's monitor, and to consider and implement strategies for improving medication 
compliance in advance. 
5.5 Investigational Drug Management 
5.5.1 Packaging and Storage 
Brivanib alaninate tablets are supplied in tightly closed high-density polyethylene (HDPE) 
bottles with desiccant canisters. The bottles are heat-induction sealed with child-resistant 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 55 of 106 
closures. MGD013 is supplied in 20 mL (single-dose) Type I USP and EP borosilicate clear 
glass vial, which is capped with a 20 mm FluroTec®-coated 4023/50 gray butyl rubber 
stopper. It is sealed with a 20 mm aluminum-plastic lid. Brivanib alaninate shall be stored at 
10 - 30 °C in a tightly closed container. MGD013 should be stored at 2℃ - 8℃. All 
investigational drugs for treatment must be stored in accordance with sponsor and 
manufacturer's instructions. They will be placed in access control places with locks that meet 
storage conditions and comprehensive safety precautions. 
All investigational drugs will be numbered according to the requirements of Good 
Manufacturing Practice (GMP). The label text should include drug name, strength, package, 
sponsor name, batch no., and expire date, protocol no., and administration and so on. 
5.5.2 Responsibilities for Reception, Storage, and Management of Investigational Drugs 
It is the responsibility of the investigator to manage the investigational products and 
equipment on its study site that are provided by the sponsor. The investigational products and 
supplies must be recorded accurately in accordance with the protocol and national laws and 
regulations, supplied as required by the study at any time and maintained, stored, dispensed, 
used and disposed according to the regulations. A specialized person should be designated by 
the investigator to receive, store, dispense and return all investigational products during the 
study, and to record the dispensing accurately. Drug dispensing management form should 
include subjects’ identification number, random number, number of the dispensed, number of 
drug bottles and number of the returned. Drugs returned from subjects to study sites must be 
marked with “returned” to distinguish them from those that are not dispensed. 
All dispensing and management records should be accessible to the Sponsor for review. 
Study monitors will verify according to drug dispensing management form and stored drugs. 
Designated drug managers will dispense the investigational drugs according to the study 
protocol and drug management manual and cooperate with monitors’ audit. 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 56 of 106 
6. Visit Schedule and Assessments 
6.1 Study visits and assessments 
6.1.1 Screening Period (Day-28 to Day0) 
The following examinations or tests are required to be completed during the screening period: 
● 
Signing ICF; 
● 
Recording demographics: date of birth, gender, race, tobacco use, alcohol intake 
history, etc.; 
● 
Medical history and physical examination; 
- 
Medical and surgical history 
- 
Past and present medical history of HCC, including the date of first diagnosis, 
pathological type of tumor, BCLC stage of initial diagnosis, history of surgical 
or loco-regional treatment, systematic treatment history, cause of disease, 
BCLC stage at enrollment, Child-Pugh liver function classification, etc. 
- 
Physical examination and vital signs (within 7 days before administration), 
including height, weight and systemic examination; ECOG performance status 
score; 
● 
Hematologic test (complete blood cell count, CBC differential count): within 7 days 
before administration; 
● 
Serum biochemistry (within 7 days before administration): including liver function 
(total bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-GT, alkaline 
phosphatase, lactate dehydrogenase, serum total protein and albumin, etc.), renal 
function (urea nitrogen or urea, creatinine), electrolytes (K, Na, Cl, Ca, serum 
phosphorus, serum magnesium), fasting blood glucose, amylase, lipase; 
● 
Thyroid function (TSH, free T3, free T4), within 7 days before administration; 
● 
Coagulation (TT, PT, APTT and INR), within 7 days before administration; 
● 
AFP test within 7 days before administration; 
● 
Urinalysis (urine protein, urine occult blood, urine red blood cell, urine glucose, 
white blood cell, urine specific gravity, PH value), within 7 days before medication; 
● 
12-lead ECG, within 7 days before administration; 
● 
Echocardiography (performed during the screening period, and whether 
examinations are required at subsequent visits is determined according to clinical 
needs); 
● 
Blood or urine HGG for female subjects with childbearing potential (except 
females who have underwent surgical sterilization or those have been menopausal 
for more than one year) to exclude pregnancy (within 7 days before administration); 
● 
Hepatitis B serologic test, and HBV-DNA (only when HbsAg is positive);  
● 
Anti-HCV antibody, HCV-RNA (only when HCV antibody is positive);  
● 
HIV serology; 
● 
RECIST 1.1 assessment (During the screening period, contrast-enhanced CT on the 
chest as well as contrast-enhanced CT/MRI on the abdomen and pelvis are 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 57 of 106 
required; contrast-enhanced CT/MRI on the abdomen and other clinically indicated 
sites are performed for subsequent assessments);  
● 
Brain MRI (To rule out brain metastasis as indicated clinically); 
● 
Assessment of previous and concomitant medications (it is required to collect the 
medication history within 30 days prior to signing the ICF); 
● 
Evaluation of adverse events; 
● 
Eligibility assessment based on inclusion and exclusion criteria (review on results 
of diagnostic examination, and assessment of inclusion and exclusion criteria); 
6.1.2 Cycle 1 
6.1.2.1 Cycle 1, Day 1 
● 
Physical examination (to assess the changes since screening period) and body 
weight 
● 
Vital signs (respiratory rate, Blood Pressure (BP), heart rate, body temperature) : on 
Cycle 1 Day 1, vital signs are examined at the following time points: prior to 
infusion of MGD013 (within 30 minutes prior to infusion), at 15, 30 minutes (± 5 
minutes) after infusion, at the end of infusion (± 10 minutes), at 1, 3 hours (± 10 
minutes) after the completion of infusion. 
● 
ECOG body performance status score 
● 
12-lead ECG 
● 
Evaluation of adverse events 
● 
Evaluation of concomitant medication 
● 
Dispense investigational drug and medication diary 
● 
Completion of intravenous infusion of MGD013 at study sites 
● 
Administration of the first dose of brivanib alaninate (combination therapy group) 
6.1.2.2 Cycle 1, Day 8 
● 
Vital signs (respiration, blood pressure, heart rate, body temperature) 
● 
12-lead ECG 
● 
Hematology 
● 
Serum biochemistry 
● 
Coagulation 
● 
Evaluation of adverse events 
● 
Evaluation of concomitant medication 
6.1.3 Cycle 2 
6.1.3.1 Cycle 2, Day 1 
● 
Physical examination (to assess the changes since screening period) and body 
weight 
● 
Vital signs (respiration, BP, heart rate, temperature): prior to infusion of MGD013 
(within 30 minutes prior to infusion), at the end of infusion (± 10 minutes), at 1 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 58 of 106 
hour (± 10 minutes) after the completion of infusion. 
● 
ECOG body performance status score 
● 
12-lead ECG 
● 
Hematology 
● 
Serum biochemistry 
● 
Coagulation 
● 
Urinalysis 
● 
Evaluation of adverse events 
● 
Evaluation of concomitant medication 
● 
Return Investigational Drug and Review Medication Diary 
● 
Completion of intravenous infusion of MGD013 at study sites 
● 
Dispensing of the investigational drugs and medication diary (combination therapy 
group) 
6.1.3.2 Cycle 2, Day 8 
● 
Vital signs (respiration, blood pressure, heart rate and body temperature) 
● 
12-lead ECG 
● 
Hematology 
● 
Serum biochemistry 
● 
Coagulation 
● 
Evaluation of adverse events 
● 
Evaluation of concomitant medication 
6.1.4 Day 1 of subsequent cycles 
● 
Physical examination (changes since the previous assessment) and body weight 
● 
Vital signs (respiratory rate, BP, heart rate, body temperature): prior to infusion of 
MGD013 (within 30 minutes prior to infusion), at the end of infusion (± 10 
minutes), at 1 hour (± 10 minutes) after the completion of infusion. 
● 
ECOG body performance status score 
● 
12-Lead ECG 
● 
Hematology 
● 
Urinalysis 
● 
Coagulation test 
● 
Serum biochemistry 
● 
Serum AFP: once every 8 weeks (±7 days) until disease progression, test 
corresponding to radiographic assessment 
● 
Assessment according to RECIST 1.1 and irRECIST: once every 8 weeks (± 7 
days) until disease progression, tumor evaluation of pelvic and abdominal cavity 
and other sites as clinically indicated 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 59 of 106 
● 
Thyroid function: once every two cycles (±3 days) 
● 
HBV-DNA (HBsAg positive subjects), once every 8 weeks (± 7 days) 
● 
HCV-RNA (HCV antibody positive subjects), once every 8 weeks (± 7 days) 
● 
Evaluation of adverse events 
● 
Evaluation of concomitant medication 
● 
Dispense investigational drug and recover medication diary (combination therapy 
group) 
● 
Completion of intravenous infusion of MGD013 at study sites (for at most 48 
cycles) 
6.2 End of Study Treatment (completion of visits within 7 days after last dose of 
investigational drugs/withdrawal)  
● 
Physical examination and body weight 
● 
Vital signs (respiration, blood pressure, heart rate, body temperature) 
● 
ECOG body performance status score 
● 
12-Lead ECG 
● 
Hematology 
● 
Urinalysis 
● 
Coagulation test 
● 
Blood or urine pregnancy test (for female with childbearing potential) 
● 
Serum biochemistry 
● 
Serum AFP 
● 
Thyroid function 
● 
Evaluation of AEs (un-recovered or new AEs need to be assessed and recorded after 
this visit until 30 days after the last dose of investigational drug; in case of serious 
AEs or AESIs, the subject will be followed continuously until recovery or 
stabilization of the adverse event.) 
● 
Evaluation of concomitant medication 
● 
Return the investigational drugs and medication dairy (combination therapy group) 
Note: If the corresponding laboratory tests or examinations are performed within 7 days, 
it is not necessary to repeat them. 
6.3 Safety Follow-up (30 days ± 7 days after end of study treatment) 
● 
Physical examination 
● 
Hematology 
● 
Blood chemistry 
● 
Evaluation of AEs (investigational drug-related SAEs after this visit should be 
evaluated and recorded) 
● 
Evaluation of concomitant medication 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 60 of 106 
6.4 Post-Treatment Assessments (Subjects in phase II are not required to have visits in 
the study site) 
● 
Subjects will receive survival follow-up and subsequent treatment follow-up to 
collect  
o 
the information (including commencement date of subsequent first anti-tumor 
treatment) of first anti-tumor treatment (including chemotherapy) after the end 
of study treatment every 60 days (± 7 days) 
o 
Subjects will receive survival follow-up after discontinuation of study 
treatment every 60 days (± 7 days) to collect the information of new malignant 
tumors 
● 
Monitoring of SAEs and irAEs: study treatment-related SAEs or irAEs ≥ grade 3 
occurring within 30 days after the last dose should be recorded and evaluated. 
● 
Tumor imaging assessments and serum AFP: If the subject is withdrawn from the 
treatment for reasons other than radiographic progression, the subject will still need to 
undergo imaging scans and AFP testing every 8 weeks (± 1 week) after discontinuation 
of study treatment until tumor progression is confirmed or subsequent antineoplastic 
therapy is initiated 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 61 of 106 
7. Study Endpoints 
7.1 Safety Assessments 
7.1.1 Laboratory Tests 
The laboratory tests will be performed at the study site in accordance with the schedule of 
study visits in Table 1. Table 3 listed required laboratory tests of this study. Specific items 
included in hemotology, biochemistry, coagulation tests and urinalysis could be adjusted 
based on local practice of each site.  
Females subjects (except females who have underwent surgical sterilization and those have 
been menopausal for more than one year) of childbearing potential should undergo pregnancy 
test. The frequencies of all laboratory tests will be determined according to the schedule of 
study visits, but unscheduled tests may be added according to the clinical judgment by the 
investigator. All test results should be filed in the original case report and recorded in the 
eCRF. 
Table 3. Laboratory tests 
Haematological 
examination 
(CBC) 
Clinical Chemistry (Serum) and 
Coagulation 
Urinalysis 
Red cell count 
Blood urea nitrogen or urea, 
creatinine 
Specific Gravity 
Hemoglobin 
Albumin, total protein 
White blood cell 
Packed cell volume 
LDH, blood glucose 
Occult blood, red blood cell 
Classification of leukocytes and 
absolute count (neutrophils, 
basophils, eosinophils, 
lymphocytes, monocytes) 
Alkaline phosphatase (ALP), GGT, 
ALT, AST, total bilirubin 
Glucose 
Platelet count 
Sodium, 
potassium, 
calcium, 
magnesium, chloride 
Protein, PH 
 
Amylase, lipase 
 
 
Activated 
partial 
thromboplastin 
time 
APTT, 
international 
standardization ratio INR 
 
 
7.1.2 Electrocardiogram Assessment 
12-lead ECG examination will be performed according to Table 1 Schedule or at the time 
when any cardiac-related adverse event occurs during the study. Examination should be 
performed after the subject has rested in the supine position for at least 10 minutes prior to 
the specified time point. Each examination should be performed in the same position and all 
ECGs should be recorded. At each time point, the record of 2 ECGs with 2 minutes apart, 
should be obtained. A standardized electrocardiograph machine should be used, and the same 
device should be used throughout the study if possible. 
All ECG assessment items will include parameters such as heart rate, QRS complex, QT 
interval, QTc, and RR interval. ECG results will be assessed by the investigator or specialist 
and will be recorded in the eCRF. If a clinically significant abnormality is found at baseline 
(screening), it should be recorded in the subject's medical history; if a clinically significant 
abnormality is reported during treatment, it will be reported as an AE. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 62 of 106 
7.1.3 Physical examination 
A standard physical examination (including appearance, skin, eyes, ears/nose/throat, head and 
neck, heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal, nervous 
system, and other body systems, as applicable) will be performed according to Table 1 
schedule of study visits. Height is measured at the screening visit only. 
7.1.4 Vital signs 
Vital signs (respiratory rate, heart rate, blood pressure, and body temperature) will be 
measured according to Table 1 schedule of study visits. Vital sign should be measured in a 
sitting position after at least 10-minute’s rest. Vital signs are only examined once at the visit 
in the screening period and that at the end of study; on Cycle 1 Day 1, vital signs are 
examined at the following time points: prior to infusion of MGD013 (within 30 minutes prior 
to infusion), at 15, 30 minutes (± 5 minutes) after infusion, at the end of infusion (± 10 
minutes), at 1, 3 hours (± 10 minutes) after the completion of infusion. For subsequent visits, 
vital signs are examined at the following time points: prior to infusion of MGD013 (within 30 
minutes prior to infusion), at the end of infusion (± 10 minutes), at 1 hour (± 10 minutes) 
after the completion of infusion. Additional vital signs examination may be performed at any 
other time points as clinically indicated. 
7.1.5 Eastern Cooperative Oncology Group (ECOG) Performance Status Score 
ECOG performance status scoring will be evaluated according to Table 1 schedule of study 
visits. Refer to Table 4 for scoring. 
Table 4. ECOG score 
Description of physical status 
Score 
Completely normal, being able to perform work before illness without restriction 
0 
Not able to carry out heavy physical work, but be able to walk around and carry out light 
physical work such as light housework or office work 
1 
Can move around, capable of self-care, but unable to carry out any work-related activities, 
confined to bed for less than 50% of the day  
2 
Self-care can only be achieved to a limited extent, with more than 50% of the daytime spent in 
bed rest or chair sitting 
3 
Complete loss of activity of daily living, unable to achieve selfcare, confined to bed or 
wheelchair 
4 
 
7.1.6 Echocardiography 
Echocardiogram for LVEF is to be done at baseline, and then performed as clinically 
indicated (e.g. cardiac symptoms, or abnormal ECG findings with clinical significance). 
7.2 Efficacy assessments 
Contrast-enhanced CT or MRI of abdomen, pelvic and contrast-enhanced CT of lungs are 
required at baseline. During the follow-up visit, the same method of radiologic assessment on 
abdomen, pelvic cavity and other clinically indicated sites should be used. All baseline tumor 
imaging assessments must be performed within 28 days prior to the start of study medication. 
If subjects receive scanning before signing an informed consent form, as long as the scanning 
imaging is within the time limit specified by the protocol, the test method meets the 
requirements for image collection, and the data are obtained, it can be used for study analysis. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 63 of 106 
Radiologic examination should be conducted on abdomen, pelvic cavity and other clinically 
indicated sites every 8 weeks (±7 days) dated from the first day of the first cycle until disease 
progression. All imaging of Phase II study must be evaluated by independent central review. 
Tumor assessment should be carried out in strict accordance with the study plan. If imaging 
assessment occurs beyond the planned visits and there is no disease progression, subsequent 
tumor assessments should still be carried out according to the original plan. 
The investigator will also evaluate imaging response by RECIST 1.1 and irRECIST criteria, 
and classify the objective tumor response by target lesion assessment into: CR, PR, SD, PD 
and NE. For the subjects with initial response as PR or CR, the response should be 
confirmed at an interval of at least 4 weeks. subjects should be administered until PD 
confirmed according to irRECIST. 
7.2.1 Blinded independent central review (BICR) procedures 
In case of disease progression / treatment discontinuation at the investigator’s discretion, or at 
other time points specified by the sponsor, all imaging films should be submitted to the center 
for review. Imaging assessment based on RECIST 1.1 and irRECIST will be conducted by 
two independent imaging experts, assisted by an adjudicator if necessary. Reviewers are 
blinded to treatment cohorts of subjects. 
7.3 Exploratory study 
In Phase I and Phase II Part 1, an exploratory study of biomarkers will be conducted. Subjects 
participating in the study should submit archived or the latest formalin-fixed and paraffin-
embedded (FFPE) tumor tissues or about 20 unstained paraffin sections (if any) during the 
screening period, which will be sent to the central laboratory designated by the sponsor. 
Collection, handling, storage and transportation procedures of samples will be addressed in 
the laboratory manual of the central laboratory. The tumor tissues will be tested as follows: 
● 
Detect immune cell infiltration (including T cell infiltration), expression of PD-1, 
PD-L1, LAG-3, MHC-II and fibrinoid protein (FGL1) in tumor tissues through 
immunohistochemistry (IHC).  
In addition, blood will be also sampled and tested in Phase I and Phase II Part 1. The peripheral 
blood will be tested for: 
● 
Cytokines in serum, including but not limited to IFN-γ, IL-2, IL-6, IL-10 and TNF-
α. 
● 
Receptor occupancy of MGD013 on PBMC using multiparameter flow cytometer 
[only limited to phase I]; 
● Characterization of immune cells using multiparameter flow cytometer, including the 
percentage of B cells, T cells (T cell subsets), NK cells and monocytes in peripheral 
blood and T cell subsets; the markers of T cell activation and / or T cell exhaustion in 
PBMCs and markers of cytolytic activity (including but not limited to PD-1, CTLA-4, 
LAG-3, TIM-3, CD25, CD69 and granzymeB) 
● 
Exploration of safety-related biomarkers, including but not limited to IFN-γ, IL-2, 
IL6, IL-10 and TNFa  
The above blood analyses will be prioritized based on the degree of subjects’ response to drugs 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 64 of 106 
and the number of FFPE sections. In addition, for subjects with immune- and infusion-related 
reactions or cytokine release syndrome, additional sampling for analysis of serum cytokines. 
Exploratory study results will be reported separately other than in the clinical study report 
(CSR). 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 65 of 106 
8. Safety Monitoring, Reporting and Management 
8.1 Definition of adverse event (AE) 
In clinical study, adverse event refers to any untoward medical occurrence in a clinical 
investigation subject administered a investigational product. The event does not necessarily 
have to have a causal relationship with study treatment. An adverse event (AE) can therefore 
be any unfavourable and unintended sign (including an abnormal laboratory finding, for 
example), symptom, or disease temporally associated with the use of an invetsigatonal 
product, whether or not considered related to the investigational product. Adverse events 
include serious adverse events (SAE) and non-serious adverse events. 
8.2 Definition of Serious Adverse Event (SAE) 
Serious adverse event refers to an adverse event which occurs during clinical trial and meets 
any of the following criteria: 
● 
Results in death; 
● 
Is life-threatening (Note: The term "life-threatening" in the definition of "serious" 
refers to an event in which the subject is at risk of death at the time of the event; it 
does not refer to an event which hypothetically might have caused death if it were 
more severe); 
● 
Requires inpatient or prolonged hospitalization (Note: Common usage of "inpatient 
hospitalization" generally would include being treated by a physician in a hospital 
for at least a 24 hour period. Emergency room visits that do not result in admission 
to the hospital should be evaluated for one of the other serious outcomes (e.g., life-
threatening; required intervention to prevent permanent impairment or damage; 
other serious medically important event).); 
● 
Results in persistent or significant disability/malfunction/incapacity; 
● 
Results in congenital abnormality or birth defect; 
Other important medical event (defined as an event events that may not be immediately 
life-threatening or result in death or hospitalisation but may jeopardize the subject or 
may require medical intervention to prevent one of above listed outcomes. These should also 
usually be considered serious. Example of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions 
that do not result in hospitalisation; or development of drug dependency or drug abuse.). 
Note: The following scenarios will not be reported as SAEs: 
- 
Any results, including death, caused by progressive disease of tumor as 
assessed by investigator. 
- 
A hospitalization or prolonged hospitalization due to economic issue or for 
purpose of reimbursement only. 
- 
A hospitalization admission is pre-planned (ie, elective or scheduled surgery arranged 
prior to the start of the study).  
8.3 Collection, Record, Follow-up and Report of Adverse Events 
8.3.1 Time Limit for Collection of Adverse Events 
The collecting and recording of adverse events will be throughout the clinical trial, from the 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 66 of 106 
signing of the informed consent form (ICF) to the end of the trial (AE will be collected until 
30 days after the last dose of investigational drugs). AEs and SAEs that occur following the 
signing of the ICF but before the first dose treatment should be recorded on Medical History 
page of eCRF form as pretreatment symptoms and signs, and not collected as AEs on the AE 
eCRF page, but if deteriorates (higher than a grade) after administration the investigational 
drug, such events should be recorded as AEs 
8.3.2 Follow-up of Adverse Events 
Investigators must follow up all adverse events until their disappearance or recovery to 
baseline, up to disease stable in case of permanent injury; if an adverse event is not recovered 
at the last visit of the study, investigators must continue to follow up the adverse event until 
disappearance or recovery to baseline level, or clinical stability. Subsequent follow-up may 
not be recorded in the eCRF, but the sponsor has the right to ask investigators to provide 
more information where necessary. 
8.3.3 Elements of Adverse Event Collection 
● 
Selection of AE term: The disease diagnosis is preferred as AE term if a unifying 
diagnosis is available; if not, the associated symptoms and signs are to be captured 
and recorded using standard medical terminology. Once the diagnosis is confirmed 
with the follow up information, the symptoms and sign should be replaced with 
diagnosis accordingly. One single event term to be recorded should only contain a 
sole event, such as a single diagnosis, sign and/or symptom. For example, if a 
subject experiences “vomiting and diarrhea”, then it need to be captured separately 
as two AEs rather than one, namely “vomiting” and “diarrhea”. 
● 
Onset date/Stop date of AE: In general, the date when first signs and/or symptoms 
appear is captured as onset date rather than the time of confirmed diagnosis, to 
prevent missing safety information or underestimating safety hazards. If the date 
when first signs and/or symptoms appear cannot be determined based on the 
available information, then the time of disease diagnosis will be used as the event 
onset date. 
● 
AE severity (CTCAE Grade 1-5): AE severity is graded from 1 to 5 according to 
the Common Terminology Criteria for Adverse Events (CTCAE 5.0); for those 
reported without assigned CTCAE Grade, the terms including “mild”, “moderate” 
and “severe” that used to describe the event severity can be converted to the 
corresponding CTCAE Grade by referring to the defined CTCAE criteria. Serious 
adverse events (SAEs) are different from severe AEs: SAEs are determined based 
on clinical outcome or medical intervention as described in Chapter 8.2, while the 
severity of AE refers to the event intensity which is usually evaluated and graded 
according to the CTCAE. A severe AE is not necessarily an SAE, e.g. nausea 
lasting for several hours may be graded as severe in CTCAE grading however 
probably not a SAE. Conversely, a stroke that caused partial disability may only be 
mild based on CTCAE grading; however, it is generally reported as a SAE. 
● 
The investigator should evaluate and provide causal relationship between the 
investigational drug and the AE, for the details please refer to 8.3.4. 
● 
Action taken with the investigational drug in response to AEs (e.g., whether the AE 
led to drug discontinuation or dose reduction, etc.). 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 67 of 106 
● 
Concomitant medication: It should be indicated whether the concomitant 
medication is for treatment of a specific AE/SAE, or part of clinical routine 
diagnosis and treatment, which should be clarified and recorded in the SAE report. 
● 
Event outcome: Outcomes of AE include complete recovery, events not yet 
resolved, recovery with sequelae, death and unknown. 
8.3.4 Causality Assessment 
The investigator’s assessment of causality must be provided for all AEs to determine if there 
is a reasonable possibility that the investigational product caused or contributed to an AE. 
"Yes" or "No" will be provided. Generally, the following factors should be considered in 
performing causality assessment: 
● 
Temporal relationship with investigational drug treatment; 
● 
Whether the symptoms and signs are consistent with the pharmacological action of 
the drug's active ingredients; 
● 
Alternative medical reasons other than the investigational drug treatment; 
● 
De-challenge results; if symptoms/signs relieved or improved upon reduction or 
withdrawal of the investigational drug; 
● 
Re-challenge results; if symptoms/signs recurred or worsened upon re-introduction 
of the investigational drug treatment; 
● 
Evidence of previous, similar incidents from literature search. 
In case of insufficient information which does not allow for a comprehensive assessment, the 
AEs could be conservatively assessed as related to the investigational drug and the reason 
need to be documented. 
8.3.5 Adverse Events based on Laboratory Examinations and Tests 
The laboratory test, vital signs, ECGs and any other safety relevant test specified in the study 
will be summarized in the clinical study report. The change of value from the baseline is 
reported as an AE only if it is medically significant. For example, worsened by 1 grade or 
higher in CTCAE grading, led to discontinuation, dose adjustment or interruption of study 
treatment or the investigator believes that this abnormality should be reported as an AE. 
When the abnormal findings in laboratory test/examinations, vital signs, ECG and other 
safety relevant test are considered related to a clinical diagnosis, then only this clinical 
diagnosis need to be reported as AE and those abnormal findings are handled as additional 
safety information related to the corresponding diagnosis. In this case, the investigator should 
use clinical terminology (e.g. anemia) rather than laboratory terminology (e.g. hemoglobin 
decreased) as applicable. 
8.3.6 Progressive Disease 
Events due to progression of the neoplasm disease which under investigation should not be 
reported as AEs or SAEs. 
8.3.7 Death 
All deaths occurring during the study, including deaths occurring within 30 days after the last 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 68 of 106 
dose of the investigational drug administration, should be reported by investigators as 
follows: 
● 
If death is caused by disease progression, the investigator should notify the 
Sponsor's monitor of the event in the next site monitoring visit and record it in 
corresponding moduleof eCRF, but it will not be reported as a SAE. 
● 
If it is not clear whether the death is caused by disease progression, the death 
should be reported as a SAE, informed to the monitor and reported to the relevant 
parties within 24 hours (refer to 8.3.9); the SAE report should evaluate whether the 
disease progression jointly contributed to the death of the subject and identify the 
main cause of death and other related factors, as appropriate; 
● 
Death cases with unknown causes must be reported as SAE, and the cause of death 
should be clarified with every effort. Autopsy may be conductive to assessment on 
the cause of death. If an autopsy is performed, the Sponsor should be notified of the 
autopsy report. 
If adverse events occurred beyond the above collection time limit: 
● 
Deaths caused by disease progression do not need to report as SAEs; 
● 
If the death is determined to be related to the investigational drug by the 
investigator, monitors and concerned parties should be notified within 24 hours (see 
8.3.8) 
8.3.8 SAE Reporting 
Any SAE occurring during the study, regardless of causal relationship to investigational drug, 
should be reported by following the SAE reporting procedures required by competent 
regulatory authorities or Independent Ethics Committee. 
The investigator should: 
(1) Immediately take appropriate medical measures, if necessary; 
(2) Record SAEs in the AE Form, SAE Form and source documents of eCRF. 
(3) The investigator should immediately (within 24 hours of becoming aware of the 
event) send the singed and dated SAE Form to Drug Safety Department of the 
Sponsor (email as follows). 
Please send SAE report to the email mailbox of Drug Safety Department of Zai Lab: 
 
The SAE reporting period starts from when the subject signs the ICF until 30 days after the 
last dose treatment. Collection and follow up on SAEs that are related to the investigational 
drugs which occurring after 30 days of the last dose will be pursued until they disappeared, or 
recovered to the baseline level or clinically stable, even if the ICF is withdrawn. 
8.3.9 Adverse Event of Special Interest (AESI) 
Given the mechanism of action and summary of the aggregate data from a set of preclinical 
and clinical studies previously conducted, the event listed as follows are selected as AESIs of 
brivanib alaninate in this trial: 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 69 of 106 
- 
Important identified risks: hypertension, RPLS, hepatic events, hypothyroidism, 
hyponatremia, proteinuria, arterial thrombotic events; 
- 
Important potential risks: hemorrhage, venous thrombotic events, left ventricular 
dysfunction, gastrointestinal perforation, and impaired wound healing; 
If an AESI meets SAE criteria, then it should be reported as such according to the standard 
SAE reporting procedure as specified in protocol. Otherwise, AESIs will be recorded on 
eCRF only for periodic review and analysis by the sponsor. 
AESIs of MGD013 include ≥Grade 3 infusion-related reactions and any immune-related 
adverse events (irAEs) leading to discontinuation and interruption of MGD013. See 8.4.1. 
All occurrences of AESIs of MGD013 must be reported to the Sponsor within 24 hours of 
awareness. The investigator should complete the "AESIs Report Form" within 24 hours of 
awareness and report the events to the sponsor by email. If an AESI meets SAE criteria, then 
it should be reported directly in accordance with standard SAE reporting procedures as 
specified. 
8.3.10 Pregnancy 
Effective contraception is required for both male and female subjects of childbearing 
potential during the study and within 120 days after discontinuation of investigational drug 
treatment. Once pregnancy is found to be pregnant following initiation of study treatment, the 
investigational drug will be permanently discontinued and the female subject will be 
withdrawn from the trial. If a female subject or a male subject's partner becomes pregnant 
during the study or within 4 months after the last dose of investigational drug adminstration, 
the investigator should be notified immediately. The pregnancy must be recorded on 
“Pregnancy Reporting Form” and reported by the investigator to the Sponsor via email within 
24 hours of becoming aware of the event. At the same time, the pregnancy also must be 
recorded on eCRF. All pregnancies must be followed until the end of pregnancy, and the 
sponsor should be informed of the pregnancy outcome information. If the outcome of the 
pregnancy meets SAE criteria (e.g., spontaneous abortion/miscarriage or therapeutic abortion 
with any detected congenital anomaly, stillbirth, neonatal death, or birth defect), it will be 
reported as SAE. The investigator should send the completed “SAE Reporting Form” to the 
Sponsor via email within 24 hours of becoming aware of the event. All pregnancies during 
the trial or within 120 days after the last dose of investigational drug should be handled in 
accordance to the procedure described in this section. 
8.3.11 Overdose 
Overdose is defined as any condition where the maximum dose recommended specified in 
the protocol is exceeded, including infusion dose in unit time. At present, there is no human 
data on overdose of MGD013 and no known antidote have been obtained. In the event of 
MGD013 overdose, the intravenous infusion should be immediately discontinued and the 
subject should be closely monitored and treated symptomatically. 
In the entire brivanib alaninate clinical program, there have been a total of 49 reports of 
overdose reports. Among these 49 reports, 20 of them were randomized to either placebo or 
comparator group, and 29 were randomized to brivanib group. The reported overdose was as 
high as 2 times (1,600 mg) the normal daily dose of brivanib alaninate or the comparator. 
Most reported cases were reported as one-time accidental overdose. There were no clinical 
sequelae reported for any overdose with one exception. One subject experienced one 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 70 of 106 
accidental overdose of brivanib alaninate (1,600 mg) on day 1 of the study treatment, but no 
overdose-related AE was reported. The subject continued to receive blinded drug therapy 
with a correct dose. The subject developed toxic dermatitis 3 weeks later. Although it was 
possibie that the study treatment with brivanib may have played a participative role in the 
development of toxic dermatitis, the toxic dermatitis was not considered to be related to 
accidental overdose. In another case, a subject with overdose of 1,600 mg for a week 
experienced extremely severe ALT/AST elevation. After study unblinding, the subject was 
found to be assigned to comparator group. 
There is no known antidote for overdosage of brivanib alaninate. In case of overdosage, the 
subject should be monitored, and supportive treatment should be administered, including 
supportive medical interventions to treat the presenting clinical manifestations. 
8.4 Management of study drug-related adverse events 
8.4.1 Prevention and treatment of MGD013-related adverse events 
8.4.1.1 Infusion-related reactions, including cytokine release syndrome (CRS) 
Infusion-related reactions related to mAbs or DARTs (including CRS) should be controlled 
according to standard practice for drugs. General guidelines for the management of such 
reactions are provided in this section; however, severe reactions may require more intensive 
interventions (e.g., steroids, anti–TNF-α antibodies, and/or IL-6 inhibitors). 
Subjects should be monitored closely for the development of infusion-related reactions 
during the MGD013 infusion. Medications and supportive measures for severe 
hypersensitivity reactions should be available for immediate intervention of an infusion 
reaction during administration of study drug and may include, but are not limited to: 
subcutaneous (SC) epinephrine (0.3 to 0.5 mL of a 1:1000 solution), antihistamines (e.g., 
diphenhydramine 25 to 50 mg IV), corticosteroids (e.g., hydrocortisone 20 to 40 mg IV push 
or equivalent, dexamethasone 10 to 20 mg IV), IV fluids, vasopressors, oxygen 
supplementation, bronchodilators, and antipyretics. In addition, resuscitation equipment and 
other supplies for the emergency management of an allergic/toxic reaction must be available. 
The subject should be treated according to the best available local practices and procedures. 
All supportive measures consistent with optimal subject care will be provided throughout the 
study according to institutional standards. 
Should symptoms of fever or chills develop, it may be difficult to distinguish among potential 
causes of the symptoms including emerging infection or infusion reaction. Subjects should be 
evaluated carefully for the presence of infection, with the acquisition of cultures and/or 
implementation of empiric antibiotic therapy, as appropriate, based on the assessment of the 
Investigator. Management guidelines for infusion-related reaction are as follows. 
Grading and Management of Infusion-related Reactions 
● 
Grade 1: Mild transient reaction; infusion interruption or intervention not indicated;  
● 
Grade 2: Therapy or infusion interruption indicated with immediate response to 
symptomatic treatment (e.g., antihistamines, non-steroidal anti-inflammatory drugs 
[NSAIDs], narcotics, IV fluids); prophylactic medications indicated for ≤ 24 
hours; 
● 
Grade 3: Prolonged (e.g., not rapidly responsive to medication and/or brief 
interruption of infusion); recurrence of symptoms following initial improvement; 
hospitalization indicated for clinical sequelae (e.g., renal impairment, pulmonary 
infiltrates); 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 71 of 106 
● 
Grade 4: life-threatening consequences; vasopressors or ventilatory support 
indicated; 
● 
Grade 5: Death. 
It is considered appropriate for grading all infusion reactions in this study, irrespective of the 
underlying mechanism of the reaction for the above CTCAE v5.0 grading scale for CRS is 
nearly identical to that for infusion reaction and allergic reaction. The Sponsor’s monitor or 
designated personnel should be contacted immediately if questions arise from the grading. 
Premedication and Prophylaxis for Infusion-related Reactions 
Prophylactic pre-infusion guidelines should be followed to mitigate the occurrence or 
severity of potential infusion reactions with study drug. Prior to the infusion of MGD013, the 
pre-medications are as follows: 
● 
Acetaminophen(or equivalent) 650-1000 mg or ibuprofen 400 mg per os (PO)  
● 
Diphenhydramine 50 mg or appropriate dose of equivalent H1 antagonist PO or IV 
● 
Ranitidine 300 mg PO or 50 mg IV; or appropriate dose of equivalent H2 antagonist 
at the discretion of the investigator 
For subjects who had infusion reactions following the first dose of MGD013 that were not 
adequately controlled with the above pre-medications, IV corticosteroids may be added to the 
pre-medication for subsequent administration. Dexamethasone 10-20 mg IV, or equivalent IV 
steroids, may be used as pre-medication in addition to acetaminophen, diphenhydramine, and 
ranitidine if the subject experiences a > Grade 2 infusion reaction with the first infusion. 
Premedication with steroids should be reduced by 50% with subsequent dose and 
discontinued thereafter, if there are no infusion reactions. 
Management of Observed Infusion Reactions 
≥ Grade 3 infusion reactions should be reported as AESIs and/or SAEs, as applicable. 
The following are treatment guidelines (which may be modified as needed by the investigator 
according to the best practices of drugs) for infusion reactions: 
Grade 1: 
● 
Slow the study drug infusion rate by 50% 
● 
Monitor the subject for worsening of condition 
● 
Continue at 50% of infusion rate and recover to the original rate after 30 minutes if 
the initial rate is tolerated. The subsequent infusions can be from 50% rate, which 
can be increased if tolerated by the subjects. 
● 
Note: Per Section 8.4.1, the following prophylactic pre-infusion medications are 
required prior to all infusions of MGD013, including future infusions for patients 
who experience Grade 1 infusion reactions:: 
- 
Diphenhydramine 25 to 50 mg (or equivalent) PO/IV 
- 
Acetaminophen (or equivalent) 650-1000 mg PO and/or ibuprofen 400 mg PO 
- 
Ranitidine 300 mg PO or 50 mg IV, or equivalen. 
Grade 2: 
● 
Stop the infusion. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 72 of 106 
● 
Administer diphenhydramine hydrochloride 25 to 50 mg IV. 
● 
Acetaminophen (or equivalent) 650-1000 mg PO or ibuprofen 400 mg PO for fever. 
● 
Oxygen inhalation and bronchodilators for mild bronchospasm. 
● 
Resume at 50% of the initial rate once the infusion reaction has resolved or 
decreased to Grade 1. The initial rate can be resumed after 30 minutes if tolerated. 
The subsequent infusions can be from 50% rate, which can be increased if tolerated 
by the subjects. 
● 
Monitor for worsening condition. If symptoms recur, discontinue the infusion; no 
further study drug will be administered at that visit. 
● 
For patients with Grade 2 infusion reactions, despite premedication with 
diphenhydramine, ranitidine or equivalent, and acetaminophen (or equivalent) 
and/or ibuprofen, corticosteroids (10-20 mg dexamethasone IV, or equivalent IV 
steroid) should be added to the premedication regimen for the next dosing of 
MGD013. Reduce corticosteroid dosing by 50% for the subsequent dose and hold 
thereafter, if there are no reactions. 
Grade 3: 
● 
Discontinue the infusion and disconnect the infusion tubing from the subject. 
● 
To avoid exacerbation of infusion reaction or CRS: do not flush the tubing, and 
withdraw residual drugs from the lumen. 
● 
Diphenhydramine hydrochloride 25 to 50 mg IV, dexamethasone 10- 20 mg IV (or 
equivalent), and other medications/treatment as medically indicated. Higher doses 
of corticosteroids (e.g., methylprednisolone 2 to 4 mg/kg IV or the equivalent) may 
also be considered for acute management. 
● 
Tocilizumab (an IL6 receptor antagonist) 4 mg/kg IV considered. 
● 
Intravenous fluids replacement, oxygen supplementation, and bronchodilators 
should be considered as appropriate. 
● 
If a Grade 3 infusion reaction occurs with MGD013, it will be discontinued for that 
day. If the symptom has resolved to baseline within 12 hours, MGD013 may be 
resumed at the next scheduled dose, with 50% of infusion rate. In addition, subjects 
should be pre-medicated with the following drugs (diphenhydramine hydrochloride 
25 to 50 mg IV; acetaminophen 650-1000 mg PO and/or ibuprofen 400 mg PO; 
corticosteroids may be considered as well (dexamethasone 10 to 20 mg IV, or 
equivalent IV steroids)) for this re-challenge and for any subsequent doses of 
MGD013. Reduce corticosteroids by 50% for the subsequent dose and withhold 
thereafter, if there are no reactions. 
● 
Subjects who have a Grade 3 infusion reaction that does not resolve within 12 hours 
despite medical management should not receive further MGD013 treatment. 
● 
Subjects who experience a second Grade 3 infusion reaction at the time of 
rechallenge of the investigtional drugs will permanently discontinue MGD013. 
Grade 4: 
● 
Discontinue the infusion and disconnect the infusion tubing from the subject. 
● 
To avoid exacerbation of infusion reaction or CRS: do not flush the tubing. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 73 of 106 
● 
Diphenhydramine hydrochloride 50 mg IV, dexamethasone 20 mg IV (or higher 
doses of steroids, e.g., methylprednisolone 2 to 4 mg/kg IV or the equivalent, as 
considered appropriate). 
● 
Tocilizumab (an IL6 receptor antagonist) 4 mg/kg IV considered. 
● 
Epinephrine or bronchodilators as indicated. 
● 
Supported ventilation and vasopressor as indicated. 
● 
Subjects who have a Grade 4 infusion reaction should not receive any further doses 
of MGD013. 
All changes in the infusion of MGD013, including interruption of the infusion and its 
duration as well as reductions in infusion rate and duration, must be recorded. 
8.4.1.2 Immune-related Adverse Events 
Blockade of immune checkpoints has been associated with several immune mediated adverse 
events that develop as a result of disruption of immune tolerance in normal tissues. They 
include but are not limited to pneumonitis, autoimmune hepatitis, glomerulonephritis, 
diarrhea or colitis, encephalitis, hypophysitis, thyroiditis, or other autoimmune 
endocrinopathies (e.g., pancreatitis and diabetes), myocarditis, and Stevens Johnson 
syndrome/toxic epidermal necrolysis. The occurrence of any of these events may indicate 
interruption or discontinuation of MGD013, and they should be evaluated and reported to the 
Sponsor as AESIs. Most low-grade immune-related AEs (irAEs) can be managed 
symptomatically. Persistent low grade or moderate toxicities may require treatment with 
corticosteroids or in refractory cases other immunosuppressive agents such as mycophenolate 
or infliximab may be required. Severe immune-related toxicities will, in almost all cases, 
require treatment with high-dose corticosteroids. 
General guidelines for management of specific immune-related toxicity / event are provided 
below. All events will be graded according to NCI CTCAE v5.0. 
Diarrhea or Colitis 
Diarrhea that develops in subjects while receiving MGD013 treatment may reflect immune 
reactivity against normal colonic epithelium and careful monitoring for potential immune-
related colitis should be instituted. Subjects should be monitored closely for evidence of 
diarrhea or other change in bowel habits as well as other signs and symptoms suggestive of 
colitis. Subjects who develop signs or symptoms including abdominal pain, abdominal 
distension, nausea, vomiting, diarrhea, or blood in the stool should be evaluated carefully for 
potential colitis. 
● 
Grade 1 diarrhea - Closely monitor the diarrhea until resolution. 
● 
Grade 2 diarrhea - Increase frequency of monitoring until resolution. For 
management of symptoms: 
- 
Loperamide/diphenoxylate 
- 
Low-dose steroids if clinically indicated 
- 
Consider management of prolonged Grade 2 diarrhea lasting more than 5 to 7 
days or relapsed diarrhea as Grade 3 diarrhea (see below) 
● 
Grade 3 diarrhea - withhold MGD013. Hospitalize subject promptly for further 
evaluation and management, including the following: 
- 
Bowel rest 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 74 of 106 
- 
Intravenous fluids replacement with close monitoring of body fluid and 
electrolytes status 
- 
Monitor frequency of bowel movements 
- 
Consider imaging to rule out bowel obstruction or perforation 
- 
Consideration of colonoscopy as appropriate 
- 
Implementation of preliminarily empirical immune suppression consisting of 
IV corticosteroids using methylprednisolone at a dose of 2 mg/kg/day (or 
equivalent) divided twice daily. As tolerated, subjects may be converted to oral 
corticosteroids (i.e., prednisone 2 mg/kg/day divided twice daily) and tapered 
as appropriate guided by the subjects’ clinical status. 
- 
Taper corticosteroids as clinically indicated 
- 
For subjects with severe colitis or those who do not respond to corticosteroids, 
additional immune suppression with anti-TNF-α antibodies (i.e., infliximab) 
should be considered early in the course. 
- 
The MGD013 should be resumed if: 
o 
It has been confirmed there is no colitis and an alternative cause of 
diarrhea is found, and 
o 
Diarrhea resolves to ≤ Grade 1 within 14 days 
● 
Grade 4 diarrhea - discontinue MGD013 and treat as for Grade 3. 
Hepatotoxicity 
Transaminases increased 
Management guidelines for subjects experiencing hepatic toxicity are as follows: 
● 
Grade 1 transaminases increased - No specific therapy required. 
● 
Grade 2 transaminases increased - For transaminases increased (3 to 5 × ULN), rule 
out viral and other etiologies. Consider imaging examinations such as ultrasound or 
CT scan and liver biopsy to ascertain etiology of hepatosis. Consider starting oral 
prednisone 60 mg/day divided twice daily, and withhold MGD013. 
- 
If it doesn't recover to ≤ Grade 1 within 48 hours, IV steroids such as 
methylprednisolone at 2 mg/kg/day divided twice daily or oral steroids such as 
prednisone 60 to 120 mg/day divided twice daily should be considered. 
- 
Monitor liver function tests at least twice weekly (or more frequently as 
clinically appropriate in the judgment of the investigator) until transaminases 
have returned to Grade 1 or baseline. 
- 
Taper corticosteroids as clinically indicated with improvement in liver function 
- 
Resume MGD013 at the next scheduled dose if no more than two doses were 
missed. 
- 
If an improvement to ≤ Grade 1 does not occur within 14 days, discontinue 
MGD013. 
● 
Grade 3 transaminases increased - withhold MGD013. 
- 
For transaminases increased > 8 × ULN, permanently discontinue MGD013. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 75 of 106 
o 
Begin immediate IV steroids; it is suggested to use methylprednisolone (2 
mg/kg/day divided twice daily). 
o 
Consider additional immune suppression with mycophenolate for subjects 
who do not respond to corticosteroids within 3 to 5 days. 
o 
Monitor liver function tests at least twice weekly (or more frequently as 
clinically appropriate in the judgment of the investigator) until 
transaminases have returned to Grade 1 or baseline. 
- 
If transaminases increased > 5× ULN and ≤ 8 × ULN: 
o 
Begin immediate IV steroids; it is suggested to use methylprednisolone (2 
mg/kg/day divided twice daily). 
o 
Consider additional immune suppression with mycophenolate for subjects 
who do not respond to corticosteroids within 3 to 5 days. 
o 
Monitor liver function tests at least twice weekly (or more frequently as 
clinically appropriate in the judgment of the investigator) until 
transaminases have returned to Grade 1 or baseline. 
o 
If the elevation does not improve to Grade 2 within 7 days and to Grade 1 
within 14 days, discontinue MGD013. 
o 
Resume MGD013 if: 
▪ 
Laboratory elevations improved to ≤ Grade 2 within 7 days and 
improved to ≤ Grade 1 or baseline within 14 days. 
▪ 
Steroids have been tapered to ≤ 10 mg/day of prednisone or 
equivalent. 
▪ 
On resuming MGD013, laboratory tests of AST, ALT, and total and 
direct bilirubin will be evaluated at least once per week for 3 
consecutive weeks. 
- 
Permanently discontinue MGD013 in the case of a second increase of AST or 
ALT to ≥ Grade 3. 
● 
Grade 4 transaminases increased - Discontinue MGD013 and treat as for Grade 3 
elevation. 
Increased Total Bilirubin 
Management guidelines for subjects experiencing increased total bilirubin are as follows: 
● 
Grade 1 increased total bilirubin - No specific therapy required. 
● 
Grade 2 increased total bilirubin - Withhold MGD013 until improvement to ≤ 
Grade 1 or baseline. 
- 
Rule out viral and other etiologies. Consider imaging examinations such as 
ultrasound or CT scan and liver biopsy to ascertain etiology of hepatosis. 
Consider oral steroids. 
- 
If an improvement to ≤ Grade 1 does not occur within 14 days, discontinue 
MGD013 and begin oral steroids. 
● 
Grade 3 increased total bilirubin - withhold MGD013. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 76 of 106 
- 
For increased total bilirubin > 5 × ULN, permanently discontinue MGD013 
and initiate IV steroids (it is suggested to use methylprednisolone 2 mg/kg/day 
divided twice daily). 
o 
If no response to corticosteroids is observed within 3 to 5 days, an 
additional immune suppression therapy with mycophenolate is 
considered. 
o 
Monitor liver function testing at least twice weekly (or more frequently as 
clinically appropriate in the judgment of the investigator) until total 
bilirubin has returned to Grade 1 or baseline. 
- 
If increased total bilirubin> 3.0 - ≤ 5 × ULN: 
o 
Begin immediate IV steroids; it is suggested to use methylprednisolone (2 
mg/kg/day divided twice daily). Consider additional immune suppression 
with mycophenolate for subjects who do not respond to corticosteroids 
within 3 to 5 days. 
o 
Monitor liver function tests including total bilirubin at least twice weekly 
(or more frequently as clinically appropriate in the judgment of the 
investigator) until total bilirubin has returned to Grade 1 or baseline. 
o 
If the elevation does not improve to Grade 2 within 7 days and to Grade 1 
within 14 days, discontinue MGD013. 
o 
Resume MGD013 if: 
▪ 
Laboratory elevations improved to ≤ Grade 2 within 7 days and 
improved to ≤ Grade 1 or baseline within 14 days. 
▪ 
Steroids have been tapered to ≤ 10 mg/day of prednisone or 
equivalent. 
o 
On resuming MGD013, laboratory tests of AST, ALT, and total bilirubin 
will be evaluated at least once per week for 3 consecutive weeks. 
o 
Permanently discontinue MGD013 in the case of a second increase of 
total bilirubin to ≥ Grade 3. 
● 
Grade 4 increased total bilirubin - Discontinue MGD013 and treat as for Grade 3 
elevation. 
Non-infectious Pneumonitis 
Management guidelines for subjects experiencing pneumonitis are as follows: 
● 
Grade 1 pneumonitis - No specific therapy required; close monitoring of lung 
function and imaging. 
● 
Grade 2 pneumonitis - Withhold MGD013. 
- 
Consider corticosteroids: 1 to 2 mg/kg/day of oral prednisone or equivalent 
divided twice daily. 
- 
Taper over 4 weeks as clinically indicated. 
- 
Resume MGD013 at next scheduled dose if pneumonitis resolves to ≤ Grade 
1 within 5 days with or without treatment. 
● 
Grade 3 and 4 pneumonitis - Permanently discontinue MGD013. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 77 of 106 
- 
Hospitalization  
- 
Recommend a pulmonary specialist consult/diagnostic evaluation including 
chest X-ray and CT scan. 
- 
Initiate maximal supportive care including IV corticosteroids (it is suggested to 
use methylprednisolone 2 to 4 mg/kg/day divided twice daily). Higher doses 
may be used in consultation with the Sponsor’s Monitor. 
- 
If no response to corticosteroids is observed within 3 to 5 days, additional 
immune suppression therapy (i.e., infliximab, etc.) can be considered. 
Skin Toxicity 
Management guidelines for subjects experiencing skin toxicity are as follows: 
● 
Grade 1 or 2 skin reactions 
- 
Symptomatic treatment with low-dose topical corticosteroids (betamethasone 
0.1% or hydrocortisone 1%) or antihistamines (diphenhydramine). 
- 
Persistent Grade 1 or 2 rash should be managed with higher dose topical 
corticosteroids and/or oral prednisone (1 to 2 mg/kg/day) if there is no 
improvements with topical therapies or the rash is accompanied by other 
dermal toxicities such as pruritus. 
● 
Grade 3 skin reactions – Withhold MGD013. 
- 
Initiate oral corticosteroids (oral prednisone 1 to 2 mg/kg/day). 
- 
MGD013 may be restarted at the next scheduled dosing if symptoms resolve to 
≤ Grade 2 within 14 days. 
- 
A Grade 3 skin toxicity that does not resolve to ≤ Grade 2 within 14 days 
after oral corticosteroids requires permanent discontinuation of MGD013. 
● 
Grade 4 skin reactions - Discontinue MGD013. 
- 
Initiate oral corticosteroids (oral prednisone 1 to 2 mg/kg/day). 
- 
Consideration should be given to start IV corticosteroids (methylprednisolone 
1-2 mg/kg/day) for Grade 4 skin toxicities; methylprednisolone should be 
tapered over 30 days if resolved to < Grade 2. 
Nephritis 
Management guidelines for subjects experiencing nephritis are as follows: 
● 
Grade 1 nephritis - No specific therapy required; close monitoring of renal function. 
● 
Grade 2 nephritis - Withhold MGD013. 
- 
Consider nephrology consultation and renal biopsy to confirm interstitial 
nephritis. 
- 
Initiate corticosteroids: 1 to 2 mg/kg/day of oral prednisone or equivalent 
divided twice daily. Taper over 4 weeks as clinically indicated. 
- 
Resume MGD013 at next scheduled dose if: 
▪ 
Nephritis resolves to ≤ Grade 1 within 14 days with or without 
treatment 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 78 of 106 
● 
Grade 3 and 4 nephritis - Permanently discontinue MGD013. 
- 
Consider hospitalization, nephrology consultation, and renal biopsy to confirm 
interstitial nephritis. 
- 
Initiate corticosteroids: 2 to 4 mg/kg/day of oral or IV methylprednisolone or 
equivalent divided twice daily. Taper over 4 weeks as clinically indicated. 
Immune-Mediated Hypophysitis 
Management guidelines for subjects experiencing hypophysitis are as follows: 
● 
Grade 1 hypophysitis - No specific therapy required. 
● 
Grade ≥ 2 hypophysitis - Withhold MGD013. 
- 
Consult endocrinologist. 
- 
Consider hospitalization. 
- 
Consider a short course of high dose IV corticosteroids: e.g., 
methylprednisolone 2-4 mg/kg/day IV (or equivalent) divided twice daily. 
- 
Initiate hormonal replacement therapy as indicated. 
- 
MGD013 may be resumed as allowed by protocol when: 
▪ 
Endocrinopathy is controlled with appropriate replacement therapy. 
▪ 
Corticosteroids reduced to ≤ 10 mg/day prednisone or equivalent. 
- 
Brain MRI recommended. 
Thyroid Toxicity 
Thyroid disorders may occur at any time during treatment with MGD013. Monitor subjects 
for changes in thyroid function and for clinical signs and symptoms of thyroid disorders per 
protocol and as indicated by clinical evaluation. Isolated hypothyroidism may generally be 
managed with replacement therapy without treatment interruption or corticosteroids, and 
treatment guidelines for hyperthyroidism are recommended below: 
● 
Grade 1 hyperthyroidism - No specific therapy required. 
● 
Grade 2 hyperthyroidism - Withhold MGD013. 
- 
Consider initiating oral corticosteroids. 
- 
A short course of corticosteroids such as methylprednisolone 1 to 2 mg/kg/day 
IV (or equivalent) divided twice daily. 
- 
MGD013 will be resumed if it is reduced to ≤ 10 mg/day prednisone or 
equivalent and stable on hormone replacement therapy (if necessary). 
● 
Grade 3 or 4 hyperthyroidism - Withhold MGD013. 
- 
Consider hospitalization and consulting endocrinologist. 
- 
IV corticosteroids such as methylprednisolone 2 to 4 mg/kg/day IV (or 
equivalent) divided twice daily. 
- 
Initiate hormonal replacement therapy as indicated. 
- 
Consider restarting MGD013 when complete resolution or disease stable on 
hormone replacement therapy within 14 days and it is reduced to ≤ 10 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 79 of 106 
mg/day prednisone or equivalent. 
8.4.2 Brivanib Alaninate-related Adverse Reactions 
Management of Hypertension 
In case of hypertension during treatment with angiogenesis inhibitors, investigators should 
take measures according to the best practices of drugs. The following treatment guideline 
may be adopted according to experience of previous antiangiogenic therapy. Consider 
cardiologist consultation to recommend the optimal dose and combination regimen in case of 
uncontrollable hypertension. 
● 
Persistent mild hypertension (systolic pressure: 140 - 149 and / or diastolic pressure: 
90-99 mmHg)  
- 
Treatment: 
▪ 
Initiate or add one antihypertensive agent at a stating dose (recommendation: 
enalapril or hydrochlorothiazide). Increase the dose gradually until blood 
pressure (BP) is under control. 
▪ 
No dose adjustment of study drugs 
● 
Persistent moderate hypertension (systolic pressure: 150 - 179 and / or diastolic 
pressure 100 - 109 mmHg) 
- 
Treatment: 
▪ 
Initiate or add one long-acting antihypertensive agent, which gradually 
increases to the maximum until improvement to mild hypertension. 
▪ 
Add the second drug if BP is partially controlled or not controlled, increase the 
dose gradually to the maximum until BP is under control. 
▪ 
Add the third antihypertensive agent if BP is not controlled or partially 
controlled within the moderate range, increase the dose gradually to the 
maximum until BP is under control. 
▪ 
When it is controlled to mild hypertension, it can be de-escalated to the next 
level according to the dose of brivanib alaninate. 
● 
Persistent severe hypertension (systolic pressure >180 and / or diastolic 
pressure: >110 mmHg) 
- 
Treatment with symptoms: 
▪ 
Discontinue the investigational drug 
▪ 
Monitor BP closely. Beware of hypotension while discontinuing the 
investigational drug 
▪ 
Consider hospitalization for close monitoring and IV treatment 
▪ 
Treat as a hypertensive crisis. 
- 
Treatment if there is no symptom: 
▪ 
Suspend the investigational drug and monitor BP closely 
▪ 
Initiate or add two antihypertensive agents, which gradually increase to the 
maximum until BP is under control. 
▪ 
If BP is not controlled, but there is no symptom, add one drug that increases 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 80 of 106 
gradually to the maximum until BP is controlled. 
▪ 
When it is controlled to mild hypertension, resume the investigational drug 
that is considered to be de-escalated to the next level according to the dose 
taken by the subject 
▪ 
Discontinue the investigational drug if it is still not controlled with three 
antihypertensive drugs at the maximum dose 
● 
Hypertensive crisis (diastolic pressure > 120 mmHg; systolic pressure > 180 mmHg 
or CNS, cardiovascular and kidney involvement) 
- 
Treatment: 
▪ 
Discontinue the investigational drug 
▪ 
Immediate treatment 
Management of Hyponatremia 
In the study of brivanib alaninate, about 1/3 subjects experienced > Grade 1 hyponatremia. In 
addition, hyponatremia is a common complication of hepatic cirrhosis and ascites. Therefore, 
blood biochemistry and renal and liver function should be monitored periodically in advanced 
HCC subjects receiving brivanib alaninate. It is recommended to adopt medical interventions 
in case of CTCAE Grade 1 hyponatremia. 
Table 5: Management of Hyponatremia Related to Brivanib Alaninate 
Electrolytes 
Hyponatremia 
CTCAE Grade 3: 
<130-120 mmol/L 
The first occurrence 
Continue the investigational drug and begin medical 
intervention until blood sodium ≥ 130 mmol/L 
Last for ≥ 7 days or 
occur for the second 
time 
Suspend the investigational drug and begin medical 
intervention 
Resume the investigational drug if blood sodium ≥ 130 
mmol/L, consider to reduce the dose to level -1 
The third occurrence 
 
Discontinue the investigational drug or discuss with 
medical monitors 
Hyponatremia 
CTCAE Grade 4: 
<120 mmol/L 
The first occurrence 
 
 
Suspend the investigational drug and begin medical 
intervention 
Resume the investigational drug if blood sodium ≥ 130 
mmol/L, consider to reduce the dose to level -1 
The second occurrence 
Discontinue the investigational drug or discuss with 
medical monitors 
8.4.3 Toxicity and Management of Combination Toxicity 
No new AEs other than toxicity related to single drug are anticipated for the combination of 
MGD013 and brivanib alaninate for they have different mechanism of action. However, some 
adverse reactions, e.g., thyrotoxicity and hepatotoxicity, may overlap. The combination 
medication group should be closely monitored for AEs. Both investigational drugs should be 
discontinued in case of any adverse events with CTCAE Grade 3 to 4 and causally related to 
study treatment. Before the study drug is resumed, the appropriate medical intervention 
should be applied until the AE is resolved to CTCAE Grade ≤1 (or baseline level if the 
event severity is higher than CTCAE Grade 1 at baseline). If the AE fails to be resolved to 
CTCAE Grade ≤1 within 28 days upon event onset, both study drugs should be 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 81 of 106 
permanently discontinued and the subject should be withdrawn from the study. 
When study treatment is to be resumed, if the investigator considers that the AE is related to 
brivanib alaninate, the treatment can be restarted at the original dose or dose reduced to next 
lower level as pre-defined, depending on the dose originally administered and event severity 
(See 8.4.2). In Phase I study, dose reduction is not allowed during the DLT observation period 
and permitted at most once for the remaining period. If treatment-related AE of CTCAE 
Grade 3-4 occurs again after dose reduction, the study treatment will be discontinued (except 
hyponatremia and hypertension that can be controlled by drugs, see 8.4.2). Once reduced, the 
dose should be maintained at lower level and dose escalation is never allowed. 
Given the mechanism of action of MGD013, it is anticipated that activation of cellular 
immune system can be manifested as immune-related AEs (irAEs). The fundamental 
principles of managing irAEs are suspension of the immune checkpoint inhibitor (ICI), a 
course of corticosteroids and routine supportive measures are given based upon the severity 
of Grade 1 - 2 irAEs, and restart the treatment without adjusting the dose after adverse events 
are resolved; discontinue MGD013 in case of drug-related Grade 3 adverse events and restart 
the drug after resolving to ≤ Grade 1 or baseline; permanently discontinue MGD013 and 
terminate the study in case of any drug-related Grade 4 adverse events. Guidelines for irAE 
management are available through the American Society of Clinical Oncology and National 
Comprehensive Cancer Network 
[23](https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf) or the 
European Society of Medical Oncology [24](https://www.esmo.org/Guidelines/Supportive-
and-Palliative-Care/Management-of-Toxicities-from-Immunotherapy). In the study, clinical 
management of MGD013-related adverse events is shown in 8.4.1. 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 82 of 106 
9. Statistical Analysis 
9.1 Analysis Set 
Statistical analysis is performed using full analysis set (FAS), per-protocol set (PPS) and 
safety set (SS). 
FAS: it includes all subjects who have received at least one dose of the investigational drug 
and have measurable tumors at baseline. 
PPS: it includes subjects with at least one post-treatment imaging assessment of tumors, good 
compliance, and no serious violation or deviation against the study protocol in FAS 
population. 
SS: it includes subjects who have received at least one dose of the investigational drug and 
undergone safety assessment. 
9.2 Sample Size Determination 
During Phase I monotherapy dose escalation study, the starting dose group (MGD013 120 mg 
Q2W) will adopt single-subject dose escalation and one subject will be enrolled. Subsequent 
dose groups and combination treatment will adopt the traditional 3+3 dose escalation 
scheme , with 3 - 6 evaluable subjects each, 30 - 43 subjects in total. 
Phase II Part 1 is a single-arm, SWOG two-stage design study with ORR as its primary 
efficacy endpoint. 
 
 
 40 subjects 
are needed 
 There are 2 stages 
for the 2nd line cohort and the radiological response (according to RECIST1.1 criteria) of 3 
and more out of 20 evaluable subjects at the first stage will support the decision to proceed to 
the second stage of subject accrual until there are 40 evaluable subjects in this cohort. 
Assuming the dropout rate is 10%, 34 subjects will be enrolled. 
 
 30 subjects are needed 
 
 Similarly, the study has two stages. In the 
first stage, if response (according to RECIST 1.1 criteria) is observed radiologically in 1 or 
more out of 15 evaluable subjects, the enrollment of second stage will be open and an 
additional of 15 evaluable subjects will be enrolled. Assuming the dropout rate is 10%, 45 
subjects will be enrolled. 
Phase II Part 2 is a expansion study and it is estimated to enroll 120 subjects to further assess 
the safety and efficacy of the investigational drug. 
9.3 Statistical Analysis Method 
9.3.1 Safety Analysis 
Safety analysis is performed in the SS. Safety parameters include: physical examination, vital 
signs, AEs and laboratory tests, ECG, etc. AEs will be coded using MedDRA System Organ 
Class and Terminology. 
The incidence rates and severity levels of adverse events, dose-limiting toxicity (DLT), 
adverse events leading to withdrawal from the study, adverse events leading to 
discontinuation, adverse events leading to death, and serious adverse events will be 
summarized. A line listing of AEs will be provided. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 83 of 106 
Each laboratory should examine the indicators and ECG, describe their changes during the 
study, use a cross-classification table to describe the normal and abnormal changes before and 
after treatment and provide a data list. Some specified parameters will be summarized 
descriptively per protocol. 
9.3.2 Efficacy Analysis 
FAS and PPS are both used for efficacy analysis, and of which, PPS is the main analysis set 
and FAS analysis can provide supporting evidence. 
Analysis method of the primary efficacy endpoint: summary of BICR-assessed objective 
response rate (ORR) after administration according to RECIST1.1. The secondary endpoints 
include investigator-assessed ORR, BICR-assessed ORR according to irRECIST, 
progression-free survival (PFS), time to tumor progression (TTP), disease control rate (DCR), 
duration of response (DoR), survival rate at fixed time points (6, 9, 12 months) and overall 
survival (OS). 
For the objective response rate (ORR), the point estimate, p-value of one-sided test and its 
95% confidence interval (95% CI) will be provided. Kaplan-Meier method was used to 
estimate the survival functions for time to tumor progression (TTP), progression-free survival 
(PFS), and overall survival (OS), respectively, and their survival curves plots, the median 
TTP, median PFS, Survival rate at fixed time points and their respective 95% confidence 
intervals (95% CI) will be provided. 
See the statistical analysis plan (SAP) for the details of Statistical Analysis. 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 84 of 106 
10. Clinical Trial Management 
10.1 Statement 
This clinical study shall be implemented and reported in accordance with the Declaration of 
Helsinki, Chinese Good Clinical Practice, ICH GCP and local appropriate regulations. 
10.2 Ethical Considerations 
Before initiating a trial, the investigator should obtain approval from the Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) for the trial protocol, informed consent form 
and any other written information to be provided to subjects. 
Before initiation of the clinical trial, approval must be obtained from the Ethics Committee. 
The approval issued by the Ethics Committee shall be made available to the investigator in 
written form. The investigator is obligated to provide the sponsor of a copy of the approval. 
The Ethics Committee approval should clearly list all the committee members involved in the 
review with their respective responsibilities. 
During the clinical study, any of issues related to the subject safety of the clinical study, such 
as changes in the clinical study protocol or subject informed consent form as well as serious 
adverse events in the clinical study, must be reported to the Ethics Committee in a timely 
manner. The completion or termination of the clinical study must also be reported to the 
Ethics Committee. 
10.3 Source Data Verification 
The investigator must properly handle all the data obtained during the clinical study, so as to 
ensure the rights and privacy of the subjects participating in the clinical study. The 
investigator must permit the monitor/auditor/inspector to consult and review required clinical 
study data to verify accuracy of original data and learn about study progress. If the original 
records cannot be verified, the investigator should agree to assist to further validation of data 
with them. 
10.4 Quality Assurance and Auditing 
The quality of all drugs and materials used in the clinical study must be controlled. The 
sponsor, personnel authorized by the sponsor or related medical management institutions 
have the right to audit the clinical study in order to ensure the authenticity of the clinical 
study data and abide by the provisions of the clinical study protocol. Subjects participating in 
the clinical study will be informed of the audit, but the privacy and data of subjects will be 
strictly protected. 
10.5 Informed consent form 
The investigator has the responsibility to explain to each subject the purpose, methods, 
benefits and potential risks of this clinical study. Signed informed consent must be obtained 
before conducting any study-specific procedures. Informed consent should be expressed in 
written form. The informed consent must be dated and signed by the subject him/herself. For 
those subjects who could not sign the informed consent form by themselves for any reasons, 
their parents, legal guardians, or protectors should sign the informed consent form. The 
original signed informed consent form and the process of obtaining informed consent should 
be preserved and documented in the case report form and relevant trial source documents by 
the investigator. 
By signing the informed consent form, the subject must also agree to allow the sponsor, the 
drug approval authorities, and the auditor and (or) the monitor to check and verify the 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 85 of 106 
obtained source data and materials related to clinical study, and all parties mentioned above 
must comply with confidentiality statement. 
10.6 Protocol Amendment 
Upon finalization of the study protocol, any changes to the protocol must be filed in details, 
which should be at least jointly signed and dated by the investigator and the sponsor, with 
version numbers indicated. 
The changes should involve the sponsor and the investigator. The revised contents should not 
be implemented before obtaining the approval of the Ethics Committee. 
10.7 Case Report Form (CRF) 
The CRO working on behalf of Zailab is responsible for data management, so as to ensure the 
authenticity, integrity, privacy and traceability of the clinical study data. 
Information has been entered by the investigator and its authorized personnel to the eCRF, 
and only the investigator with a physician qualification certificate can sign on the 
clinical/safety evaluation conclusion. Any changes to the eCRF will be automatically 
recorded in the system after the input of source data. 
10.8 Monitoring 
The Sponsor will designate a monitor for on-site monitoring. Monitors should operate in 
compliance with the company’s standard operation procedure (SOP). They should perform 
regular visits from the start to the end of study.  
The monitors will have access to relevant source data of the clinical study, and review CRF 
according to SOP to confirm information completeness, accuracy and consistency with 
original data. 
CRFs, copies of lab tests and medical tests must be accessible to clinical monitors, auditors 
and health authorities for review at any time. Monitors should review all CRFs and informed 
consent forms. 
10.9 Confidentiality Agreement and Subject Privacy 
The Investigator must ensure that the confidentiality of the information about the Sponsor 
and the investigational drug provided or disclosed by the Sponsor for the clinical study, and 
such information can only be used upon authorization by the Sponsor. 
The commitment is independent, effective and sustained until the permission of the Sponsor. 
The Investigator also commits to keep confidentiality to a third party for any confidential 
information provided or disclosed by the Sponsor and the investigational products. Any 
intention to use such information must be approved by the Sponsor and agreed upon. 
Investigators are obligated to protect the privacy of subjects participating in clinical study. In 
all the documents submitted to the sponsor, the identity of any subject in the clinical study 
will be coded by the subject number, while the subject’s name, admission number should not 
show up. The investigator must appropriately keep name and address of clinical trial subjects, 
as well as enrollment table corresponding to clinical study subject number. These enrollment 
tables will be strictly kept confidential and stored by the investigator. 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 86 of 106 
11. Publication of study protocol and results 
Zai Lab (Shanghai) Co., Ltd., as the sponsor, has exclusive rights to this study. The 
manuscript and publication will reflect the cooperation among investigators and 
investigator’s institution and Zai Lab. Authors will be identified before drafting of the 
manuscript. Many study institutions and investigators are participating in this study, unless 
prior consent has been obtained from Zai Lab, individual participating institution or 
investigator shall not publish any data related to the clinical study. Zai Lab has the final right 
to determine how the manuscript and its relevant publication will be disclosed. 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 87 of 106 
12. Data Archival 
According to the requirements of relevant laws and regulations, the investigator should 
properly keep source records related to the clinical study. Copies of all clinical study data 
must be retained for at least 5 years after approval for marketing. It is the responsibility of the 
Sponsor to inform the Investigator/Study Site of when it is no longer necessary to further 
retain such data. 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 88 of 106 
13. References 
(1) Liver Cancer Fact Sheet. Lyon: IARC; International Agency for Research on Cancer. 
Globocan 2012. 
(2) Zhu, Ran Xu, et al. "Epidemiology of hepatocellular carcinoma in the Asia-Pacific 
region." Gut and liver 10.3 (2016): 332. 
(3) Llovet, Josep M., et al. "Molecular therapies and precision medicine for hepatocellular 
carcinoma." Nature Reviews Clinical Oncology (2018): 1. 
(4) Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018). 
Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nature reviews 
Clinical oncology, 15(2), 95. 
(5) Llovet, Josep M., et al. "Sorafenib in advanced hepatocellular carcinoma." New England 
journal of medicine 359.4 (2008): 378-390. 
(6) Cheng, Ann-Lii, et al. "Efficacy and safety of sorafenib in patients in the Asia-Pacific 
region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, 
placebo-controlled trial." The lancet oncology 10.1 (2009): 25-34. 
(7) Kudo, Masatoshi, et al. "Lenvatinib versus sorafenib in first-line treatment of patients 
with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority 
trial." The Lancet 391.10126 (2018): 1163-1173. 
(8) Bruix, Jordi, et al. "Regorafenib for patients with hepatocellular carcinoma who 
progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-
controlled, phase 3 trial." The Lancet 389.10064 (2017): 56-66. 
(9) Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin 
plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients 
with advanced hepatocellular carcinoma from Asia. J Clin Oncol, 2013;31（28）:3501-
3508. 
(10) Qin S, Cheng Y, Liang J, et al. Efficacy and Safety of the FOLFOX4 Regimen Versus 
Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup 
Analysis of the EACH Study. Oncologist, 2014；19（11）：1169-1178. 
(11) El-Khoueiry AB, Sangro B, Yau T, et al: Nivolumab in patients with advanced 
hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 
dose escalation and expansion trial. Lancet 389:2492-2502, 2017. 
(12) Zhu, Andrew X., et al. "Pembrolizumab in patients with advanced hepatocellular 
carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-
label phase 2 trial." The Lancet Oncology 19.7 (2018): 940-952. 
(13) Bang YJ, et al. Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with 
advanced biliary tract cancer: interim results of KEYNOTE-028 [abstract] Eur J 
Cancer. 2015;51(Suppl. 3):S112. 
(14) Diaz L, Marabelle A, Kim TW, et al: Efficacy of pembrolizumab in phase 2 KEYNOTE-
164 and KEYNOTE-158 studies of microsatellite instability high cancers. 2017 ESMO 
Congress. Abstract 386P. Presented September 11, 2017.  

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 89 of 106 
(15) Long, L, Zhang, X, Chen, F, Pan, Q, Phiphatwatchara, P, Zeng, Y, et al., The promising 
immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. 
Genes Cancer, 2018. 9(5-6): p. 176-189. 
(16) Woo, S R, Turnis, M E, Goldberg, M V, Bankoti, J, Selby, M, Nirschl, C J, et al., 
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function 
to promote tumoral immune escape. Cancer Res, 2012. 72(4): p. 917-27. 
(17) Huang, R Y, Eppolito, C, Lele, S, Shrikant, P, Matsuzaki, J, and Odunsi, K, LAG-3 and 
PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen 
antitumor immunity in a murine ovarian cancer model. Oncotarget, 2015. 6(29): p. 
27359-77. 
(18) Grosso, J F, Kelleher, C C, Harris, T J, Maris, C H, Hipkiss, E L, De Marzo, A, et al., 
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and 
tumor-tolerance systems. J Clin Invest, 2007. 117(11): p. 3383-92. 
(19) Fukumura, Dai, et al. "Enhancing cancer immunotherapy using antiangiogenics: 
opportunities and challenges." Nature Reviews Clinical Oncology (2018). 
(20) Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating 
hypoxia. Cancer Cell. 2014; 26:605–622 
(21) Huang Y, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the 
immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl 
Acad Sci USA. 2012; 109:17561–17566. 
(22) Lin J, Wang A, Shi W, et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with 
advanced intrahepatic cholangiocarcinoma (ICC): Preliminary data and correlation with 
next-generation sequencing. Presented at: 2018 Gastrointestinal Cancers Symposium; 
January 18-20, 2018; San Francisco, CA. Abstract 500. 
(23) https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf  
(24) Haanen, J. B. A. G., et al. "Management of toxicities from immunotherapy: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of 
Oncology28.suppl_4 (2017): iv119-iv142. 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 90 of 106 
14. Appendix 
Appendix A Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) 
Guideline 
1. 
Overview of Evaluation Process 
Tumor burden will be recorded at the baseline. First, the reviewer will determine lesions 
suitable for repeated quantitative evaluations ("measurable" lesions). Among measurable 
lesions, the reviewer will select a set of lesions for quantitative follow-up throughout the study 
("target" lesions). RECIST 1.1 recommends method maximizing the measurement 
reproducibility or reliability to measure target lesions and calculate the tumor burden of target 
lesions (sum of diameters). All tumor lesions not selected for quantitative evaluation will be 
recorded and qualitatively followed up as "non-target" lesions. 
At each follow-up visit, the reviewer will evaluate the target lesion, by measuring and 
calculating the sum of diameters in an appropriate method, to compare with baseline value (for 
observing partial response) and with the minimum value observed before this time point (also 
referred to as the "minimum", for observing disease progression). The reviewer will also 
qualitatively evaluate non-target lesions and look for new lesions, to provide overall response 
of the subject at a specific visit by combining the information of target lesions, non-target 
lesions, and new lesions. The relevant efficacy endpoints will be evaluated based on overall 
response in the sequential visits and corresponding dates. 
2. 
Baseline Tumor Measurement 
2.1 
Measurement of Lesions 
All lesions should be measured in metric unit and with a caliper when clinical evaluation is 
required. All baseline assessments should be as close to the initiation of treatment, up to a 
maximum of 4 weeks prior to the initiation of treatment. 
Lesions other than lymph nodes are measured by CT or MRI scan for the longest diameter. 
Typically, it is measured from the axial plane. Lymph nodes, even though not affected by tumor, 
have normal anatomical structures in imaging examination. At baseline and subsequent visits, 
only the short diameter of lymph nodes is required to calculate the sum of diameters of target 
lesions. 
At baseline assessment, tumor lesions and/or lymph nodes will be classified as measurable or 
unmeasurable lesions as follows: 
2.1.1. Measurable Tumor Lesions 
Tumor lesions can be accurately measured, and the longest diameter on the measurable plane 
should be the following minimum size at least: 
● 
CT scan: 10 mm (CT scan slice thickness ≤5 mm) 
● 
MRI scan: 10 mm or twice the slice thickness plus any interval thickness, whichever 
is greater 
● 
At least 10 mm measured by caliper in the clinical examination (lesions that cannot 
be accurately measured by caliper are unmeasurable lesions) 
● 
Chest X-ray: 20 mm 
Malignant lymph nodes: pathologically enlarged and measurable, the short diameter of lymph 
nodes must be ≥15 mm in CT scan (recommended CT scan slice thickness ≤5 mm). At 
baseline and follow-ups, only short diameters are measured and followed up. The size of lymph 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 91 of 106 
node is generally reported in two-dimensional data on the image plane (CT as the axial plane 
and MRI as the coronal or sagittal plane). For example, the short diameter of a 20 mm × 30 
mm abdominal lymph node is 20 mm, and it can be considered as a malignant, measurable 
nodule. In this case, 20 mm is the measurement of lymph node as a target lesion. 
2.1.2. Unmeasurable Tumor Lesions 
Unmeasurable tumor lesions include small lesions (the longest diameter <10 mm or short 
diameter of pathological lymph node ≥10 mm while <15 mm) and truly unmeasurable lesions. 
Truly unmeasurable lesions include: leptomeningeal lesions, ascites, pleural or pericardial 
effusions, breast inflammatory lesions, cutaneous or pulmonary lymphangitis, peritoneal 
metastases, and abdominal mass/enlargement of abdominal organs identified in the physical 
examination but cannot be measured by repeatable imageology. 
Pathological lymph nodes (with the short diameter ≥10 mm while <15 mm) should be 
considered as unmeasurable lesions. Lymph nodes with the short diameter <10 mm should be 
considered non-pathological and not be recorded for follow-up. 
2.1.3. Some Special Considerations for Lesion Measurability 
Bone lesions, cystic lesions, and lesions that have received prior topical treatment should be 
noted separately: 
Bone lesions: 
● 
Bone scan, PET scan, and bone radiograph are not imaging techniques suitable for 
measurement of bone lesions, but they are conductive to confirm the presence or 
absence of bone lesions. 
● 
Osteolytic lesions or mixed osteolytic and osteoblastic lesions with identifiable soft 
tissue component can be assessed using cross-sectional imaging techniques (e.g., CT 
or MRI), and are considered measurable if the soft tissue component meets the 
definition of measurable lesions as described above. 
● 
Osteoblastic lesions are not measurable. 
Cystic lesions: 
● 
Simple cysts that meet radiographic criteria should not be considered as malignant 
lesions (neither measurable nor non-measurable lesions) because they are by 
definition simple cysts. 
● 
Cystic metastatic “cystic lesions” are considered measurable lesions if meeting the 
definition of measurability mentioned above. If the same subject has a non-cystic 
lesion, it should be preferred as the target lesion. 
Lesions that have received prior topical treatment: 
● 
Tumor lesions located in previously irradiated areas or areas that have received other 
topical treatment are typically not considered as measurable lesions unless the lesion 
has disease progression, or is irradiated more than 6 months prior to the enrollment. 
2.1.4. Measurability Description of Assessment Methods  
At baseline and follow-up assessments, the assessment methods and techniques should be 
consistent for assessment of each clearly documented lesion. Except lesions that cannot be 
assessed by imaging examinations while can be assessed by clinical examination, all lesions 
must be assessed by imaging examinations. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 92 of 106 
CT, MRI: CT is the method currently used with optimal repeatability to measure target lesions 
for efficacy evaluation. The measurability of lesions for CT scan in this guideline is based on 
the assumption of CT slice thickness ≤5 mm. When CT slice thickness >5 mm, the minimum 
size of measurable lesion should be at least 2 times the slice thickness. In some cases (e.g., 
whole body scanning), MRI is acceptable. MRI slice thickness (to determine the measurability) 
refers to the distance from the top of one slice to that of the next one (including any slice 
interval). 
If a subject is known not to use contrast medium for CT scan due to allergy or renal 
insufficiency prior to the enrollment, the subject should undergo chest non-contrast CT, 
abdominal and pelvic MRI. If a subject experiences iodine-contrast allergy during the study, it 
should be dealt with in the same method (chest non-contrast CT, abdominal and pelvic MRI). 
It should be noted that altered examination may result in the lesion unevaluable following this 
time point. 
Clinical lesions: Clinical lesions can only be considered measurable when they are superficial 
and with the diameter ≥10 mm measured by caliper. For skin lesions, it is recommended to 
keep color photographs of lesions with a ruler or length standard on file. 
Chest X-ray: CT has higher sensitivity than X-ray examination (especially to confirm new 
lesions), and therefore chest CT is preferred instead of chest X-ray. The chest X-ray lesion with 
clear boundary surrounded by pneumatic lung tissue can be regarded as a measurable lesion. 
However, CT is preferred than X-ray, even if non-contrast CT. 
Ultrasound: Ultrasound is not used to evaluate the lesion size; therefore, it is not suitable for 
measurement of lesions. 
3. 
Assessment of Tumor Response 
3.1 
Overall Assessment of Tumor Burden and Assessment of Measurable Lesions 
It is required to assess the baseline total tumor burden as a reference for subsequent 
measurements to assess objective response or disease progression. This protocol only involves 
subjects with measurable disease at the baseline. The measurable disease is defined as the 
presence of at least 1 measurable tumor lesion (as detailed above). 
3.1.1. Baseline Recording of Target and Non-target Lesions 
The target lesion is a subset of measurable lesions. The definition of measurable lesions has 
been provided above. If there are 1 or more measurable lesions at the baseline, up to 5 lesions 
in all affected organs (up to 2 lesions in each organ) can be combined as the baseline target 
lesion to record and measure. It indicates that if a subject only has 1 or 2 affected organs, at 
most 2 (1 site) and 4 measurable lesions (2 sites) will be recorded. Other lesions in each organ 
are recorded as unmeasurable lesions (even though CT scanning >10 mm). The target lesion is 
selected according to the lesion size (the lesion with the longest diameter is preferred), and the 
target lesion should represent all affected organs as much as possible, and can be measured 
repeatedly. In a few cases, once the largest lesion cannot be measured repeatedly, it should 
select the submaximal lesion that can be measured repeatedly. Paired organs (lungs, kidneys, 
etc.) should be regarded as a single organ. All lymph nodes are also considered as a single 
organ. 
The sum of diameters of all target lesions (the longest diameter of non-lymph node lesions and 
short axis of lymph node lesions) are reported as the baseline sum diameters. If lymph node is 
the target lesion, only the short axis is calculated for the sum as described above. The baseline 
sum diameters of target lesions will be taken as reference to assess the objective response. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 93 of 106 
All other lesions (or diseased sites), including pathological lymph nodes, should be recorded 
as non-target lesions at the baseline. It is not required to measure non-target lesions, but only 
recorded as “present” or “disappeared”, or “significantly progressed” in rare cases. Moreover, 
multiple non-target lesions in the same organ can be recorded as one item in the CRF (e.g., 
"multiple pelvic lymph node enlargement" or "multiple liver metastases"). 
3.2 
Criteria for Tumor Response 
This section provides definitions of objective tumor response determined based on target tumor 
lesions: 
Evaluation of Target Lesions 
● 
Complete Response (CR): Disappearance of all target lesions. Any pathological 
lymph nodes (target and non-target) must have reduction in short axis to <10 mm. 
● 
Partial Response (PR): At least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters. 
● 
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of 
target lesion (including the baseline sum if that is the smallest on study) taking as 
reference the smallest on study. In addition to the relative increase of 20%, the sum 
must also demonstrate that an absolute increase of at least 5 mm. 
● 
Stable Disease (SD): Neither sufficient shrinkage to quality for PR nor sufficient 
increase to quality for PD, taking as reference the smallest sum diameters while on 
study. 
Special Considerations for Evaluation of Target Lesions 
Lymph nodes: For lymph nodes identified as target lesions, actual short axis measurement (on 
the same anatomical plane as the baseline exam) should be always recorded, even if it is 
reduced to <10 mm while on study. It indicates that the sum of lesions may not be 0 if lymph 
nodes are taken as target lesions, even if the criteria for CR have been met, because the normal 
lymph node is defined as short axis <10 mm. Therefore, when designing the case report form 
or using other data collection methods, data of lymph nodes as target lesions should be collected 
in separate module/chapter, and requiring the short axis of all lymph nodes <10 mm if the 
criteria for CR have been met. For PR, SD, and PD evaluation criteria, the actual measurement 
of short axis of lymph nodes will be included in the sum of the diameters of target lesions. 
Target lesions “too small to be measured”: All target lesions (lymph nodes or non-lymph 
nodes) having been recorded at the baseline should be recorded for its actual size (even if the 
lesion is very small, e.g., 2 mm) at each subsequent assessment. However, in some cases, 
lesions recorded as target lesions at the baseline (including lymph node target lesions) may be 
blurry in the subsequent CT scans, which makes it difficult for radiologists to determine an 
accurate measurement and therefore may report as "too small to measure". In such case, a value 
should be still recorded in the CRF. The detailed recording rules are as follows: 
● 
If the radiologist considers that the lesion may have disappeared, the measurement 
should be recorded as 0 mm. 
● 
If it considers that the lesion is still present but not clear and too small to be measured, 
a default of 5 mm should be recorded and marked with BML (below the measurable 
limit) (Note: This rule is not applicable to lymph nodes since the size of normal lymph 
nodes is typically determined, and retroperitoneal lymph nodes are wrapped in fat; 
however, if lymph nodes are considered present but not clear and too small to be 
measured, in such cases, it can also be recorded as a default of 5 mm and marked 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 94 of 106 
with BML). The default value is derived from the CT scan slice thickness (but it does 
not vary with CT slice thickness). The measurement of these lesions may be non-
repeatable; therefore, the default value helps to avoid tumor response or progression 
owing to measurement errors. It is important to reiterate that if the radiologist can 
give an actual measurement, even if <5 mm, it should be recorded without marking 
of BML (BML corresponding to <). 
Treatment-induced lesion division and fusion: If a non-lymph node lesion is divided, the 
sum of the longest diameters of divisions should be calculated in the sum of target lesions. 
Similarly, if there is lesion fusion (merge) with interface remaining between lesions, the sum 
of the longest diameters of each lesion is calculated in the sum of target lesions. If the lesions 
have been fully fused, the vector of the longest diameter is taken as the largest and longest 
diameter of the "fused lesion". 
Evaluation of Non-Target Lesions 
This section provides the criteria for tumor response determined based on non-target lesions. 
Although some non-target lesions are in fact measurable, there is no need to measure these 
lesions, but to make qualitative assessments at the time points specified in the protocol. 
● 
Complete Response (CR): Disappearance of all non-target lesions and normalization 
of tumor marker levels. All lymph nodes must be non-pathological in size (<10 mm 
short axis). 
● 
Non-CR/Non-PD: Persistence of at least one non-target lesion or/and maintenance of 
tumor marker level above the normal limits. 
● 
Progressive Disease (PD): unequivocal progression of non-target lesions as overall 
assessment regardless of the status of target lesions. 
Special Considerations for Evaluation of Progressive Disease of Non-Target Lesions 
The definition of progressive disease of non-target lesions is supplemented as follows: 
If the subject has measurable disease concomitantly: In such case, the substantial and 
significant deterioration of non-target lesions is required to reach the conclusion of 
“unequivocal progressive disease”, even if the target lesion is SD or PR, the overall tumor 
burden is significantly increased to require termination of treatment. The small "increase" in 
the size of one or more non-target lesions is normally insufficient to determine as unequivocal 
progressive disease. Therefore, in the case of target lesions achieving SD or PR, it is rare to 
make the assessment of overall progressive disease based only on changes in non-target lesions. 
If the subject has only unmeasurable lesions: It occurs in some phase III clinical studys not 
requiring measurable lesions in the inclusion criteria, and the above basic viewpoints are 
applicable. However, in this case, there are no measurable lesions as reference to assess 
increased tumor burden of unmeasurable lesions. Since it is not easy to quantify the 
deterioration of non-target lesions (By definition: If all lesions are indeed unmeasurable), if the 
overall tumor burden increase assessed based on changes in unmeasurable lesions is 
comparable to that in size of measurable lesions assessed as PD (i.e., tumor burden increase 
manifested as a 73% increase in “size” (equivalent to a 20% increase in the diameter of 
measurable lesion)), it is considered to determine as progressive disease. Similar examples 
include pleural effusion from “micro” to “large amount”, lymphatic lesions from localized to 
disseminated or substantial disease progression requiring adjustment of treatment regimen. If 
"unequivocal progressive disease" is observed, overall progressive disease can be considered 
at the time point of assessment. Ideally, unmeasurable lesions are assessed by objective criteria, 
while it is hard to achieve due to the nature of such unmeasurable lesions, therefore the tumor 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 95 of 106 
burden increase to reach the conclusion of progressive disease based on unmeasurable lesions 
must be significant and substantial increase. 
New Lesions 
The appearance of new malignant lesions usually indicates disease progression; therefore it is 
very important to identify new lesions and give proper explanation. There are no specific 
criteria for the imaging findings of new lesions, but it should be clear: neither varying with 
different scanning techniques or imaging mode, nor taking suspected non-tumor lesions (e.g., 
some "new" bone lesions may be just the recovery or deterioration of original lesions) as new 
lesions. 
This is especially important when the subject's baseline lesion has PR or CR. For example, the 
necrosis of liver lesion may be reported as a “new cystic lesion” in CT scan, but actually it is 
not a new tumor lesion. 
Anatomical lesions identified in the follow-up assessments while not found in the baseline 
exam will be considered as new lesions, suggesting progressive disease. For example, if a 
subject with visceral lesion at the baseline assessment is examined with metastases in brain CT 
or MRI on study, the brain metastases will be taken as the evidence of PD, even though the 
brain imaging is not performed at the baseline. 
If a new lesion is hard to identify, e.g., being too small, further treatment and follow-up 
assessments may clarify whether it is a new lesion. If the subsequent scans confirm as a new 
lesion, it should be evaluated as progressive disease, and the time to progression should be the 
date of initial scanning. 
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) 
FDG-PET can serve as a supplement for CT scan to assess progressive disease (especially for 
suspected "new" lesions). New lesions identified by FDG-PET can be assessed according to 
the following rules: 
● 
If the baseline FDG-PET finding was negative, while positive in the follow-up FDG-
PET, the new lesion has a sign of PD. 
● 
FDG-PET was not performed at the baseline, and FDG-PET indicates a positive 
result at the follow-up: 
o 
If the positive result in follow-up FDG-PET is confirmed by CT as a new lesion, 
PD is determined. 
o 
If the positive result fails be confirmed as a new lesion by CT (original lesion or 
it is uncertain whether there is lesion at the PET-positive site), subsequent CT 
scans are required to determine whether there is progressive disease at the site 
actually (if confirmed, the date to progression is the date of initial FDG-PET 
scan). 
o 
If the positive findings of follow-up FDG-PET are consistent with existing 
lesions in the prior CT scan, and there is no progression as shown in the 
anatomical image of the lesion, there is no PD. 
3.3 
Considerations for Response Evaluation 
When lymph node lesions have been included in the sum of target lesions and they are reduced 
to the physiological size (<10 mm), measurement data are still shown in the scan results. Even 
if lymph nodes are normal, this measurement should be recorded to avoid exaggerating the 
degree of progressive disease based on lymph node enlargement. It suggests that the sum tumor 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 96 of 106 
diameter recorded in the case report form (eCRF) of CR subjects may not be "0". 
If the subject's overall health condition deteriorates and requires termination of treatment, but 
there is no objective evidence of PD at the time point, it should be reported as "symptom 
deterioration". Even if the treatment is terminated, its objective progression should be recorded 
positively. Symptom deterioration is only one reason for the discontinuation of treatment in 
clinical study, rather than a specific term for assessment of objective response of tumors. The 
objective response of such subjects should be determined through a comprehensive assessment 
of target lesions, non-target lesions, and new lesions in Table 1 and 2. 
In some cases, it is difficult to distinguish between residual lesions and normal tissue. When 
the assessment of complete response depends on this determination, it is recommended to 
assess residual lesions (fine needle aspiration/biopsy) prior to classifying them to complete 
response. 
For the findings undetermined as progressive disease (e.g., very small and undetermined new 
lesion, cystic changes or necrosis of the lesion, etc.), the treatment can be continued until the 
next scheduled evaluation. If progressive disease is confirmed in the following scheduled 
evaluation, the date to progression should be the date on which the disease progression has 
been previously suspected. 
3.4 
Determination of Missing Evaluation and Non-evaluable 
If lesion imaging/measurement cannot be done at a particular time point, the subject is not 
evaluable at that time point. If only partial lesion can be measured in an evaluation, it is 
typically considered unevaluable at that time point unless there is convincing evidence that the 
missing lesion does not affect the overall response at that time point. Such cases happen mostly 
in the progressive disease. 
For example, the sum of 3 measurable lesions in one subject was 50 mm at baseline, but only 
2 lesions were evaluable at the follow-up, with a sum of 80 mm, regardless of impact of the 
missing lesion, the subject still experiences progressive disease. If one or more target lesions 
cannot be evaluated due to absent scanning or poor image quality affecting observation for 
evaluation, the subject is unevaluable, and therefore the response of target lesion is “not 
evaluated”. Similarly, if one or more non-target lesions are “not evaluated”, the overall 
response of non-target lesions should be “not evaluated” (except unequivocal progression). If 
the response of target or non-target lesions is “not evaluated”, the overall response is “not 
evaluated” (except there is clear evidence for progressive disease) as it is equivalent to 
unevaluable at that time point. 
3.5 
Response Evaluation at Specific Time Points 
The tumor response should be assessed at each time point specified in the protocol. Appendix 
A-Table 1 provides the summary of overall response at each time point for subjects with 
measurable disease at baseline. 
If the subject has only unmeasurable lesions (non-target), Appendix A-Table 2 is used for 
evaluation. 
Appendix A-Table 1. Response of subjects with Target (+/- Non-target) Lesions at Specific 
Time Points:  
Target Lesions 
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
CR 
No 
CR 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 97 of 106 
CR 
Non-CR/Non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD/not evaluated 
No 
PR 
SD 
Non-PD/not evaluated 
No 
SD 
Not evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and NE = no 
evaluated. 
Appendix A-Table 2. Response of Subjects with Only Non-target Lesions at Specific Time 
Points:  
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
No 
CR 
Non-CR/Non-PD 
No 
Non-CR/Non-PDa 
Not evaluated 
No 
NE 
Unequivocal PD 
Yes or No 
PD 
Any 
Yes 
PD 
CR = complete response, PD = progressive disease, and NE = no evaluated. 
a “Non-CR/Non-PD” is preferred over “stable disease” for non-target diseases since SD is increasingly 
used as an endpoint for assessment of efficacy. 
 
References: 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan; 45(2):228- 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 98 of 106 
Appendix B. Immune-Related RECIST Guidelines 
The immune-related RECIST (irRECIST) are adapted from Wolchok 2009. 
All patients will be required to have at least 1 measurable lesion to be considered as having 
measureable disease at baseline for the determination of eligibility for this study. 
Measureable lesions are defined below. 
1 Measurability of Tumor at Baseline 
1.1 DEFINITIONS 
At baseline, tumor lesions/lymph nodes will be categorized measurable or non-measurable as 
follows: 
1.1.1 Measurable 
Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in 
the plane of measurement is to be recorded) with a minimum size of: 
• 10 mm by CT scan (CT scan slice thickness no greater than 5 mm). 
• 10 mm caliper measurement by clinical exam (lesions which cannot be accurately 
measured with calipers should be recorded as non-measureable). 
• 20 mm by chest X-ray. 
Malignant lymph nodes: To be considered pathologically enlarged and measureable, a 
lymph node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice 
thickness no greater than 5 mm). At baseline and in follow-up, only the short axis will be 
measured and followed. See also notes below on ‘Baseline documentation of target and non-
target lesions’ for information on lymph node measurement. 
1.1.2 Non-measurable 
All other lesions, including small lesions (longest diameter < 10 mm or pathological lymph 
nodes with ≥ 10 to < 15 mm short axis) as well as truly non-measurable lesions. Lesions 
considered truly non-measureable include leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
abdominal masses/abdominal organomegaly identified by physical exam that is not 
measureable by reproducible imaging techniques. 
1.1.3 Special considerations regarding lesion measurability 
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment:  
Bone lesions: 
• Bone scan, PET scan or plain films are not considered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence 
or disappearance of bone lesions. 
• Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue 
components, that can be evaluated by cross sectional imaging techniques such as CT 
or MRI can be considered as measurable lesions if the soft tissue component meets 
the definition of measurability described above. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 99 of 106 
• Blastic bone lesions are non-measurable. 
Cystic lesions: 
• Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measureable nor non-measurable) since they 
are, by definition, simple cysts. 
• ‘Cystic lesions’ thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability described above. 
However, if non-cystic lesions are present in the same patient, these are preferred for 
selection as target lesions. 
Lesions with prior local treatment: 
• Tumor lesions situated in a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are not considered measurable unless there has been 
demonstrated progression in the lesion prior to study enrollment. 
1.2 Specifications by methods of measurements 
1.2.1 Measurement of lesions 
All measurements should be recorded in metric notation, using calipers if clinically assessed. 
All baseline evaluations should be performed as close as possible to the treatment start and 
never more than 4 weeks before the beginning of the treatment. 
1.2.2 Method of assessment 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging based evaluation 
should always be done rather than clinical examination unless the lesions(s) being followed 
cannot be imaged but are assessable by clinical exam. 
Clinical lesions: Clinical lesions will only be considered measurable when they are 
superficial and ≥10 mm diameter as assessed using calipers (e.g., skin nodules). For the 
case of skin lesions, documentation by color photography including a ruler to estimate the 
size of the lesion is suggested. As noted above, when lesions can be evaluated by both 
clinical exam and imaging, imaging evaluation should be undertaken since it is more 
objective and may also be reviewed at the end of the study. 
Chest X-ray: Chest CT is preferred over chest X-ray, particularly when progression is an 
important endpoint, since CT is more sensitive than X-ray, particularly in identifying new 
lesions. However, lesions on chest X-ray may be considered measurable if they are clearly 
defined and surrounded by aerated lung.  
CT, MRI: CT is the best currently available and reproducible method to measure lesions 
selected for response assessment. This guideline has defined measurability of lesions on CT 
scan based on the assumption that CT slice thickness is 5 mm or less. When CT scans have 
slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice 
the slice thickness. MRI is also acceptable in certain situations (e.g., for body scans). 
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement. Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator dependent, it cannot be 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 100 of 106 
guaranteed that the same technique and measurements will be taken from one assessment to 
the next. If new lesions are identified by ultrasound in the course of the study, confirmation 
by CT or MRI is advised. If there is concern about radiation exposure at CT, MRI may be 
used instead of CT in selected instances. 
Endoscopy, laparoscopy: The utilization of these techniques for objective tumor evaluation 
is not advised. 
Tumor markers: Tumor markers will not be used to assess objective tumor response. 
2 Tumor Response Evaluation 
2.1 Assessment of overall tumor burden and measurable disease 
To assess objective response or future progression, it is necessary to estimate the overall 
tumor burden at baseline and use this as a comparator for subsequent measurements. Only 
patients with measurable disease at baseline should be included. Measurable disease is 
defined by the presence of at least one measurable lesion (as detailed above). 
2.2 Baseline documentation of ‘target’ and ‘non-target’ lesions 
Where more than one measurable lesion is present at baseline all lesions up to a maximum of 
five lesions total (and a maximum of two lesions per organ) representative of all involved 
organs should be identified as target lesions and will be recorded and measured at baseline. 
For example, in instances where patients have only one or two organ sites involved, a 
maximum of two and four lesions respectively will be recorded). Target lesions should be 
selected on the basis of their size (lesions with the longest diameter), be representative of all 
involved organs, but in addition should be those that lend themselves to reproducible repeated 
measurements. It may be the case that, on occasion, the largest lesion does not lend itself to 
reproducible measurement in which circumstance the next largest lesions which can be 
measured reproducibly should be selected. 
Lymph nodes merit special mention since they are normal anatomical structures which may 
be visible by imaging even if not involved by tumor. As noted previously, pathological nodes 
which are defined as measurable and may be identified as target lesions must meet criterion 
of a short axis of ≥ 15 mm by CT scan. Only the short axis of these nodes will contribute to 
the baseline sum. The short axis of the node is the diameter normally used by radiologists to 
judge if a node is involved by solid tumor. Nodal size is normally reported as two dimensions 
in the plane in which the image is obtained (for CT scan this is almost always the axial plane; 
for MRI the plane of acquisition may be axial, sagittal or coronal). The smaller of these 
measures is the short axis. For example, an abdominal node which is reported as being 20 
mm x30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this 
example, 20 mm should be recorded as the node measurement. All other pathological nodes 
(those with short axis ≥ 10 mm but < 15 mm) should be considered non-target lesions. 
Nodes that have a short axis < 10 mm are considered non-pathological and should not be 
recorded or followed. 
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated and reported as the baseline sum diameters. If lymph nodes 
are to be included in the sum, then as noted above, only the short axis is added into the sum. 
The baseline sum diameters will be used as reference to further characterize any objective 
tumor regression in the measurable dimension of the disease. 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 101 of 106 
All other lesions (or sites of disease) including pathological lymph nodes should be identified 
as non-target lesions and should also be recorded at baseline. Measurements are not required 
and these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal 
progression’. In addition, it is possible to record multiple non-target lesions involving the 
same organ as a single item on the case record form (e.g., ‘multiple enlarged pelvic lymph 
nodes’ or‘multiple liver metastases’). 
2.3 Response criteria 
This section provides the definitions of the criteria used to determine objective tumor 
response for target lesions by immune-related response criteria (i.e., irRECIST). 
2.3.1 Evaluation of target lesions 
Immune-Related Complete Response (irCR): Disappearance of all target lesions. Any 
pathological lymph nodes (whether target or non-target) must have reduction in short axis to 
< 10 mm. 
Immune-Related Partial Response (irPR): at least a 30% decrease in the sum of diameters of 
target lesions, taking as reference the baseline sum diameters. 
Immune-related Progressive Disease (irPD): at least a 20% increase in the sum of diameters 
of target lesions, taking as reference the smallest sum on study (this includes the baseline sum 
if that is the smallest on study). In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm. 
Unlike conventional RECIST criteria, the appearance of new measurable lesions does not 
automatically denote disease progression under immune-related response criteria. Rather the 
dimensions of new measurable lesions are added to overall sum of tumor diameters for 
determination of objective response status. Patients will not be considered as having 
progression unless the new overall sum of diameters has increased by > 20% from the 
smallest sum of tumor diameters achieved while on study. 
Immune-Related Stable Disease (irSD): Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on 
study. 
2.3.2 Special notes on the assessment of target lesions 
Lymph nodes. Lymph nodes identified as target lesions should always have the actual short 
axis measurement recorded (measured in the same anatomical plane as the baseline 
examination), even if the nodes regress to below 10 mm on study. This means that when 
lymph nodes are included as target lesions, the ‘sum’ of lesions may not be zero even if 
complete response criteria are met, since a normal lymph node is defined as having a short 
axis of < 10 mm. In order to qualify for irCR, each node must achieve a short axis < 10 mm. 
For irPR, irSD and irPD, the actual short axis measurement of the nodes is to be included in 
the sum of target lesions. 
Target lesions that become ‘too small to measure. While on study, all lesions (nodal and 
nonnodal) recorded at baseline should have their actual measurements recorded at each 
subsequent evaluation, even when very small (e.g., 2 mm). However, sometimes lesions or 
lymph nodes which are recorded as target lesions at baseline become so faint on CT scan that 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 102 of 106 
the radiologist may not feel comfortable assigning an exact measure and may report them as 
being ‘too small to measure’. When this occurs it is important that a value be recorded on the 
case report form. If it is the opinion of the radiologist that the lesion has likely disappeared, 
the measurement should be recorded as 0 mm. If the lesion is believed to be present and is 
faintly seen but too small to measure, a default value of 5 mm should be assigned (Note: It is 
less likely that this rule will be used for lymph nodes since they usually have a definable size 
when normal and are frequently surrounded by fat such as in the retroperitoneum; however, if 
a lymph node is believed to be present and is faintly seen but too small to measure, a default 
value of 5 mm should be assigned in this circumstance as well). This default value is derived 
from the 5 mm CT slice thickness (but should not be changed with varying CT slice 
thickness). The measurement of these lesions is potentially non-reproducible, therefore 
providing this default value will prevent false responses or progressions based upon 
measurement error. However, if the radiologist is able to provide an actual measure, that 
should be recorded, even if it is below 5 mm. 
Lesions that split or coalesce on treatment. When non-nodal lesions ‘fragment’, the longest 
diameters of the fragmented portions should be added together to calculate the target lesion 
sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid 
in obtaining maximal diameter measurements of each individual lesions. If the lesions have 
truly coalesced such that they are no longer separable, the vector of the longest diameter in 
this instance should be the maximal longest diameter for the ‘coalesced lesion’. 
2.3.3 Evaluation of non-target lesions 
This section provides the definitions of the criteria used to determine the tumor response for 
the group of non-target lesions. While some non-target lesions may actually be measureable, 
they need not be measured and instead should be assessed only qualitatively at the time 
points specified in the protocol. 
Immune-Related Complete Response (irCR): Disappearance of all non-target lesions. All 
lymph nodes must be non-pathological in size (< 10 mm short axis). 
Non-CR/Non-PD: Persistence of one or more non-target lesions(s) 
Immune-Related Progressive Disease (irPD): Unlike conventional RECIST 1.1, new 
measurable lesions or increases in the size of non-target lesions do not define PD in isolation 
in the immunerelated response criteria. Rather, immune-related PD is established if the sum 
of diameters is > 20% of the nadir of the sum of diameters for a given patient. 
2.3.4 New Lesions 
The appearance of new malignant lesions alone does not denote disease progression. Instead, 
the diameter of new lesions is added to the sum of diameters for target and non-target lesions. 
2.4 Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the study treatment 
until the end of treatment taking into account any requirement for confirmation. The patient’s 
best overall response assignment will depend on the findings of both target and non-target 
disease. 
2.4.1 Time Point Response 
It is assumed that at each protocol specified time point, a response assessment occurs. For 
patients experiencing irCR or irPR, a confirmatory scan obtained no less than 4 weeks after 
the original scan is required to confirm the objective response. For patients experiencing 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 103 of 106 
irPD, but who demonstrate acceptable tolerability of treatment as evaluated by the 
Investigator, a 
confirmatory scan obtained no less than 4 weeks after the original scan is required for the 
confirmation of irPD. 
Immune-Related Complete Response (irCR): Complete disappearance of all target and 
nontarget lesions and no new lesions. The short axis of all lymph nodes must be ≤ 10 mm. 
Immune-Related Partial Response (irPR): The sum of diameters has decreased ≥ 30% from 
the baseline, but does not meet the criteria for irCR. 
Immune-Related Stable Disease (irSD): The patient does not meet criteria for irCR, irPR, or 
irPD. 
Immune-Related Progressive Disease (irPD): The sum of diameters for target lesions and new 
measureable lesions has increased by ≥ 20% from the nadir sum of diameters. 
2.4.2 Missing assessments and inevaluable designation 
When no imaging/measurement is done at all at a particular time point, the patient is not 
evaluable (NE) at that time point. If only a subset of lesion measurements are made at an 
assessment, usually the case is also considered NE at that time point, unless a convincing 
argument can be made that the contribution of the individual missing lesion(s) would not 
change the assigned time point response. 
2.4.3 Best overall response: all time points 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 104 of 106 
The best overall response is determined once all the data for the patient is known. 
Complete or partial responses may be claimed only if the objective response is confirmed on 
a follow-up scan obtained no less than 4 weeks after the initial scan demonstrating an 
objective response. Absent this subsequent radiographic confirmation, irCR or irPR 
designations will be considered as unconfirmed responses.  
2.4.4 Special notes on response assessment  
When nodal disease is included in the sum of target lesions and the nodes decrease to 
‘normal’ size (< 10 mm), they may still have a measurement reported on scans. This 
measurement should be recorded even though the nodes are normal in order not to overstate 
progression should it be based on increase in size of the nodes. As noted earlier, this means 
that patients with irCR may not have a total sum of ‘zero’ on the case report form (CRF). 
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration”. Every effort should be made to document objective progression 
even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an 
objective response: it is a reason for stopping study therapy. The objective response status of 
such patients is to be determined by evaluation of target and non-target disease as shown in 
Table. 
2.5 Confirmation/Duration of response 
2.5.1 Confirmation 
Objective responses should be confirmed by CT and/or MRI scans obtained no less than 4 
weeks after the original scan. 
2.5.2 Duration of overall response 
The duration of overall response is measure from the time measurement criteria are first met 
for irCR/irPR (whichever is first recorded) until the first date that recurrent or progressive 
disease is objectively documented (taking as reference for progressive disease the smallest 
measurements recorded on study). The duration of overall complete response is measured 
from the time measurement criteria are first met for irCR until the first date that recurrent 
disease is objectively documented. 
2.5.3 Duration of stable disease 
Stable disease is measured from the start of the treatment until the criteria for progression are 
met, taking as reference the smallest sum on study (if the baseline sum is the smallest, this is 
the reference for calculation of irPD). 
 
Reference: Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al., Guidelines 
for the evaluation of immune therapy activity in solid tumors: immune-related 
response criteria. Clin. Cancer Res, 2009. 15(23): p. 7412-7420. 
 
 
 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 105 of 106 
Appendix C. Barcelona Clinic Liver Cancer (BCLC) 
Stage 
PST 
Tumor 
Liver function 
Stage A 
 
 
 
 
A1 
0 
Single tumor 
No portal hypertension, bilirubin 
normal 
 
A2 
0 
Single tumor 
Portal hypertension, bilirubin 
normal 
 
A3 
0 
Single tumor 
Portal hypertension, bilirubin 
abnormal 
 
A4 
0 
1 - 3 tumors, <3 cm 
Child-Pugh A-B 
Stage B 
0 
Large multinodular tumors 
Child-Pugh A-B 
Stage C 
1-2 
Vascular invasion or 
extrahepatic spread 
Child-Pugh A-B 
Stage D 
3-4 
Any stage 
Child-Pugh C 

ZL-MGD013-202 
Zai Lab 
Clinical Study Protocol 
Project ZL-MGD013-202 Version: amendment 1 Confidential 
Page 106 of 106 
Appendix D. Child-Pugh Classification 
Compensated and decompensated liver cirrhosis are a rough estimate for liver function of 
subjects with liver cirrhosis. It is difficult to divide the boundary of the two stages, and the 
severity of subjects at decompensated stage also varies greatly. Child (1964) divided the five 
indexes, including serum bilirubin, ascites, serum albumin level, prothrombin time and 
general condition into three grades (1, 2, 3) for scoring. The lowest score of 5 indicators is 5, 
and the highest score is 15, classifying as grade A, B, and C according to the score. 
Child-Pugh Scoring and Scale on Severity of Liver Disease 
Measure 
Score 
1 
2 
3 
Hepatic encephalopathy 
None 
Grade 1-2 
Grade 3-4 
Ascites 
None 
Mild 
Moderate and over 
PT prolongation 
or INR 
1-3 sec 
<1.7 
4-6 sec 
1.7-2.3 
>6 sec 
>2.3 
Total serum bilirubin 
(μmol/L) 
<34 
34-51 
>51 
Serum albumin (g/L) 
>35 
28-35 
<28 
Note: Class A 5-6; class B 7-9; class C 10-15; 
 
Class A and better class B (i.e., score 7) can be enrolled.